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Background
Driving-impairing medicines and traffic safety
Participation in road traffic using motorized vehicles is intrinsically 
part of modern society. Driving a motorized vehicle is a complex task 
and it requires appropriate cognitive and psychomotor skills, such 
as alertness, concentration, reaction time or visual acuity [1-3]. The 
complexity of the interaction between man, motorized vehicle and 
traffic can turn driving into a hazardous task. Data from the year 2010 
showed that in Europe more than 31.000 people lost their lives and over 
1.473.000 were injured in road accidents [4]. It is widely recognized 
that alcohol is one of the main contributors to road accidents and 
there is solid evidence demonstrating a positive association between 
alcohol consumption and increased traffic accident risk [5-8]. Less 
widely recognized is the role of certain medicines play in traffic 
accidents. According to a recent European study [9], benzodiazepines 
were found to be the third most frequently detected substance in 
seriously injured drivers and the second most frequently found 
substance in road-accident fatalities. The number of epidemiological 
studies concerning the influence of medicines on driving fitness has 
increased over the past recent years. Such studies have shown a 
positive association between the exposure to psychotropic medicines 
and the risk of having a traffic accident [5-8, 10-16]. This positive 
association is particularly clear for benzodiazepines [8, 10, 17-20]. 
However the evidence showing a positive relationship between the 
intake of other commonly prescribed psychotropic medicines (e.g. 
antipsychotics, antidepressants, anxiolytics, opioid analgesics, etc.) 
and the elevated risk for traffic accidents is not as straightforward as 
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it is for benzodiazepines [7-10, 12, 13, 17, 21-23]. Furthermore, the 
severity of the impairing effects of medicines can increase if combined 
with alcohol or other psychoactive substance [20, 24]. Considering 
that the prescription of psychoactive medicines has been increasing 
over the years [25] and that these substances have the potential to 
impair driving fitness, it is not surprising that traffic safety associated 
to the risk of driving under the influence of medicines has received 
more attention from regulatory bodies at European level. 
In 2003, the European Commission launched the 2003-2010 
European Road Safety Action Programme. This Action Programme set 
the goal of halving the number of road deaths from 54,000 down to 
27,000 by 2010 [26]. In order to accomplish such an ambitious goal, 
six main areas of action were defined [26]:
1) encouraging road users to improve their behaviour through stricter 
compliance with existing legislation and with basic safety rules;
2) using technical progress to make vehicles safer; 
3) encouraging the improvement of road infrastructures by 
identifying and eliminating accident black spots; 
4) safe commercial goods and passenger transport by reducing the 
number of accidents involving heavy vehicles and by regulating the training of commercial drivers and the compliance with driving and 
rest periods; 
5) examining best practice with regard to post-accident medical care of road accident victims, and 
6) accident data collection, analysis and dissemination of the 
priority fields of action. 
As a part of the Road Safety Action Programme (point 1 mentioned 
above), and within the 6th European Union (EU) framework, the 
European Commission funded the five-year (2006-2011) European 
DRiving Under the Influence of Drugs, Alcohol and Medicines (DRUID) 
project [27]. DRUID, one of the biggest research projects ever carried 
out in the EU on drugs and driving, brought together 19 European 
countries and 37 institutes [27]. The DRUID consortium comprised 
a multidisciplinary group of academic, research, medical and 
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governmental institutions and was organized in seven, interrelated 
and interactive, Work-Packages (WP). Each WP had its own aims and 
methodology [27]. In general, the main aims of the DRUID project 
were [27]:• provide scientific support to the EU transport policy makers by 
suggesting guidelines, legislation, enforcement and rehabilitation 
measures to combat impaired driving;• understand how traffic safety is affected by the use of psychoactive 
substances (alcohol, illicit drugs, and medicines), by establishing 
risk thresholds for relevant psychoactive substances, and • combine the knowledge from different problem areas in new 
practical approaches to reduce the risk of driving under the influence 
of psychoactive substances and, therefore, decrease the number of 
road victims.
Alongside these objectives, the DRUID project also took into consideration the importance of the development of information 
materials for health care professionals (HCPs) regarding the potential 
risk associated with the use of any kind of psychoactive substances. In 
addition, guidelines were developed to make HCPs aware of their role on how to inform patients who need to drive and take driving-impairing 
medicines (DIMs) adequately and effectively. This was done by giving 
HCPs clear and easy-to-understand estimations of the potential risk 
of being involved in a traffic accident, and if and when it is safe to 
drive their car, leaving it up to the patient to decide whether they will 
drive their car or not [27]. General information materials available to 
patients regarding the influence of medicines on driving fitness and 
traffic safety are not as widespread as those available for alcohol, 
drugs or speeding [28]. It can, therefore, be assumed that driving 
under the influence of medicines is not yet part of the community’s 
health awareness, even if patients have the right to receive sufficient 
information necessary to support decision making [29]. 
Information concerning driving-impairing medicines 
Access to and availability of information regarding medicines in 
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general has changed greatly over the past two decades. The digital era 
and the Internet revolutionized access to both print and electronic 
information materials, which are readily and always available [30]. 
This improved access to information about health care in general may 
be responsible for a greater involvement of patients regarding health 
issues and may contribute to an increase in patients’ knowledge 
regarding medicines and/or illnesses. However, generalizations about 
patients’ knowledge about medicines should be done carefully. This 
is particularly true with respect to patients’ knowledge regarding the 
driving-impairing effects of some medicines. There are only a few 
published studies showing low levels of knowledge and awareness among patients in regards to the impairing effects of various medicines 
on driving fitness [31-33].Research conducted in Europe and United States has concluded 
that patients generally like to be well informed about the risks [34] 
and side-effects [34-36] of the medicines they take. This implies 
that a risk message needs to be communicated and well understood 
by patients. From a clinical and health management standpoint, risk 
communication can be defined as one-to-one communication in which the intervention includes a stimulus to patients to weigh the risks and 
benefits of a treatment choice or behavioural (risk reducing) change 
[37]. Such definition implies that risk communication has evolved 
from a perspective on how to inform the target population (patients) 
about technical aspects (undesirable effects of a medicine) into a more 
dynamic dialogue among HCPs and patients, which aims at helping 
patient to weigh risks and benefits. In this way, risk communication 
becomes central to effective decision-making in modern health care 
[37-40] and constitutes the basis for informed patient consent [40-42]. There are various sources of information that patients can use to 
seek more knowledge regarding their medicine(s), and in particular 
it’s influence on driving fitness. Health care providers, such as general 
practitioners (GPs) and pharmacists are frequently acknowledged as 
an important source of medicine information for patients [30]. Another 
important source of information is the patient information leaflet (PIL). 
The inclusion of a PIL in medicines’ boxes is mandatory (according 
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to the articles 54, 55 and 59 from the amended European directive 
2001/83/EC) [43], being available to all consumers of medicines.
Most of the medicines known to impair driving fitness are prescription 
medicines and thus the first warning regarding impairing effects 
should be given to patients by the prescriber (general practitioner or 
a medical specialist), followed by a similar advice from pharmacists. 
In both cases, the information provided orally should be reinforced 
by written information. Patient-provider communication, if centred 
to patients’ needs and expectations [44] and based on a strong and 
well-established relationship [45], has been shown to result in higher 
rates of compliance [46, 47], increased patient satisfaction, improved 
medical outcomes, and decreased number of malpractice claims 
[47]. Patient-centeredness during counselling implies, however, that 
the information is personalized to each individual patient. Tailoring 
communication to meet patients’ needs and preferences may be a 
challenge for providers, [44] but it is the foundation for a collaborative 
and trustworthy relationship between patients and providers. The 
establishment of a trustworthy relationship increases the likelihood 
of patients being educated about medicines ensuring a better 
understanding of how to use their medications safely, effectively and 
confidently. It also supports a patient’s informed decision-making, 
empowerment, and autonomy.Both general practitioners and pharmacists are aware of the fact that each patient is unique and, therefore, that medicines can impair their 
driving ability differently [29, 48]. Thus, assessment has to be done on a 
case-by-case basis. The individualization of the information is essential 
to communicate with patients about the risks of accident involvement 
under different treatment conditions [29]. In order to provide 
adequate advice to patients, HCPs need to be well aware and informed of the risks associated to DIMs and need to know how to communicate 
the message effectively. Typically, HCPs update their knowledge 
regarding the undesirable effects of medicines from the following 
sources of information: PILs, scientific publications, product-specific 
mailings from pharmaceutical industry, and clinical (prescribing or dispensing) guidelines containing patient-oriented recommendations 
16 | Chapter 1
[29, 48, 49]. Unfortunately, up-to-date, practical recommendations for 
HCPs on how to inform patients on DIMs are scarce and professional 
guidelines regarding safe prescribing and dispensing of DIMs are an 
exception more than a rule among EU countries [29, 50].  Up to now, 
all existing information materials on this matter are based on the report of a working group within the International Council on Alcohol, 
Drugs and Traffic Safety (ICADTS) [49], where several guidelines for 
prescribing and dispensing DIMs, as well as recommendations and 
implementation strategies for improving prescribing and dispensing 
practices are available. 
Patient information leaflets are an important pillar of written 
information concerning medicines for patients and can be found 
in all medicines’ boxes. Despite being widely available and meant 
for patients, there has been considerable criticism regarding PILs’ 
readability and comprehensibility [30]. This brings into question the 
usefulness of PILs’ if patients cannot fully or properly understand 
the message being conveyed. The PIL encompasses many sections 
including one regarding the effects of the medicine on ability to drive 
and use machines. Within the EU, it is mandatory for pharmaceutical 
companies to provide data on the influence of medicines on driving 
ability as well as on the use of machinery [51]. This information has 
a dedicated section in the summary of the product characteristics 
(SmPC) of a medicine. The SmPC is translated into a meaningful 
message for patients and presented in the patient information leaflet 
(PIL), part of the medicine’s package. The most recent Guideline for the 
Summary of Product Characteristics (SmPC) [52] differentiates levels 
of impairment as a) no or negligible influence, b) minor, c) moderate 
influence, or d) major influence on driving fitness, with some important 
guidance in special circumstances. Yet, the text presented in the PILs is 
general and does not distinguish the severity of impairment, since the 
EU directive states to “mention, if appropriate, possible effects on the 
ability to drive vehicles or to operate machinery” [43].  
In January 1992, the European Committee for Medicinal Products for 
Human Use (CHMP) first introduced a differentiation between levels of 
driving-impairment in a note on guidance for the SmPCs [29, 53]. The 
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note assumes special relevance since DIMs may affect patients’ fitness 
to drive differently, suggesting that medicines can be categorized 
according to their level of driving-impairment. A review of the existing 
classification/categorization of medicines and driving was performed 
in 2008 resulting in the identification of 15 different approaches [54]. 
Different categorization systems are currently available across Europe. 
Yet, criteria for establishing a categorization system for potentially 
impairing medicines has been neither clearly published nor officially 
adopted at the European level [54]. This suggests the need to establish 
criteria for developing a standardized categorization system, which 
can be equally applied throughout Europe making patients aware of 
the risks of driving under the influence of DIMs. 
A way of communicating driving-impairment risks is by using 
pictograms, which have been increasingly recommended and used 
to convey warnings and other safety-related information [55, 56] 
and are particularly useful for increasing a patient’s understanding 
of risk [41, 42, 57]. In health care, pictograms are known to enhance 
comprehension [55, 56, 58-62], recall of information [55, 56, 58-62] 
and adherence [55, 60], as well as facilitate communication across 
language barriers [63].  The clear advantages associated with the use of pictograms in health care transcends the fact that in their simplest form 
pictograms are just figures representing ideas and concepts which can 
not always be verbally clearly explained to all patients. This inability 
to clarify certain medical concepts verbally affects the comprehension 
of the message [64, 65]. Elderly and less well-educated patients are 
particularly vulnerable to misunderstandings and often times have 
difficulties interpreting the message being conveyed [65-68]. 
Pictograms to convey safety information regarding the influence of 
medicines on driving fitness Pictograms showing the potential risk of driving while using DIMs 
have been developed in some European Union countries. The design 
of the pictograms currently used is diverse, as illustrated in Table 1. 
In the Netherlands, DIMs have a yellow warning label that is affixed 
to the medicines’ package. The label is based on a well-accepted 
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practice guideline for pharmacists and GPs introduced in 1973, but it 
is not mandatory [54, 69]. The yellow sticker contains only written 
information that refers to the possible influence a  medicine has on the 
ability to react adequately as well as the increased risks a medicine has 
when combined with alcohol. 
Since 1981, medicines in Norway that may reduce the ability to drive 
or operate machines have a red triangle on the box [70]. This warning 
label has been adopted in all Nordic countries [54, 70]. However, 
Sweden officially waived the use of such warning labels as of July 2007 due to the fact that such a warning did not encompass all factors that 
play a role in driving impairment, such as individual variation, fatigue 
or illness being treated [54]. 
In France, a country where a categorization system based on different 
levels of driving impairment was officially adopted, a graded pictogram 
reflecting the different categories was designed and printed on the 
box of all medicines that have the potential to impair driving fitness. 
The type of pictogram affixed to the box depends on the category 
attributed to the medicine: category 1 (low driving impairment), 
category 2 (moderate driving impairment), or category 3 (high driving 
impairment) pictogram. Between 2005 and 2008, pharmaceutical 
companies gradually began including the pictograms on the boxes of 
DIMs [15, 71] destined for the French market.
More recently, Spain introduced the use of warning labels related to 
medicines and driving. Since 2011, all medicines that influence driving 
ability must have a red triangle with a black car inside printed on the 
box [72, 73].  
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Country Pictogram / warning label






Must be affixed on medicines that 
may reduce the ability to drive or 
operate machines.
France
Affixed on medicines based on the level of driving-impairment a 
medicine can cause.There are three categories of risk:
Category 1 (niveau 1) – low driving-
impairment;
Category 2 (niveau 2)  – moderate 
driving-impairment;
Category 3 (niveau 3) – severe 
driving-impairment.Each pictogram is accompanied with 
a side-text.
Netherlands Warning sign referring to the possible influence of a medicine on 
the ability to react adequately.
Romania Affixed on medicines that are 
contraindicated to drivers.
Slovenia
Used for medicines that may reduce 
the ability to drive or operate 
machines. Used for medicinal products which 
significantly reduce the ability to drive or operate machines
Spain Pictogram used in all medicines that 
Can impair driving fitness.
Table 1 – Overview of the pictograms related to the influence of driving-impairing medicines on 
driving fitness, currently in use in Europe. 
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Despite current knowledge and the existence of the above-mentioned regulations and guidelines, there is a need to go one step further and 
answer some key questions to come to a better understanding of patient’s knowledge of the use medications while driving and their 
affects on the patient’s ability to drive safely. These unanswered 
questions include: what do patients actually know about driving-
impairing medicines; are patients aware of the traffic risk of driving 
under the influence of medicines; can the knowledge patients acquired 
be translated into changes in their driving behaviour; what can be 
done to facilitate the communication of risk; and can warning labels 
be effective in communicating risk of driving under the influence of 
medicines? All these questions bring us to the main objectives of this 
thesis. 
Objectives of the dissertation
The main objectives of this thesis are: • assess knowledge about DIMs and their influence on driving 
fitness as well as reported behaviour of patients who drive while 
taking driving-impairing medicines;• define the criteria and methodology for the development of a 
categorization system for commonly used medicines based on their 
influence on fitness to drive; • develop and evaluate the effectiveness and preference, at the 
patient level, of a warning symbol encompassing the different levels 
of impairment derived from the categorization system as well as 
identify patients’ preferences for a pictogram based on their age and 
education level; • evaluate the effect a training course developed for community 
pharmacists has on the patients’ knowledge and reported behaviour 
level at the start of treatment.
This PhD dissertation was based on the work developed within 
the EU DRUID project, WP4 Categorization and WP7 Dissemination & 
Guidelines. 
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Outline of the dissertation
Chapter 2 refers to a multi-country study conducted in Belgium, 
Germany, the Netherlands, and Spain. Patients’ knowledge and reported 
behaviour concerning driving under the influence of medicines were 
evaluated and compared. 
Chapter 3 presents the established criteria for the development of 
the DRUID categorization system for potentially driving-impairing 
medicine currently available on the EU market. This categorization 
system is primarily targeted towards HCPs, patients, and policy makers and allows differentiation among medicines’ different levels of 
impairment and, as a consequence, different levels of traffic risk.  Based on those different levels of risk, a pictogram model was developed depicting the risk levels derived from the DRUID categorization 
system. In Chapter 4, the effectiveness of two distinct pictograms in communicating risk messages associated to driving-impairing 
medicines is investigated. In Chapter 5, age and education level, which 
can influence preference for a certain type of pictogram, are studied.In Chapter 6, the results from a pharmacist’s training with DRUID information materials concerning driving-impairing medicines and its 
impact on patients’ knowledge and reported behaviour are presented. 
Finally, Chapter 7 summarizes and discusses the main findings of 
this dissertation. Some considerations regarding practice implications 
and recommendations for future research are also presented.
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Abstract
Background: Reports on the state of knowledge about medicines 
and driving showed an increased concern about the role that the use 
of medicines might play in car crashes. Much of patient knowledge regarding medicines comes from communications with healthcare 
professionals. This study, part of the DRUID (Driving Under the 
Influence of Drugs, alcohol and medicines) project, was carried out 
in four European countries and attempts to define predictors for 
knowledge of patients who use driving-impairing medicines. The 
influence of socio-demographic variables on patient knowledge was 
investigated as well as the influence of socio-demographic factors, 
knowledge and attitudes on patients’ reported behaviour regarding 
driving under the influence of medicines. 
Methods: Pharmacists handed out questionnaires to patients who 
met the inclusion criteria: 1) prevalent user of benzodiazepines, 
antidepressants or first generation antihistamines for systemic use; 2) 
age between 18 and 75 years old and 3) actual driver of a motorised 
vehicle. Factors affecting knowledge and reported behaviour towards 
driving-impairing medicines were analysed by means of multiple 
linear regression analysis and multiple logistic regression analysis, 
respectively.
Results: A total of 633 questionnaires (out of 3.607 that were 
distributed to patients) were analysed. Patient knowledge regarding 
driving under the influence of medicines is better in younger and 
higher educated patients. Information provided to or accessed by 
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patients does not influence knowledge. Patients who experienced side effects and who have a negative attitude towards driving under 
the influence of impairing medicines are more prone to change their 
driving frequency behaviour than those who use their motorised 
vehicles on a daily basis or those who use anti-allergic medicines.
Conclusions:  Changes in driving behaviour can be predicted by 
negative attitudes towards driving under the influence of medicines 
but not by patients’ knowledge regarding driving under the influence 
of medicines. Future research should not only focus on information 
campaigns for patients but also for healthcare providers as this might 
contribute to improve communications with patients regarding the 
risks of driving under the influence of medicines.
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Introduction
It has been known for many years that the consumption of 
psychoactive substances, such as alcohol, sedatives, anxiolytics, 
antidepressants or illicit drugs, has a negative effect on the ability 
to drive [1]. In fact, either alone or in combination, alcohol and 
psychoactive substances increase the risk of having a traffic accident 
[1-7]. According to the European Commission’s Directorate-General 
for Mobility and Transport, Road Safety Unit, 25% of accidents 
involve alcohol, medicines, or illicit drugs. These accidents are directly 
responsible for the loss of 10.000 lives due to car crashes in Europe 
every year [8]. Worldwide, governments and authorities invest a great 
amount of money and effort in changing the behavior of road users 
not only with respect to the use of seat belts and speed limits but 
also towards driving under the influence of alcohol, illicit drugs and 
medicines. Despite all the attempts and all the road safety campaigns 
that have been launched, traffic accidents are still responsible for more 
than 40,000 deaths and 1.7 million injuries across Europe [9].
Therefore, special efforts are needed in order to have a better 
knowledge of the various aspects of this specific problem and to 
develop appropriate solutions. This is the reason why an EU-project 
under the acronym of DRUID (Driving under the Influence of Drugs, 
Alcohol and Medicines) [10] was funded by the European Com- 
mission. DRUID aims not only to improve the possibilities of detecting 
drug-influenced driving in Europe but also to combat the scourge of 
drunk-driving and find answers to the question of the use of drugs or 
medicines that affect people’s ability to drive safely.
Reports on the state of knowledge about drugs and driving [1] showed 
an increased concern about the role that the use of medicines might 
play in traffic accidents. It has been estimated that 5-10% of medicines 
impair driving performance [2] as a consequence of their effects or 
side effects. This is the reason why it is so important to inform drivers who use driving-impairing medicines of the risks of driving under 
the influence. Research conducted in European countries has shown 
that patients do want to be informed about their medicines, their 
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risks [11] and side-effects [11-13]. Similarly, in the U.S., two-thirds of 
patients reported the desire to be informed of all possible side effects 
of their medicines [14]. Much of patient knowledge regarding their medicines comes from communication with healthcare professionals, 
such as general practitioners and pharmacists, media exposure, and 
reading the safety information on the medicine’s label [15]. Age and 
educational level seem to influence patient awareness and knowledge 
as health literacy decreases with increasing age [15].
In order to better understand and predict human behaviour, some 
theories have been derived to describe and explain how and why people 
behave the way they do. The theory of planned behaviour (TPB), the 
theory of interpersonal behaviour (TIB), and other more recent models 
with direct application in health research are examples of what has 
been done in the field of predictive behaviour. TBP was first suggested 
by Fishbein and Ajzen [16] and TIB is an extension of TBP. Both theories 
focus on intentions that are personal decisions to perform behaviour 
and are based on someone’s knowledge about themselves and about 
the world around them. In TBP, intensions are based on attitudes 
towards the behaviour, subjective norms, and perceived behaviour 
control. These three aspects form an intention that, ultimately, leads 
to a behaviour. TIB, on the other hand, integrates normative and social 
factors into TBP. In this theory, perceived consequences of behaviour 
and habits are predictors of intentions that, like in the TBP, lead to 
behaviour. It might be true that influencing attitudes do not always 
result in a change of behaviour.  Nevertheless, recent studies state that 
attitude is linked to traffic violations, especially when related to speed 
limits violations [17], use of seat belts [18], and driving under the 
influence of alcohol. Having the TBP and TIB as a main reference, this 
research attempts to determine predictors that can influence not only 
patients’ reported behaviour, but also their knowledge. In a simplified 
way, the theoretical reasoning behind the construction of the models 
was based on the assumption that socio-demographic characteristics 
play a central role in knowledge (evaluated as knowledge about risk of 
having a traffic accident). Both socio-demographic characteristics and 
knowledge in combination with attitudes, defined as feelings towards 
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driving under the influence « of medicines, were used to predict 
reported behaviour (in terms of change in driving frequency and/or 
in terms of change in the use of medicines). Figure 1 exemplifies the 
model that was developed based upon mentioned theoretical insights. 
The present study is part of DRUID, and it was conducted in 4 countries.




The study was conducted in four countries: Belgium, Germany, Spain 
and the Netherlands, in 2007. The reason why these four countries 
were selected is because the Ministry of Transport or the national organization of pharmacists developed materials related to drugs and 
driving, and, therefore, they were very sensitive to the topic and, as a 
consequence, more willing to participate.
The questionnaire used in our study was derived from a previous 
Dutch national survey [19]. The original questionnaire was constructed 
by a multi-disciplinary team of experts and tested in over a 1000 
consumers and patients.
Patients received the questionnaire through their pharmacy. 
Knowledge Reported 
behaviour
Socio-demographic characteristics• Country• Gender• Age• Educational level
Frequency of use of motorized vehicles




34 | Chapter 2
Pharmacists were asked to hand out a questionnaire to approximately 
1.000 patients (per country) who went to a community pharmacy and 
met the established inclusion criteria (see below).
The study was approved by the Medical Ethical Committee of the 
Universitair Medisch Centrum Groningen (University Medical Centre 
Groningen), the Netherlands as well as by the Medical Ethics Committee 
of the Universidad de Valladolid (Spain) and Ghent University Hospital 
Medical Ethics Committee (Belgium). Patient anonymity was ensured 
and all data were kept confidential.
PharmaciesDifferent approaches were used to select the pharmacies, depending 
on the country.Belgium
In Belgium, only Flemish pharmacies were approached. A message 
was spread through the APB (Algemene Pharmaceutische Bond – 
Belgian Pharmaceutical Association) and Escapo (an authorised 
wholesaler) to a selected number of pharmacies (93 in total). A total of 
40 pharmacies (43% response rate) agreed to participate in the study.
Germany
In collaboration with ABDA (Bundesvereinigung Deutscher 
Apothekerverbände – Federal Union of German Associations of 
Pharmacists), a total of 3.600 pharmacies, part of the ABDA network, 
were invited to participate in the study, from which 38 pharmacies 
(1% response rate) accepted the invitation.The NetherlandsThe pharmacies invited to participate in the Dutch patient 
questionnaires were selected among all the pharmacies that already 
cooperated with the University of Groningen, Pharmacy (RuG-Pha). 
Pharmacies that were participating in on-going projects were excluded. 
A total of 93 pharmacies were invited to participate in the study and 
36 pharmacies (39% response rate) accepted the invitation.
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Spain
In Spain, the institute responsible for the dissemination of the 
questionnaires was the University of Valladolid (UVa), in collaboration 
with the Spanish Society of Community pharmacies (Sociedad Espańola 
de Farmacia Comunitaria). Nationalwise, a total of 80 pharmacies were 
invited to participate. Of these, 35 (44% response rate) were actually 
enrolled in the study.
Pharmacists who agreed to participate in this study were not 
trained for this study. Yet, all participating pharmacists were provided 
with detailed information about the study, which included a list of participant inclusion criteria translated into the national language 
of each country. The reliability of the method to select patients was 
assured by addressing questions covering the inclusion criteria in 
the questionnaire and by excluding the patient from the analysis 
whenever the inclusion criteria were not fulfilled. Pharmacists looked 
for potential participants during working hours for a period of 3 weeks.
Patient inclusion criteria
Patients were eligible to participate in the study if they met the following inclusion criteria:
1) the patient uses anyone of the following medicines that are 
known to impair driving ability:• Benzodiazepines (as hypnotic or anxiolytic): flunitrazepam, 
flurazepam, loprazolam, nitrazepam, zopiclon, alprazolam, 
bromazepam, buspirone (> 2dd 10mg), chlordiazepoxide, 
diazepam, lorazepam, oxazepam.• Antidepressants (tricyclic or tetracyclic antidepressants): 
amitriptyline, nortriptyline, clomipramine, dosulepin, doxepin, 
imipramine, mianserin, maprotiline.• Antihistamines (1st generation antihistamines): clemastine, 
dexchlorpheniramine, promethazine, cyproheptadine, 
tripelennamine, hydroxyzine.
2) the patient is a prevalent user (2nd prescription or more); ensuring 
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that they experienced any possible side effects and resulting changes 
in reported behaviour.
3) the patient is 18 - 75 years of age, as it is known to be the age 
group that actively participates in driving and that takes medicines.
4) the patient actually drives a motorised vehicle in traffic (is to be 
asked at the time of dispensing).
When the patient met the four criteria mentioned above, he/she 
was asked to participate in the survey. A patient information letter, a paper questionnaire, and a stamped addressed return envelope were 
given to patients who agreed to participate in the study. Participants 
filled in the questionnaire at home and no information on the time for 
completion of the questionnaire was asked.
Non-respondents
No records on the non-respondents were kept. This methodological 
decision was made for a practical reason based on the extra administrative work that pharmacists would have to do, which would 
have drastically decreased the number of pharmacists enrolled in the 
study. As a consequence, it is not possible to correlate participants’ 
refusal patterns with time consumed filling in the questionnaire, age, 
gender, or any other socio-demographic variable.
QuestionnaireThe questionnaire was developed in English and, after consensus 
about the content, it was translated into the national language of 
each participant country (it was decided to use only a Dutch version 
for Belgium). Thereafter, reverse translation back into English was 
performed to ensure consistency between the translations.
The questionnaire consisted of 43 questions (39 closed questions 
and 4 open questions). The questions were grouped into 6 topics of 
interest covering general information (including information related 
with the inclusion criteria), participation in traffic, medicines in traffic, 
use of medicines, information about medicines, and attitude towards 
reported behaviour in traffic. By doing so, it was possible to collect data 
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on general items regarding the patient characteristics as a participant 
in traffic and about patients medicine use. Specific items to assess 
patient knowledge, attitude, and reported behaviour were gathered 
as well. The questionnaire was provided as an Additional file 1 to the 
journal and can be find online. While pre-testing the questionnaire, it 
was verified that it would take between 15 and 20 min to be completely 
filled in.
Dependent variable constructionKnowledgePatient knowledge regarding medicines that have a hazardous 
influence on driving ability was assessed with respect to the 
knowledge about the risk of having a traffic accident when driving 
under the influence of driving-impairing medicines. By using a 5-scale 
parameter (1 = totally disagree and 5 = totally agree), patients could 
agree (or disagree) with the following sentences: “the risk of having a 
road accident is smaller when you have just started  taking a driving-
impairing medicine compared  to long term treatment” or “the risk 
of having a road accident is similar when you take more of a driving-
impairing medicine than prescribed” or “the risk of having a road 
accident remains the same when you use several driving-impairing 
medicines at the same time.” The internal consistency of the scale was 
checked by means of the Cronbach alfa coefficient (0.64) and the sum 
score was calculated.
Reported behaviour
Patient reported behaviour was analysed in terms of a change in 
their frequency of driving (yes or no) or in terms of changing the use of 
driving-impairing medicines (yes or no). For each questions, the sum 
score of the different statements was calculated. Table 1 shows the 
answers participants provided, as well as the number of participants 
that answered each question.
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Statements on changes in frequency of driving N=305
Participants decided not to change frequency of driving because:• “I did not think the information was relevant to me”; 25• “It was not feasible for me to change my frequency of driving”; 41• “I did not notice any negative effects that influenced my driving 
ability”;
108• “I found information stating that the medicine does not have any 
driving-impairing effects”;
32• “other reasons”. 19
Participants decided to change frequency of driving because:• “I decided not to drive my motorised vehicle anymore”; 17• “I decided to drive/ride a motorised vehicle less often”; 26•   “I decided to drive/ride a motorised vehicle on less parts of the day” 
(e.g. only during day light);
19• “other reasons”. 18Statements on changes in the use of driving-impairing medicines N=296Participants decided not to change the use of driving-impairing medicines 
because:• “I did not think the information was relevant to me”; 78• “There was no alternative medicine available”; 62• “other reasons”. 46Participants decided to change the use of driving-impairing medicines 
because:• “I decided not to use the medicine”; 4• “I decided to use (most of) the medicine at night instead of during 
the day”;
62• “I decided to only use the medicine when I did not need to drive”; 24• “I asked for or I was prescribed a medicine causing less impairment 
of the ability to drive”. 8
•  “other reasons”. 12
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Independent variable construction
The following variables were included in the multi- and logistic- 
regression analysis:• country (Belgium, Germany, the Netherlands and Spain).• patient gender and age category (18-25; 26-34; 35-44; 45-54; 55-
64; 65-75. Age category 55-64 was used as reference as it is the age 
group that takes more medicines).• educational level (not completed primary school, completed 
primary school, lower vocational training, intermediate vocational 
training and university degree entered as dummy variables in the 
analysis. Intermediate vocational training was used as reference).• use of motorised vehicles (participants were considered as 
“frequent users” when they used their motorised vehicle “5-7 days 
per week” or “2-4 times per week”; “sporadic users” were the ones 
using a motorised vehicle “2-4 times per month” or “once a month 
or less” or “never.” The scale to assess frequency of driving was 
previously used in other studies in this same field [20]).• experienced side effects that can potentially impair driving ability 
such as sleepiness or drowsiness, decrease of alertness, problems 
concentrating, blurred vision and dizziness (yes/no).• information received from healthcare providers related with the 
influence of medicines on driving ability (yes/no).• information looked up by patients themselves, related to the 
influence of medicines on driving ability (yes/no).• whether patients read the Patient Information Leaflet (PIL) 
or not (yes/no). This question did not attempt to investigate 
comprehension. Instead, it was used to know whether patients used 
the PIL as source of information.• patient attitude - In order to assess patient attitudes towards 
the use of medicines that potentially impair patients while driving, 
a 5-scale parameter (1 = totally disagree and 5 = totally agree) 
was used to analyse patient’s opinion in relation with the use of impairing medicines and driving as well as the consequences of 
driving under the influence of impairing medicines. In both cases, 
the internal consistency of the scale was checked by means of the 
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Cronbach Alfa’s coefficient (0.85 and 0.69 respectively) and the sum 
score was calculated. To investigate patient attitude towards the use of impairing medicines, questions such as “when I drive while using 
driving-impairing medicines I endanger my personal safety” or 
“when I have been prescribed a driving-impairing medicine I choose 
not to use my car and choose other types of transportation” or “when 
I have been prescribed a driving-impairing medicine, I try to use my 
car as little as possible” were asked. Questions such as “the risk of 
driving under the influence of driving-impairing medicines is being 
exaggerated” were used to address patient attitude towards the 
consequences of driving under the influence of impairing medicines.
Data-analysisGuidelines were developed for all participating countries in order 
to ensure that data entry was conducted the same way. Additionally, 
all databases were checked for undefined values and extreme outliers. 
Data were analysed using SPSS 16.0 for Windows.
Descriptive analysis was used to report on respondent characteristics 
such as gender, age and educational level. Multiple linear regression 
analysis was used to identify patient knowledge about driving while 
using medicines that might impair driving ability, whereas reported 
behaviour was analysed by means of multiple logistic regression. 
Multiple linear regression analysis could not be used in both situations 
because this statistical test is only applicable when the dependent 
variable is continuous (which is the case with investigating participant 
knowledge). As behaviour is a dichotomous variable (yes/no), multiple logistical regression was applied in order to predict which factors 
influence patient behaviour. Knowledge and reported behaviour were 
considered as dependent variables of the equation. Independent 
variables, those that can theoretically influence the dependent 
variables, consisted of country, gender, age category, educational 
level, use of motorised vehicles, self-report of experienced side 
effects, information about medicines (either received from healthcare 
providers, looked up by patients themselves, or stated in the PIL), 
intake of medicines, knowledge itself, and, finally, attitudes towards 
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use of medicines and driving and towards driving under the influence. 
Prior to the construction of the models, univariate analysis of variance 
was conducted to verify whether or not there was an interaction effect 
between the consumption of medicines and age influencing patients’ 
knowledge. As no interaction effects between medicines’ consumption 
and age were found, it was decided not to include them, as variables, in 
the models. A p-value < 0.05 was considered as statistically significant.
Result
Data collected from 633 questionnaires (overall response rate of 
18%) were used, as shown in Table 2. Ninety-three questionnaires that 
were returned could not be used for the analysis for several reasons: 
questionnaires came back with no answers (54.6%); questionnaires 
belonging to patients that did not meet the inclusion criteria 
(36.4%); and questionnaires with no reference to the medicines that 
participants were taking and, simultaneously, patients stated not 
taking any medicine (3.3%).
Table 2 - Number of responses per country.
The relevant characteristics of the study population are summarised 
in Table 3. The majority of the respondents were female and almost 
50% of the total population was between 35 and 54 years old. 
Regarding educational level, there is a slightly higher number of 
patients with a university degree (27.6%) compared to other levels of 
education. Another relevant characteristic of participants is how often 
Country
Number of questionnaires sent out to pharmacies
Number of questionnaires returned Response rate (%)
Number of questionnaires used in the 
analysis (after screening the  inclusion criteria)Belgium 1000 144 14.4 136
Germany 880 162 18.4 146The Netherlands 830 150 18.1 136Spain 960 270 28.1 215Total 3670 726 17.75 (mean) 633
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they use motorised vehicles. Participants of our study were mainly 
frequent users of motorised vehicles, meaning they used their car on a 
daily or weekly basis.
Table 3 – Characteristics of respondents, per country. 
Country p-value*Belgium Germany Netherlands Spain
Total number of 
participants























26-34 11.8 10.3 5.9 20.5
35-44 18.4 24.7 26.5 27.0
45-54 32.4 21.2 23.5 22.8
55-64 15.4 19.2 27.2 14.0
65-75 14.7 22.6 13.2 8.4
Educational level










Completed primary education 14.7 32.2 5.9 19.1
Lower vocational training 22.8 32.2 19.1 16.7Intermediate vocational training 25.7 17.8 41.9 19.5
University 22.8 16.4 25.7 39.5










Frequent users 66.9 65.1 52.2 68.8
Use of driving-impairing medicines










Use of 2 medicines 28.1 25.0 23.5 21.2
Use of 3 medicines 5.9 4.2 4.5 2.8
Use of 4 medicines 0.7 0.0 0.8 0.9
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Country p-value*Belgium Germany Netherlands Spain










Yes 48.5 51.4 62.7 70.1
Knowledge b
About the risk of having a road accident when using medicines c 2.4 (1.0) 2.4 (1.1) 2.3 (1.0) 2.3 (0.9) 0.882
Attitude bUse of medicines and driving c 2.3 (0.9) 2.8 (1.4) 1.9 (0.8) 2.1 (1.1) <0.001*Consequences of driving 
under the influence of impairing medicines d 3.5 (0.9) 4.0 (0.9) 3.4 (0.9) 3.6 (0.8) <0.001*










Yes 38.1 28.1 19.0 25.8










Yes 42.1 44.6 18.7 43.2a The percentage refers to within the country.
b Knowledge and attitude results presented in terms of mean (standard deviation). c 5-item scale (1=totally disagree; 2=disagree; 3=no opinion; 4=agree; 5=totally agree). 
Totally disagree means that the patient does not perceive any risk of driving under the 
influence of medicines. d 5-item scale (1=totally disagree; 2=disagree; 3=no opinion; 4=agree; 5=totally agree). 
Totally disagree means that patients have a negative opinion on the influence of medicines 
on driving performance and about the consequences of that behaviour.  
* p-value < 0.05 considered to be statistically significant. P-value was calculated by means of 
the Chi-square test. Concerning self-reported medication that patients were taking, within countries, antidepressants were the most stated medicines 
(42.0%; n = 266) followed by anti-allergics (36.2%; n = 229), sedatives 
(27.5%; n = 174), and tranquilisers (26.5%; n = 168). Figure 2 shows 
the percentage of self-reported use of medicines. Antidepressants are 
the most frequently used group of medicines in each country except in Spain, where there is a higher percentage of anti-allergics and where there is a homogenous prevalence of consumption of sedatives, 
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tranquilisers, and antidepressants. In the Netherlands, the prevalence 
of use of anti-allergics is the lowest. Only in Belgium is the trend of 
use of medicines the same as self-reported medication. An average 
of medication use in the 4 countries shows that patients took 1.32 
medicines. 71.1% (n = 443) of the patients stated that they were taking 
only one medicine category at a time, and 0.6% (n = 4) of the patients 
combined all four medicine categories. 
Figure 2 - Self-reported use of medicines by respondents per country (percentage within 
country).
With regard to side effects, 40.4% (n = 252, Table 3) of patients 
stated that they did not experience any type of adverse effect. Only 
in Germany the percentage of patients who experienced side effects 
was higher than those who did not. From those who experienced 
side effects, “sleepiness” (24.1%) was most often stated, followed by 
“decrease in alertness” (12.7%), “problems concentrating” (10.6%), 
“dizziness” (5.8%), and “blurred vision” (4.2%). For all studied 
medicines, relevant side-effects were all listed in the PIL, which is 
accessible to patients and was read entirely by 55.8% (n = 348) of the 
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respondents; 30.6% (n = 191) of patients read only parts of the PIL. 
In Belgium, the percentage of patients stating they were not 
informed was higher, though not significantly than any other country. 
63.6% (n = 84) of Belgian participants did not receive this information. 
Considering the four countries together, 62.5% (n = 349) of the patients 
received information from healthcare providers.
Patient knowledge about the risk of having a road accident was similarly 
low in all countries (Belgium and Germany 2.4 and the Netherlands and 
Spain 2.3 on average on a 5-item scale, where 5 is the highest score). 
Regarding reported behaviour (Table 3), 26.2% of patients were in 
favour of a change in driving frequency, while 37.2% were in favour of 
a change in the use of driving-impairing medicines. In terms of attitude towards the use of medicines while driving, patients disagreed with 
the statements that were presented in Belgium (average of 2.3), in the 
Netherlands (average of 1.9) and in Spain (average of 2.1); in Germany, 
patients did not have an opinion (average of 2.8). With respect to 
the attitudes towards driving under the influence of medicines, only 
German patients agreed (average of 4.0) with the fact that the risk of 
driving under the influence of medicines was exaggerated.
Knowledge
Multiple linear regression analysis was used to assess factors 
influencing patient knowledge (Table 4) towards driving-impairing 
medicines. As previously mentioned, knowledge was considered in 
terms of risk of having a road accident. From Table 4, it is clear that 
independent variables explain 10.6% (adjusted R2) of the differences 
found between patients. The age of the patient is correlated with 
the knowledge about the risk of being involved in a traffic accident: 
the younger the patient the greater the knowledge about the risk. Regarding educational level, knowledge is higher among patients with 
an academic degree. Information patients received from healthcare 
providers, looked-up by patients themselves, or the information stated 
in the PIL did not appear to contribute to patient knowledge. The use 
of motorised vehicles had no effect on patient knowledge. Self-report 
of experience of side effects was also not significant.
46 | Chapter 2
Table 4 - Predictors for patient knowledge on risks of having a road accident: multiple linear 
regression analysis.






(Germany used as reference)
-Belgium 0.02 (0.798)The Netherlands 0.00 (0.982)Spain -0.04 (0.529)
Gender 
(0 = male; 1 = female)
-0.03 (0.487)
Age categories








(Intermediate vocational training used as reference)
-
Not completed primary school -0.14 (0.002)*
Completed primary school -0.03 (0.621)
Lower vocational training -0.05 (0.297)
University 0.18 (<0.001)*
Use of motorised vehicles
(0 = sporadic users; 1 = frequent users)
-0.04 (0.330)
Experienced side effects
(0 = no side effects; 1 = side effects)
0.05 (0.283)
Information received from healthcare providers 
(0 = no information was provided; 1 = information was provided) 0.00 (0.970)
Information looked for patients
(0 = no information was looked for; 1 = information was 
looked for by patients)
0.00 (0.927)
Information from the PIL
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Reported behaviourMultiple logistic regression was performed to assess the impact 
of patient reported behaviour with respect to changes in frequency 
of driving and the use of driving-impairing medicines (Table 5). The 
independent variables explain 34.8% and 27.3% (adjusted R2) of the 
variance for changes in driving frequency and in the use of driving-
impairing medicines, respectively. Patients were more likely to change 
their frequency of driving when they are between 26 and 34 years 
old, when they report side effects, and when they have a negative 
attitude towards driving under the influence of impairing medicines. 
In contrast, patients who drive frequently and those who take anti-
allergics tend to change their driving frequency less often compared to 
users of tranquilisers (Table 5). Concerning the model that takes into account changes in the use of driving-impairing medicines, patients 
who reported having experienced side effects and those who have 
knowledge about having a traffic accident appeared to change the use of driving-impairing medicines more often than those who came from 
the Netherlands or those who take antidepressants (Table 5).
Table 5 - Changes in driving frequency and in use of driving-impairing medicines: multiple 
logistic regression analysis.
Change in driving 
frequency (n=305)





95% CI for OR Odds-
ratio
95% CI for ORlower upper lower upper
Country 
(Germany used as reference)Belgium 2.00 0.53 6.41 0.79 0.29 2.19The Netherlands 0.69 0.21 2.26 0.24* 0.08 0.69Spain 0.63 0.23 1.72 0.46 0.20 1.07Gender
(0 = male; 1 = female)
1.70 0.97 3.00 1.18 0.77 1.80
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Change in driving 
frequency (n=305)
Change in the use of driving-impairing 
medicines (n=296)Age categories
(category 55-64 used as reference)
18-25 4.87 0.93 25.49 0.81 0.18 3.52
26-34 4.17* 1.14 15.25 1.78 0.59 5.42
35-44 2.08 0.71 6.15 1.72 0.68 4.31
45-54 2.75 0.97 7.84 1.79 0.71 4.54
65-75 1.62 0.48 5.84 0.60 0.19 1.95Educational level
(Intermediate vocational training used as reference)
Not completed primary school 1.14 0.17 7.65 0.76 0.14 4.15
Completed primary school 2.78 0.95 8.11 2.13 0.81 5.61
Lower vocational training 2.20 0.82 5.90 0.79 0.33 1.88
University 1.46 0.57 3.71 0.98 0.43 2.20Use of motorised vehicles
(0 = sporadic users; 1 = frequent users) 0.35* 0.18 0.69 0.58 0.31 1.10
Experienced side effects
(0 = no side effects; 1 = side effects)
3.18* 1.40 7.21 3.39* 1.68 6.82Medicines
(Tranquilisers used as reference)Sedatives 0.77 0.36 1.62 1.07 0.55 2.08Antidepressants 0.84 0.42 1.68 0.24* 0.12 0.50Anti-allergics 0.24* 0.10 0.58 0.82 0.40 1.66
Knowledge about the risk of having a road accident
(0 = totally disagree; 5 = totally agree) 0.932 0.65 1.33 1.49* 1.09 2.03AttitudeUse of medicines and driving
(0 = totally disagree; 5 = totally agree) 0.88 0.64 1.20 1.08 0.82 1.43
Driving under the influence of 
driving-impairing medicines (0 = 
totally disagree; 5 = totally agree)
2.23* 1.43 3.50 1.29 0.91 1.85
Adjusted R2 0.348 0.273
p-value (model) < 0.001* < 0.001*
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Discussion
The present survey showed that socio-demographic variables, such as 
age and educational level, influenced patient knowledge about causes 
of road accidents: younger and higher educated patients had better 
knowledge. Information that might have been provided to or accessed 
by patients contributed to patient knowledge regarding the risk of 
having a traffic accident. In contrast, patient reported behaviour did 
not appear to be influenced by any of the socio-demographic variables 
considered in the analysis. Instead, frequency of driving changed 
due to experience of side effects and attitudes towards driving under 
the influence of driving-impairing medicines. The use of motorised 
vehicles and intake of anti-allergic medicines had less influence on 
the frequency of driving. Regarding changes  in the use of driving-impairing medicines, our model suggested that such changes were 
mainly influenced in a positive manner (meaning a change in reported 
behaviour) by experienced side effects and knowledge about the risk of 
having a road accident and negatively influenced  by country (specifically 
the Netherlands) and by the use of anti-depressant medicines.
Among the 4 participating countries, self-reported medication use 
indicated that patients took, on average, 1.3 medicines that are known 
to be driving-impairing. For antihistamines [21] and antidepressants 
[22], a dose-dependent negative effect on driving was found in road-side 
tests previously conducted in the Netherlands. Nevertheless, patients 
still drive their car (or any other motorised vehicle) on a daily basis, 
which could be explained by the fact that they no longer experience 
side-effects. This is supported by previous research showing that an 
increased number of patients using psychotropic medicines regularly 
do not refrain from driving their car [23].
Sleepiness, decrease in alertness, problems concentrating, dizziness 
or blurred vision were reported at least one time during treatment by 
almost 60% of the participants. These side effects are presumed to be 
potentially dangerous for driving ability [15]. However, experiencing 
side effects does not seem to be enough to make patients quit driving. 
At best, experiencing side effects will change patients’ frequency of 
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driving. This could indicate that patients tend to underestimate the risk 
that is associated with driving under the influence of medicines [15] 
and that their knowledge about medicines’ side effects is limited [14] 
or that the side effects occurred at other times than when they were 
driving. On the other hand, a fair percentage (40%) of patients did not 
report any side effects. This could be explained by the long term use 
of medicines (a requirement to be included in the study; see criteria 
inclusion section), which may result in the development of a tolerance 
to the side effects [23], or by the relationship between medicine use 
and side effects, for example in Spain 70.1% of patients stated having 
experienced side effects, which can be related with the high prevalence 
(40.9%) of use of first generation anti-allergic medicines.
KnowledgeMuch of patients’ knowledge regarding medicines and side effects, in general, comes from communication with their general practitioner 
[14, 15]. Similar to the existing literature, the present study shows 
that the majority of the participants received information about the 
influence of their medicines on their ability to drive from healthcare 
providers (both general practitioners and community pharmacists). 
The only exception was seen in Belgium, where more than 60% of the 
participants stated not having been informed about medicines and 
driving. Several studies [24, 25] concluded that the communications 
between clinicians and patients about the potential risk of medicine 
is often incomplete. If so, it is crucial to increase physician awareness 
of potentially driving-impairing medicines in order to improve the 
communication with patients who could benefit from better and more 
complete counselling.The information that patients received from healthcare providers, 
or that patients looked up themselves, did not appear to be effective 
enough to influence patient knowledge regarding the risk of being 
involved in a traffic accident. This is in line with previous research 
where it is shown that patients who are at a greater risk of being 
involved in a traffic accident due to medicines do not necessarily have 
more knowledge of increased risk [15]. Age and educational level 
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appear to be the only two variables capable of influencing patient 
knowledge about the risk of having a road accident. Younger patients and patients with a higher educational level seem to have greater 
health literacy (knowledge) and, as a consequence, bigger awareness of the danger of using medicines and driving than older patients 
and those with lower educational level. The theoretical model that 
was developed (Figure 1) is supported by the findings concerning 
knowledge, as socio-demographic characteristics had both a positive 
and negative impact on patient knowledge.
Reported behaviour
Age is the variable with a greater positive impact in the model: 
participants between 26 and 34 years-old are the ones more likely 
to change their driving behaviour. Patient self-report of side effects 
also correlates positively with changes in frequency of driving; this 
means that patients who felt side effects are more likely to change 
their driving behaviour. The same holds true for attitude towards 
driving under the influence of medicines. This variable positively 
influences the model, meaning that patients with a stronger attitude 
towards the consequences of driving under the influence are the ones 
changing the frequency of driving. Conversely, the use of motorised 
vehicles influences patient reported behaviour negatively, i.e. the more 
patients drive the less they change their driving behaviour in terms of 
frequency of driving. The use of anti-allergic medicines also correlates 
negatively with the model, making patients taking these medicines less 
prone to change their frequency of driving. This could be due to the 
fact that patients might not be aware that anti-allergic medication has 
a negative effect on driving ability or that side-effects occur when the 
patient is not driving. Another explanation for this fact could be due 
to the less sedative effect of the 2nd generation antihistamines, and, 
therefore, patients do not recognize any signs of impairment on their 
psychomotor abilities and, as a consequence, patients feel safe to drive.
Living in the Netherlands, experiencing side effects, using 
antidepressants, and knowledge about the risk of having a traffic 
accident are the factors that significantly account for changes in 
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the use of medicines. Patients living in the Netherlands and using 
antidepressant medicines change the use of medicines less often. This 
could be due to the fact that antidepressants are well known to affect 
driving. As a consequence, healthcare providers, such as physicians 
or pharmacists, can immediately provide patients with preventive 
measures (for example, taking the medicines at night), which might 
reduce the negative effects of the medicines on driving ability resulting 
in a less need to change driving frequency.
In contrast, self-report of experiencing side effects and knowledge 
about risk of being involved in a road accident contribute positively to 
change in the use of driving-impairing medicines. This means the more 
side effects a patient experiences and the greater their knowledge 
about the side effect, the bigger the chances that they will change the 
intake of their medicines.
Similarly to knowledge, the findings on predictors for patients’ 
reported behaviour support the theoretical model developed. 
Reported behaviour is not always influenced by the same range of 
variables, meaning that behavioural actions result from a combination 
of different factors that ultimately lead to an action.
Limitations and future perspectives
The results of this study should be considered in the light of several 
strengths and limitations. The major limitation of this study is the 
low response-rate, in all 4 participating countries. As a consequence, 
results should be considered with care and conclusions should be 
drawn with caution, as the results might not be representative of the 
whole driving population that takes driving-impairing medicines. 
However, the actual number of questionnaires that was handed out 
to patients was not known but the authors believe it was smaller than 
3607, meaning that the actual response rate could be higher than 18%. 
There could be, as well, a potential selection bias. To ensure that only data referring to patients who met the inclusion criteria were part 
of the analysis, the survey included questions covering the inclusion 
criteria. Nevertheless, the authors are confident that it is possible to 
draw relevant conclusions.
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Main results were achieved based on patient self-report of 
medicine use, and knowledge, attitude and behaviour related with 
medicines and driving. Self-report is a widely and valuable method 
in social sciences research [26]. Therefore, the authors trust that the 
information stated by patients concerning consumption of medicines 
is in line with pharmacy dispensing records [15] and the same stands 
true for self-report behaviour that is known to be an accurate proxy 
for observed behaviour [27]. With the present study, it was possible to 
determine which variables and to what extent they influence patient 
knowledge and reported behaviour towards medicines that influence 
driving ability in 4 European countries. In addition, given the fact that 
especially the explained variance for knowledge is quite low (10.6%), 
other variables, such as health literacy, history of car accidents, 
or ethnicity may play an important role in patient knowledge and 
reported behaviour and should be considered in further research.
To our knowledge, only one American study [15] addressed the 
problem of knowledge about medicines that can impair driving. 
However, the study conducted by MacLennan et al. was very much oriented to the knowledge that older adults who face serious driving 
safety and mobility issues have. The present study attempts to 
reflect knowledge and reported behaviour of a much broader and 
heterogeneous population, which makes it relevant for the field of 
medicines and driving and traffic safety. By accessing predictors for 
patient knowledge and reported behaviour, it is possible to develop 
more effective campaigns that point out exactly what is relevant for 
the patients, i.e. campaigns tailored to the patients’ needs. At the same 
time, it is possible to give positive feedback to patients who already 
possess good knowledge (and therefore do not need to change) and 
also to help patients’ with making decisions of whether they should 
drive their car or not while taking driving-impairing medicines.
Future research should not only focus on information campaigns for 
patients but also for healthcare providers. Interventions that might 
raise awareness about the topic and might improve communication 
with patients about the risk of driving under the influence of 
psychotropic medicines are important topics for future research, as 
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well. As current information does not effectively contribute to patient 
knowledge, the authors believe there is the need for more effective ways 
to communicate information to patients, which might be capable of increasing patient knowledge and changing patient attitudes towards 
driving under the influence of medicines. New strategies to enhance 
communication could make use of pictograms on the box of medicines 
that are known to impair driving fitness. Well designed pictograms are known to improve comprehension and recall of information and can 
be used to trigger the discussion between healthcare providers and 
patients. This could potentially contribute to increasing the patient’s 
knowledge about the use of medicines that might affect driving fitness.
Finally, research can also contribute to develop, implement, and evaluate guidelines and other information materials and/or tools 
that aim to provide decision support to physicians and pharmacists 
in prescribing and dispensing potentially impairing medicines. 
Additionally, the information provided to patients during the 
consultation can be improved if healthcare providers know how to advise their patients, which leads to the conclusion that the advice to 
the patient should be part of the developed information materials as 
well. Without a doubt, this is also a task for implementers or policy 
makers.
Conclusions
Patient knowledge regarding driving under the influence of 
medicines does not predict changes in driving behaviour. Rather, a 
negative attitude towards driving under the influence of medicines is 
a better predictor of changes in patients’ driving behaviour.
Patients’ knowledge is influenced by socio-demographic parameters 
such as age and educational level. Behavioural changes can be 
explained both in terms of changes in frequency of driving and in 
terms of changes in the use of driving-impairing medicines. Patients 
who experienced side effects and who have negative attitudes towards 
driving under the influence of impairing medicines are more prone to 
change their driving behaviour (positive influence in behaviour) than 
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those who use motor vehicles on a daily basis or those who use anti-
allergic medicines. Patients who experienced side effects and who have a good knowledge of risks of having road accidents seem to change the 
use of driving-impairing medicines more easily than those who come 
from the Netherlands or take antidepressant medicines.
Future research should focus on more effective ways to increase patient knowledge and to help patients’ decision making towards 
driving behaviour and medication intake. This could be done by implementing new strategies of communication in order to prevent 
patients from driving under the influence of medicines. Special attention 
should be paid to healthcare providers as they are the main source of 
information for patients. By increasing healthcare provider awareness 
about medicines and driving, we believe that patient knowledge will 
also increase and as a consequence could be responsible for a decrease 
in patients’ driving frequency or a stabilisation in patient behaviour 
regarding changes in the use of medicines.
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Abstract
Aims: To illustrate (i) the criteria and the development of the DRUID 
categorization system, (ii) the number of medicines that have currently 
been categorized, (iii) the added value of the DRUID categorization 
system and (iv) the next steps in the implementation of the DRUID 
system.
Methods: The development of the DRUID categorization system 
was based on several criteria. The following steps were considered: 
(i) conditions of use of the medicine, (ii) pharmacodynamic and 
pharmacokinetic data, (iii) pharmacovigilance data, including 
prevalence of undesirable effects, (iv) experimental and epidemiological 
data, (v) additional data derived from the patient information leaflet, 
existing categorization systems and (vi) final categorization. DRUID 
proposed four tiered categories for medicines and driving.
Results: In total, 3054 medicines were reviewed and over 1541 
medicines were categorized (the rest were no longer on the EU market). 
Nearly half of the 1541 medicines were categorized 0 (no or negligible 
influence on fitness to drive), about 26% were placed in category 1 
(minor influence on fitness to drive) and 17% were categorized as 2 or 
3 (moderate or severe influence on fitness to drive).
Conclusions: The current DRUID categorization system established 
and defined standardized and harmonized criteria to categorize 
commonly used medications, based on their influence on fitness to drive. 
Further efforts are needed to implement the DRUID categorization 
system at a European level and further activities should be undertaken 
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in order to reinforce the awareness of health care professionals and 
patients on the effects of medicines on fitness to drive.
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IntroductionDriving a motor vehicle is a multifaceted task and it requires 
appropriate cognitive and psychomotor skills (e.g. alertness, 
concentration, reaction time, visual acuity) [1–3]. Medication can 
adversely affect these driving-related skills, and, consequently, be a 
hazard to traffic safety [4, 5].
The European Council Directive 83/570/EEC of October 1983 
established that the summary of product characteristics (SmPC) has 
to contain information on medicines‘ “effects on the ability to drive 
and to use machines” [6]. In October 1991 the European Committee 
for Medicinal Products for Human Use (CHMP) provided a Note for 
Guidance for the SmPC in which it was stated that section 4.7 of 
medications registered from 1 January 1992 had to indicate, on the 
basis of the pharmacodynamic profile, reported adverse drug reactions 
(ADRs) and/or impairment of driving performance or performance 
related to driving based on three different levels of impairment with 
respect to the ability to drive and/or operate machines [7, 8]. However, 
this rule has never been implemented [9].
In September 2009, a new SmPC guideline was issued, which 
established that “on the basis of the pharmacodynamic and 
pharmacokinetic profile, reported adverse reactions and/or specific studies in a relevant target population addressing the performance 
related to driving and road safety or using machines, specify whether 
the medicinal product has: (i) no or negligible influence, (ii) minor 
influence, (iii) moderate influence or (iv) major influence on these 
abilities” [10]. These new guidelines were partly based on the proposal 
sent to the European Medicines Agency (EMA) by DRUID Work Package 
(WP) 4 partners during the consultation phase for the revision of the 
SmPC guidelines, in March 2008.
Despite the above-mentioned regulations, at this moment, a 
European categorization system has not yet been established, and 
warning systems for medications that potentially impair driving have 
mainly been developed and/or implemented at national levels [8, 11].
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Existing categorization systems on medicines and driving
A review of the existing classification/categorization and labelling 
systems for medicines and driving was performed in 2008 and 15 
different approaches were identified [12]. The categorization/labelling 
systems differed significantly and were not standardized, making 
them difficult to understand. In most cases [13–17], the categorization 
systems were developed by different and unrelated bodies, societies or researchers and were, in general, aimed at improving the prescription 
and dispensing of medicines to the patients and drivers. The identified 
categorization systems often included a limited number of medicines 
belonging to a few different therapeutic groups (e.g. antihistamines, 
anxiolytics, etc) and were not legally binding. However, the review 
also identified a couple categorization/labelling systems that were 
developed by regulatory bodies, included the use of pictograms and 
were legally binding [18, 19].
In 1973, the Netherlands became the first country to introduce a list 
of medications that can impair driving abilities. Besides the list, the use 
of a yellow warning sticker on medication boxes was established and 
implemented [20]. In 1981, Denmark, Finland, Iceland, Norway and 
Sweden adopted a warning label. The label consisted of a red triangle 
printed on packages of “especially dangerous” medications, and it is 
currently still in use in Denmark, Finland, and Norway. Most recently, 
France [18] and Spain [19] developed a categorization/labelling of all 
available medicines using technical interdisciplinary groups formed 
from their respective national medicines regulatory agency [21, 22] 
The introduction of pictograms (three-tier labelling system in France 
and two-tier in Spain) to be added on the packages of certain medicines 
became legally binding in both countries.It is important to point out that although different categorization 
systems are currently available across Europe, the criteria for the 
establishment of a categorization system for potentially impairing 
medications has neither been clearly described nor published nor 
been officially adopted at European level [12].
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The DRUID project and its categorization system on medicines and driving
The Driving under the Influence of Drugs, Alcohol and Medicines 
(DRUID) project is an integrated project funded by the European 
Commission. The main aim of DRUID is to give scientific support to 
European Union (EU) transport policy by establishing guidelines and 
measures that combat impaired driving [23].
The DRUID WP4 aims to provide the basis and the methodology 
for the development of a European classification/labelling system 
for medications with respect to their impact on fitness to drive. 
Furthermore, it also focuses on the development of a classification of 
relevant therapeutic groups that are currently on the market in Europe 
as well as new medications approved by the European Medicines 
Agency (EMA) in the years 2007–2009 [23].
Aims of the study
This paper illustrates: (i) the criteria and the development of the 
DRUID categorization system, (ii) the number of medicines that 
have currently been categorized and the distribution of the DRUID 
categories across the Anatomical Therapeutic Chemical (ATC) index, 
(iii) the importance of this system, its implications for health care 
professionals (HCPs) and patients, and its strengths and limitations 
and (iv) the next steps in the implementation of the DRUID system and 
some general recommendations.
Methods
The development of the DRUID categorization system was based on 
the criteria that were established by a group of experts in the field of 
medicines and driving, involved in the DRUID WP4, and based on their 
consensus [24].
The four DRUID categories on medicines and driving
In 2006, the DRUID group established and agreed that, according to 
its influence on fitness to drive, a medicine could be categorized as 
follows (Figure 1):
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• category 0 (no or negligible influence on fitness to drive),• category 1 (minor influence on fitness to drive),• category 2 (moderate influence on fitness to drive),• category 3 (severe influence on fitness to drive).
The proposed categorization is in line with the recently approved 
SmPC guidelines, which were adopted in September 2009 by the 
EMA [10]. Furthermore, the DRUID experts decided to develop, for 
each category, practical information to be used by HCPs for patient 
counselling purposes as well as simple warning labels that could be 
easily understood by patients (labelling) (Figure 1).
Figure 1 – DRUID categorization system for medicines and driving. 
The DRUID categorization of medicines and driving
The ATC classification list [25] was used as a starting point for the 
selection of the relevant groups of medicines to be categorized. The 
aim was to categorize all available medicines on the European Union 
market for each selected ATC group.
Chapter 3 | 67
Figure 2 shows the process that was followed in order to identify 
all those medications that are currently avail- able on the EU market. 
In general, a medicine was considered available on the EU market if it was commercialized in at least two of the following European 
countries: Belgium, France, Germany, Greece, the Netherlands, Spain, 
United Kingdom and Ireland. If the above-mentioned criterion was not 
fulfilled, the medication was not included in the categorization process.
Figure 2 – Identification process of medicines available on the EU market.
After a meeting with the French Health Products Safety Agency 
(AFSSAPS) experts in categorizing medications affecting driving 
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performance, the DRUID WP4 group decided to adopt a procedure 
similar to the one used in France and more specifically to evaluate the following information and data:
1) conditions of use of the medicine in the EU market
2) pharmacodynamic and pharmacokinetic data
3) pharmacovigilance data (including prevalence of undesirable effects reported in the SmPC)
4) experimental and epidemiological data
5) additional data derived from the patient information leaflet (PIL) 
and existing categorization systems and information from other sources
6) synthesis and final categorization.
Figures 3 and 4 summarize the methodology that was followed in 
order to assign a category to a selected medicine.
Figure 3 – Methodology for the DRUID categorization system for medicines and driving. 
The conditions of use of the medicine, pharmacodynamic, 
pharmacokinetic and pharmacovigilance data (including prevalence of 
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undesirable effects) were derived from the SmPC [10], whereas point 
4 (experimental and epidemiological data) was based on a scientific 
literature search.
The SmPC and PIL of the selected medications were found online, 
in one of the following websites: Medicines and Healthcare products 
Regulatory Agency (MHRA) [26], Electronic Medicines Compendium 
(eMC) [27], or Irish Medicines Board (IMB) [28], or retrieved from 
national medicines regulatory agencies as needed. In case of recently 
approved active substances, the SmPC was found on the EMA website 
[29]. The selection of the above mentioned medicines regulatory affairs 
agencies was simply based on the fact that the required information 
had to be available either in English or in a language that could be fully 
understood by DRUID WP4 partners.
Specific sections of the SmPC and PIL were used to retrieve details 
on the active substance presentations and strength, indications, 
posology, route of administration (step 1), pharmacodynamic and 
pharmacokinetic profile (step 2), effects on the ability to drive and 
use machines (step 5) and undesirable effects related to driving and 
operating machines (step 3).
With respect to the undesirable effects, their occurrence was 
considered as a key point, especially if experimental and epidemiological 
data were lacking or limited. This type of information was found in 
section 4.8 of the SmPC and, when not available, was retrieved from 
the available literature.
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Figure 4 - Flowchart representing the methodology that was followed during the DRUID 
categorization process. Legend: SmPC, Summary of Product Characteristics; PIL, Patient 
Information Leaflet; EMA, European Medicines Agency; MHRA, Medicines and Healthcare 
products Regulatory Agency; eMC, Electronic Medicines Compendium; IMB, Irish Medicines Board
Generally speaking, only those adverse reactions that could affect the 
ability to drive and that were reported as common (>1/100, <1/10) or 
very common (>1/10) were considered to be relevant, as in accordance 
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with the most recent EMA categorization on frequency of undesirable 
effects, side effects or adverse reactions. In cases of rare or very rare 
undesirable effects, or if certain severely impairing effects occur, for 
example sudden sleep attacks, the DRUID partners recommended that 
this should be mentioned in the PIL.
Table 1 reports the criteria used for assigning a medicine to a specific 
category whenever experimental or epidemiological data were lacking 
or limited.
Table 1 - Relationship of the undesirable effects category in the SmPC to the DRUID categorisation 
system.
Table 2 lists the undesirable effects that could impair the ability to drive, and, therefore, were taken into account in the categorization 
process.
Declaration of undesirable effects that can 
potentially impair the fitness to drive safely
DRUID Category
Very common (> 1/10) Category 2 or 3
Common (>1/100, <1/10) Category 1
Rare (>1/10,000, <1/1,000) or very rare (<1/10,000) Category 0
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Table 2 - List of undesirable effects that can impair driving ability that were considered for the 
categorisation of active substances based on their level of driving impairment.
Data sources for the scientific literature evaluation included the 
electronic databases Medline, Science Direct and PsycINFO. The search 
was performed by using these combinations of keywords: “active 
substance name and psychomotor performance”, “active substance 
name and automobile driving” and “active substance name and traffic 
accidents”. The final data selection was limited to full text articles 
published in English and other languages that included references to 
side effects, experimental and pharmacoepidemiological studies and 
case reports on each active substance to be categorized and its possible 
System organ class Selection of side effects that can impair the ability to drive 
safely
Nervous system disorders
Somnolence, dizziness, drowsinessConfusion - cognitive disorder- disorientation
Involuntary movement disorders: ataxia, tremor, parkinsonism, 
acute dystonic (dyskinesia) and dyskinetic reactions (dystonia)Convulsions - seizures
Psychiatric disorders
Perception disturbances (hallucination, visual hallucination, 
auditory hallucination, illusion)
Psychotic reactions and  psychotic disorder (including paranoia 
psychosis)
[Other: emotional lability, mood swings, aggression, 
nervousness, irritability, personality disorders, thinking 
abnormal, abnormal behaviour, euphoric mood, restlessness 
(emotional state of excitement), depersonalisation] 
Eye disorders
Diplopia or double visionBlurred vision Accommodation disorders
Visual acuity reduced
Photophobia
[Other: visual field defect, peripheral vision loss, altered visual 
depth perception, oculogyric crisis]
Ear and Labyrinth disorders VertigoHearing loss
[Other: buzzing, tinnitus]
Metabolism and nutrition disorders HypoglycaemiaVascular disorders Hypotension
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driving impairment. No restrictions concerning the publication year 
were applied.
Additional steps consisted of reviewing section 4.7 of the SmPC 
“Effects on ability to drive and use machines” and the PIL section 
on “Driving and using machines” as well as reviewing the previous 
categorization (if available) of the medicine in Belgium, France, the Netherlands, Spain and the International Council on Alcohol, Drugs 
and Traffic Safety (ICADTS) list.
In the cases of severely impairing medicines, recently approved 
medications, or medicines belonging to the ATC groups N and R06, all the collected data were compiled in fact sheets with a standardized 
lay-out, which were used during the active substance evaluation 
procedure and the approval of its final category.
After evaluating all the available data, a provisional category was 
assigned to each active substance. The provisional category was 
proposed and discussed during WP4 meetings, where a final and 
definitive category was assigned and approved by all WP4 partners.
It is important to note that the DRUID methodology on the 
categorization of medicines affecting driving fitness allows not only to 
categorize an active substance but also to revise a previously assigned 
category, in cases where new evidence emerges, by following the same 
5 step approach (Figure 4).
Medicines to be categorizedThe following ATC groups were considered in the categorization process:
A – Alimentary tract and metabolism
B – Blood and blood forming organs
C – Cardiovascular system
D – Dermatologicals
M – Musculoskeletal system
N – Nervous system
R – Respiratory system
S – Sensory organs
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Results
Three thousand fifty-four medicines were considered for inclusion 
into the categorization process. Of these 3054 medicines, 1513 were 
not categorized because they were not available on the EU market.
The distribution of the 1541 categorized medicines (see 
supplementary data) was as follows (Figure 5): Category 0 50.3%, 
Category 1 26.0%, Category 2 11.2%, Category 3 5.8%, Multiple 
categories 4.4% and Depending on the medicine in combination 2.3%. 
This figure shows that the majority of medications belong to either 
category 0 or category 1 (Figure 5).
Figure 5 - Distribution of the 1541 categorised medicines within the different DRUID categories.
It is important to note that the term “multiple categories” refers to 
the fact that a certain medication could be included in more than one 
category. There could be several reasons for this, such as different 
routes of administration of the same active substances (e.g. topical, 
oral, parenteral, etc), different pharmaceutical formulations (e.g. 
aqueous vehicle, cream, drops or ointment, etc.), different dosages 
administered, etc.
With respect to the terminology “depending on medicines in 
combination”, it is relevant to observe that this approach was used when 
the categorization depended on the combination of the medication 
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under evaluation with another active substance. In these cases, since 
the ATC classification [18] often did not report the medicine used in 
combination, it was decided not to use a final category but to follow 
the above-mentioned approach.
Table 3 gives an overview of the distribution of the medicines in each 
category, stratified by ATC group. It is apparent from this table that 
the N group contains the highest number of category 3 medications. 
A detailed description of the category distribution within the N group 
is depicted in Table 4. The N05 sub-group shows the highest number 
of category 3 medicines, followed by the N01 sub-group. The N05 sub-
group also contains the highest number of medications assigned to 
more than one category.














A - ALIMENTARY TRACT AND 
METABOLISM
243 234 69 8 1 4 4 563
B - BLOOD AND BLOOD 
FORMING ORGANS
86 135 1 1 2 225
C - CARDIOVASCULAR 
SYSTEM
246 90 200 11 1 548
D - DERMATOLOGICALS 156 192 1 4 353
M - MUSCULO-
SKELETAL SYSTEM
88 22 44 28 15 197
N - NERVOUS SYSTEM 346 9 30 86 53 36 560
R - RESPIRATORY 
SYSTEM
195 62 24 32 10 5 14 342
S - SENSORY ORGANS 153 31 31 6 11 18 16 266
TOTAL 1513 775 400 172 90 68 36 3054
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Table 4 – Number of medicines from the ATC group, N- NERVOUS SYSTEM MEDICINES, 















N01 ANESTHETICS 31 3 3 1 12 10 60
N01A  Anesthetics, general 20 11 1 32
N01B Anesthetics, local 11 3 3 1 1 9 28
N02 ANALGESICS 93 2 7 10 3 7 122
N02A Opioids 31 2 7 40
N02B Other analgesics and 
antipyretics
52 2 6 1 1 62
N02C Antimigraine preparations 10 1 9 20
N03 ANTIEPILEPTICS 23 14 4 2 43
N03A Antiepileptics 23 14 4 2 43
N04 ANTIPARKINSON 16 3 16 1 36
N04A  Anticholinergic agents 10 4 1 15
N04B Dopaminergic agents 6 3 12 21
N05 PSYCHOLEPTICS 107 4 16 26 12 165
N05A Antipsychotics 31 13 8 9 65
N05B Anxiolytics 23 1 3 7 1 35
N05C Hypnotics and sedatives 53 3 11 2 69
N06 PSYCHOANALEPTICS 62 2 10 20 7 1 102
N06A Antidepressant 37 1 7 12 7 1 65
N06B Psychostimulants, 
agents used for ADHD and Nootropics 22 3 4 29
N06C Psycholeptics 
and psychonaleptics in 
combination
2 2
N06D Anti-dementia drugs 1 1 4 6
N07 OTHER NERVIOUS 
SYSTEM  DRUGS
14 2 3 9 1 3 32
N07A Parasympathomimetics 6 2 1 9
N07B Drugs used in addictive disorders 2 2 1 4 1 2 12
N07C Antivertigo preparations 2 1 2 5
N07X Other nervous system drugs 4 1 1 6
TOTAL 346 9 30 86 53 36 560
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Discussion
The current DRUID categorization system establishes and defines 
standardized and harmonized criteria to categorize commonly 
prescribed medicines based on their influence on fitness to drive. To 
date, this system nearly embraces the full ATC index and it intends 
to provide a complete coverage of the most commonly prescribed 
medications in Europe. This categorization procedure is developed by 
a European group of experts and is meant to go beyond the national 
context to address a broader European scenario and involve different 
facets of health care practice.
The categorization system could be seen as a tool to improve 
prescribing and dispensing procedures both at a national and European level and, therefore, as an instrument to inform and involve 
HCPs better [11, 30]. In this respect, it is important that HCPs know 
the fundamentals of the categorization system and use it properly in 
order to inform fully their patients about the risks of driving under the 
influence of impairing medicines. Furthermore, HCPs should be able 
to distinguish between the four levels of impairment and, if possible, choose the least impairing medication within the same therapeutic 
group. Moreover, this system should encourage HCPs to update their 
knowledge on medicines and driving in order to be prepared to answer 
questions that patients might have on this topic [8, 11].
The DRUID categorization system should also be used as a tool to 
motivate HCPs to provide patients with clear information, communicate 
to patients the risk associated with driving under the influence of 
medicines and catalyze health care professional-patient discussions, 
leading to both safer prescriptions and patients who are more 
conscientious about their decision on whether or not to drive [8, 11, 30].
This classification could be a useful tool in helping patients be more involved in the decision-making process, understand the hazards of 
some medications to traffic safety and remind them to use caution 
while driving until their individual responses to their therapy have 
been well established.
To our knowledge, this is the first time that the European Commission 
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assigned an expert group in the field of medicines and driving the task 
of establishing the criteria for a European classification system and 
developing a categorization system for relevant therapeutic groups 
of medications with respect to their impact on driving skills. The 
categorization efforts were carried out by an international group of 
DRUID partners, coming from six different institutions in Europe, 
and gathered all their scientific competence, knowledge, expertise, 
and experience in the field of road safety research and practice. All 
the available data from multiple sources were collected according to 
a standardized step-by-step procedure, which allows for the future maintenance and/or revision of the current DRUID categorization 
system as new evidence emerges in the future, and it also allows for the 
constitution of a consistent evidence-based classification methodology 
to categorize new medications prior to their market authorization. 
Last but not least, as reported above, the DRUID categorization system 
encompasses the entire ATC list. Therefore, it is the first categorization 
system to provide a nearly complete overview of the influence of 
frequently prescribed medications on the ability to drive. Additionally, 
in the cases of severely impairing medications (e.g. medicines from 
the N group), the system is integrated with fact sheets which concisely 
emphasize the key points of the categorization and can be easily used 
as a support mechanism in HCPs’ daily practice [24].
Lastly, some limitations of the DRUID categorization system should 
be considered. In particular, special attention should be paid to the 
fact that a category is attributed to the single medicine, given to an adult, for its main indication, in a normal dosage, and at the start of 
the treatment [7, 8, 17]. Therefore, if a medication is not prescribed 
according to these conditions, it is crucial to bear in mind that the 
categorization system can only be used as background information, 
and it is necessary to carefully assess all the individual risk factors and 
avoid strict adherence to the medication classification. Furthermore, 
the system is focused on the effects of medications on fitness to drive 
and, consequently, the role of the disease, which could also influence 
fitness to drive, is not considered and certainly needs further attention 
while counselling the patient [7, 8].
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Finally, the categorization system should always be associated with 
proper patient counselling in order to avoid any misunderstandings from the patient’s side and to ensure that the patient receives adequate information allowing him/her to make a consistent decision with the 
message given by the medication category.
Next steps and recommendations
The categorization system presented in this manuscript was developed within the DRUID project and, therefore, in a European 
context. As a consequence, the DRUID partners agreed that the 
European regulatory authorities should to be informed about this 
categorization process. This should lead to discussion and consensus 
on the criteria hereby proposed and special efforts should be carried 
out to implement the current system at both international and national 
level, with consideration country specific circumstances.In this respect, it is important to underline that the DRUID consortium 
[31] previously approached the EMA Pharmacovigilance Working 
Party (PhVWP) in order to obtain its contribution in relation to the 
development of the categorization/labelling system for medications 
that impair driving [32]. In June 2011, the PhVWP agreed that any 
information on the influence of medicines on driving ability should 
be simple and helpful to the patient and, therefore, be reflected in the 
package leaflet. Furthermore, the PhVWP recommended including in 
the package leaflet a two-tier risk classification system differentiating 
between medicinal products with a potential for relevant influence on 
driving (moderate or major influence) and medicinal products without 
a potential for relevant influence (no or minor influence). Finally, the 
PhVWP recognized that this two-tier risk classification system could 
be further divided to include a maximum of four categories at the 
discretion of Member States [32]. This consensus is an important step in the harmonization of information on the potential for a medicine’s 
impairing effects on fitness to drive. However, it would be desirable 
for Member States to be provided with further discretionary activities, 
which could be used to reinforce the awareness of HCPs and patients 
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on the effects of medicines on fitness to drive.Since the categorization requires constant revision, it is also advised 
that an expert working group on medicines and driving be established 
to keep the system functional, up-to-date, and reliable.
Furthermore, it is recommended that special attention be paid 
to educating those who might play an active role in traffic safety. In 
this respect, medical and pharmacy schools should develop targeted educational programmes covering the issue of medication use and 
driving. Police officers and driving instructors should be adequately 
trained on this topic so that they are able to transfer knowledge about 
the effects of certain medications on a person’s ability to drive to 
potential patients who may drive in traffic.
Finally, a guideline should be developed to explain the use of the 
categorization system to HCPs and to serve as a support mechanism 
in the decision-making process. On the other hand, since the PIL 
is the most accessible source of information for patients, it would 
also be advisable to develop an effective strategy to communicate 
the risk related to the use of medicines and driving. For instance, a 
straightforward grading system could be included in the patient 
package leaflet and warning labels in the form of pictograms could be 
printed on the medication box to provide clear instructions about the 
use of the medication and driving to patients.
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Abstract
Objectives: To evaluate and compare the effectiveness of 2 pictograms in communicating risk in terms of respondents’ level of understanding, estimated level of driving risk, and intention to change 
driving behaviour. The added value of a side-text was also investigated.
Methods: Two experiments were conducted among 270 drivers 
visiting a pharmacy. Experiment one used a 2 (rating model vs. 
triangle model pictogram, same side-text) × 3 (minor vs. moderate vs. 
severe driving risk) between-subjects design. Respondents (n = 30 per 
condition) were exposed to one of the 6 conditions. To verify the added 
value of the side-text, a 2 (rating model with side-text vs. rating model 
without side-text) × 3 (same categories as before) between-subjects 
design was used.
Results: Although the majority of the respondents understood 
that the pictograms were related to driving behaviour, less than 
10 percent and about 36 percent of the respondents looking at the 
triangle model and at the rating model, respectively, understood it 
fully. For all categories of risk, respondents who saw the rating model 
pictogram associated the pictogram significantly more often with risk of medication intake for driving than those who saw the triangle 
model pictograms. Those exposed to the triangle model overestimated 
the driving risk of the lowest category and underestimated the risk of 
the highest category; 78.8 percent of the respondents stated they were 
(very) likely to change their driving behaviour if they were confronted 
with the pictogram. The added value of the side-text was not confirmed.
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Conclusions: Despite not being fully self-explanatory in conveying 
warnings and safety-related information, the pictograms evaluated in this research provided good insight into the different levels of driving 
risks, especially the rating model pictogram, because respondents’ 
intentions to change their driving behaviours increased with higher 
categories of risk. The added value of the side-text in the rating model 
pictogram was not confirmed in this research. Pictograms can be seen 
as a valuable means to reinforce both written and spoken information 
given to patients by health care providers at the time of consultation.
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Introduction
It has been known for many years that the consumption of psychoactive 
substances, such as sedatives, anxiolytics, or antidepressants, has risks 
and a potentially negative effect on the ability to drive [1] yet not much 
has been done to evaluate risk communication with regard to driving 
under the influence of driving-impairing medicines; for example, by 
using pictograms.Risk communication is central to effective decision-making in 
modern health care [1-5] and constitutes the basis for informed patient 
consent [4-6]. Risk communication can be defined as an interactive 
process of exchange of information about risk [7-11], leading to a better 
understanding and better decisions about clinical management [5, 12]. 
It stimulates patients to weigh the risks and benefits of a treatment 
choice or behavioural (risk-reducing) change [2, 13]. Visual displays of risk information, such as pictograms, are known to increase patient 
understanding of risk [4, 6, 10]. Pictograms are increasingly being 
recommended and used to convey warnings and other safety-related 
information [14, 15] and are useful to communicate information to 
patients with low literacy [15-21].
Pictograms are known to enhance comprehension [14-17, 19, 
22, 23], recall of information [14-19, 23, 24], adherence [14, 19], 
and communication across language barriers [25]. To be effective, 
pictograms should make use of familiar objects and symbols [16, 18, 
21]. The design should be simple, realistic, and with limited content 
[18] and the pictogram should, at all times, be self-explanatory [19]. If these requirements are not considered during the development of pictograms, there is a higher chance that the message and/or concepts 
will be beyond patients’ understanding.
Pictograms in Traffic Safety
In 2005, the European Union suggested the introduction of a 
compulsory and harmonized pictogram on medicines’ packaging 
for driving-impairing medicines. Such pictograms should be based 
on the European classification of drugs according to their effects in 
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the European Road Safety Action Programme as part of the “efforts 
to combat the scourge of drink-driving and find solutions to the issue 
of the use of drugs and medicines” [26]. Some European countries 
have already developed pictograms showing the potential risk of 
driving-impairing medicines [27] but only in France [28] and Spain 
[29] is the use of pictograms on the package of such medicines legally 
binding. France is the only country where a 3-tier labelling system 
was developed and printed on the box of all medicines depending on 
their level of risk (categories 1 to 3, Figure 1; [30, 31]), which can be seen as an advantage when compared to other pictograms that make 
no distinction between different levels of risk. However, the pictogram 
system existing in France (referred to as triangle model pictogram from this point forward) had the disadvantage of not showing all levels of 
risk in one picture. The triangle pictogram in isolation reflects which 
level of risk medicines represent (risk category) but has no frame of 
reference related to other levels of risk.
Figure 1 – Triangle model pictogram on medicines and driving.
Considering the latter, a new pictogram system was developed within 
the European DRUID (DRiving Under the Influence of Drugs, medicines 
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and alcohol) project [32] (from this point forward, this pictogram will 
be referred as rating model pictogram) as a proposal to communicate 
the risk of driving under the influence of medicines to patients [33].
In the rating model pictogram (Figure 2), the various risks of 
impairing driving ability are displayed horizontally in a bar. From left 
to right, categories range from 0 (no impairment, which means no 
driving risk) to 3 (severe impairment, associated with a severe driving 
risk), which clearly places each level of risk within a range from 0 to 
3, making it clear to the subject that the different levels of risk are 
relevant. A traffic-light colour was given to each category because 
people tend to associate the colour red with danger, the yellow with 
caution, and the green with safety [34]. Therefore, green (category 0), 
yellow (category 1), orange (category 2), and red (category 3) colours 
were chosen to represent each category.
Finally, the category attributed to a medicine is indicated by a 
triangle with a black car inside, because triangles are commonly 
associated with a warning message and the car is related to driving. 
A small text on the top of the pictogram saying “your risk in traffic” was added to avoid misunderstandings, allowing patients to associate 
the risk of taking this medicine and driving. The pictogram can also be 
supplemented with side-texts. The side-text selected for each category 
is the same as the one present in the triangle model (Figure 1)
Figure 2 - Rating model pictogram with side-text: (a) category 1; (b) category 2; and (c) category 3. 
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Objectives of the Study
The aim of the this study was to evaluate and compare the effectiveness of the rating and triangle model pictograms in communicating risk associated with driving-impairing medicines in terms of understanding, estimated level of driving risk, and intention 
to change driving behaviour. The added value of a side-text in the 
rating model pictogram was assessed as well. The triangle model 
pictogram was selected for comparison because it was the only existing 
pictogram with a distinction between 3 different categories or levels of 
impairment and, as such, the only alternative yet for comparison.
Methods
Design
Two experiments were conducted among patients with a driver’s 
license visiting a pharmacy. The first experiment involved a 2 (rating 
model pictogram vs. triangle model pictogram) × 3 (categories of 
impairment: minor driving risk vs. moderate driving risk vs. severe 
driving risk) between-subjects design. The participating patients (n = 
30 per condition) were exposed to one of 6 conditions in which the 
pictogram (rating model or triangle model pictogram) and the risk 
category (category 1, 2, or 3) were manipulated.
For the triangle model, the original pictogram was used, exactly as it 
is printed on the box of medicines known to impair driving fitness in 
France. As for the rating model, it was used as developed within DRUID. 
Both pictograms had the same side-text. In the second experiment, 
the added value of the side-text was examined by using a 2 (rating 
model with side- text vs. rating model without side-text) × 3 (minor 
vs. moderate vs. severe driving risk) between-subjects design. Here, 
the respondents were exposed to the rating model pictogram with or 
without side-text and one of the 3 risk categories.
With the main aim of determining whether the questions asked during the interview were clear and to measure the average length 
of the interview, a pre-test was conducted among 20 patients from a 
community pharmacy in Groningen, not part of the actual study.
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A structured interview was carried out involving participants (N = 
270) visiting 1 out of 4 selected Dutch community pharmacies located 
in Groningen and actively participating in traffic with motorized 
vehicles was carried out. Participants younger than 18 years old and 
those who could not speak or read Dutch were considered not eligible 
for the interview and were excluded.
The pictograms were affixed on a medicine box created for the present 
study. In total, 9 groups of 30 participants each were created: 3 rating 
pictograms with side-text (categories 1, 2, and 3), 3 triangle pictograms 
with side-text (categories 1, 2, and 3), and 3 rating pictograms without 
side-text (categories 1, 2, and 3). Participants were randomly exposed 
to a medicine box with 1 of these 9 pictograms. Because the rating 
pictograms with side-text could be used for both experiment 1 and 
experiment 2, one group served both experiments. Table 1 shows how 
participants were distributed in each group. In The Netherlands, no approval  from the medical ethics committee 
is needed for studies like this, because the study only included an 
interview about interpretation of pictograms in a general context (not 
related to received medication) after explicitly asking for patients’ 
consent. Moreover, all health care professionals and respondents 
involved were adequately informed about the nature of the study 
and participated voluntarily and anonymously. Participants were 
interviewed in the waiting area of the pharmacy by a research associate.
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Table 1 - distribution of participants in experiments 1 and 2.
Experiment 2 – Added value of the side-text – rating model pictogram with side-text versus 
rating model pictogram without side-text
A total of 180 participants were included in the analysis where the pictogram (rating model 
pictogram with side-text versus rating model pictogram without side-text) and the risk 
category (category 1, 2 or 3) were manipulated. 
90 participants evaluated the rating model pictogram with side-text*. Three sub-groups 
were created to analyse each of the categories:
30 respondents evaluated category 1 
30 respondents evaluated category 2 
30 respondents evaluated category 3 
90 participants evaluated the rating model pictogram without side-text. Three sub-groups 
were created to analyse each of the categories:
30 respondents evaluated category 1 
30 respondents evaluated category 2 
30 respondents evaluated category 3 
* Respondents who saw the rating model pictogram with side-text were the same in experiment 
1 and 2.
Experiment 1 – Rating model pictogram versus triangle model pictogram (both with side-text). 
A total of 180 participants were included in the analysis where the pictogram with side-text 
(rating versus triangle model) and the risk category (category 1, 2 or 3) were manipulated. 
90 participants evaluated the rating model pictogram*. Three sub-groups were created to 
analyse each of the categories:
30 respondents evaluated category 1 of the rating model pictogram
30 respondents evaluated category 2 of the rating model pictogram
30 respondents evaluated category 3 of the rating model pictogram
90 participants evaluated the triangle model. Three sub-groups were created to analyse each of the categories:
30 respondents evaluated category 1 of the triangle model pictogram
30 respondents evaluated category 2 of the triangle model pictogram
30 respondents evaluated category 3 of the triangle model pictogram
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Measurements
Due to the specificities of the questions related to risk perception, 
no validated examples of questionnaires were available. As such, the 
questionnaires were developed within the research group. Questions 
related to intention to change driving behaviour were based on 
extensive work by [35]. For the evaluation of the pictograms, the same 
measurements were used as in the study conducted by van Weert et 
al [36].Understanding of the Pictogram
First, respondents were asked to give their free interpretation of 
the pictogram they were exposed to. The answers to these questions 
were discussed and judged by 2 of the researchers (S.P.M. and R.H.). 
An answer given by a respondent was considered to be fully correct 
when a reference to traffic and to driving risk in traffic (minor, 
moderate, and severe), expressed by the category of the pictogram 
(category 1, category 2, and category 3, respectively), was made. 
This was considered to be a key element in the interpretation of the 
meaning of the pictogram because the category is what differentiates 
different levels of risk of driving under the influence. The remaining 
answers, not necessarily wrong but incomplete, were interpreted 
and coded depending on the type of answer. Respondents’ answers 
were categorized as (1) not correct (low level of understanding of the 
meaning of the pictogram) if answers were not traffic related or related 
to the category; (2) traffic-related answers but describing a different 
category than the one shown; (3) traffic-related answers without 
a reference to the risk mentioned by the risk category; and (4) fully 
correct (high level of understanding) whenever participants’ answers 
were traffic related with a correct reference to the risk depicted by the 
pictogram category.Evaluation of the Pictograms
Respondents were asked to rate the pictogram on 5 items with a 
7-point semantic differential scale that has been used in a previous 
study [36]. Items related to perceived ease (1 = difficult, 7 = easy), clarity 
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(1 = not clear, 7 = clear), complexity (1 = complex, 7 = not complex), 
ease of understanding of the pictogram (1 = difficult to understand , 7 = easy to understand ), and level of ambiguity (1 = ambiguous, 7 = not 
ambiguous) were used to estimate respondents’ overall evaluations of 
the pictograms. Cronbach’s alpha of the overall scale was 0.90
Estimated Level of Driving Risk
Respondents could select one of the options given by a 5-point Likert scale ranging from harmless (1) to very dangerous (5). The options were thereafter coupled with the categories of impairment as follows: • category 0: Likert scale options 1 and 2 = very safe and safe;• category 1: Likert scale option 3 = little danger; • category 2: Likert scale option 4 = dangerous; and• category 3: Likert option 5 = very dangerous.
The questions on risk perception were developed specifically for this 
study.Intention to Change Driving Behaviour
To answer the question, “How likely would you change your driving 
behaviour if this pictogram was affixed to your medicine box?” a 
5-point Likert scale, adapted from the theory of planned behaviour 
questionnaire developed by Azjen [35], was used (1 = very unlikely to 
5 = very likely). Participants were also asked how they would change 
their driving behaviour if a pictogram was shown on the medicine box. 
Answers to this question were driving equally, slightly less often, less 
often, much less often, and not anymore.Sociodemographic CharacteristicsSociodemographic items included in the questionnaire were gender, 
age, and educational level.
Analysis
Descriptive analysis was conducted to analyze respondents’ 
characteristics, such as gender, age, and education level. A chi-square 
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test of independence was used to investigate differences in gender, 
education level, and understanding of the pictograms between 
conditions (pictogram system) and an analysis of variance (ANOVA) was 
used to test whether there were differences in age between conditions.
To test the effects of the pictograms in experiment 1, two separate 
ANOVAs were conducted with the estimated level of driving risk and 
the intention to change driving behaviour as dependent variables 
and the pictogram systems (rating model vs. triangle model) and risk 
categories (category 1, category 2, and category 3) as factors. The same 
analyses were conducted in experiment 2 but with the pictograms with 
and without side-text (rating model with side-text vs. rating model 
without side-text) and risk categories (category 1, category 2, and 
category 3) as factors. t-Test analyses were carried out to investigate 
differences in the categories (category 1, category 2, and category 3) 
within the pictogram systems included in experiment 1 (rating model 
vs. triangle model) and in experiment 2 (rating model with side-text 
vs. rating model without side-text) for the same dependent variables.
Results
A total of 360 persons were approached. Of those 360 persons, 32 
(75% females) did not possess a driver’s license and were excluded. 
Of the remaining 328 persons, 58 (62.1% females) did not want to 
take part of the study for several reasons: no time (44.8%), no interest 
(29.3%), not feeling fit due to illness (12.1%), and other reasons 
(13.8%). The net response of the study was 82.3 percent: 270 out of 
328 persons participated.
Table 2 summarizes the relevant characteristics of the participants. 
The total study population was equally distributed in terms of gender 
(N = 137; 50.7% males). The mean age of the participants was 48.4 
years old and almost half of the respondents had a university degree 
(N = 123; 45.6%). A chi-square test for independence showed no 
significant differences between gender and pictogram model (rating 
model with and without side-text and triangle model), χ2 (2, N = 270) 
= 1.452, P = .484. The same analysis was conducted to investigate 
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the association between education level and pictogram model. No 
significant association was found between these 2 variables, χ2 (4, 
N = 270) = 1.278, P = .865. A one-way ANOVA test between age and 
pictogram model showed no significant differences, F (2, N = 270) = 
0.242, P = .785, η2 = 0.001.
Table 2 – Characteristics of the respondents, stratified per pictogram (N=270).
Understanding of the Pictogram
Respondents were asked to interpret the pictogram they were 
shown. Answers were judged from right to wrong (see Methods 
section). As illustrated in Figure 3, 72.2 percent of the participants 
who were shown 1 of the triangle model pictograms (N = 90) did 
not make any reference to any category of impairment, compared to 
46.7 and 36.0 percent of the respondents who looked at the rating 
model with and without side-text, respectively. The percentage of fully 
correct answers (traffic related with correct reference to categories of 
risk) was significantly higher with the rating model pictograms when 
compared to the triangle one (experiment 1), χ2 (3, N = 180) = 23.939, 
P < .001. No statistically significant differences were found between 




Rating Model with 
side-text
(experience 1 and 2) 
(n=90)





N % N % N %
GenderMale 42 46.7 50 55.6 45 50.0 0.484a
Female 48 53.3 40 44.4 45 50.0
Age (in years)Mean ± standard 
deviation (s.d)
47.78 ± 14.57 48.19 ± 14.33 49.23 ± 14.52 0.785bMinimum 21 20 20
Maximum 78 75 78
Educational level
Low 20 22.2 15 16.7 19 21.1 0.865aIntermediate 30 33.3 34 37.8 29 32.2
High 40 44.4 41 45.6 42 46.7
a P-value calculated with the Chi-square test. 
b P-value calculated with ANOVA.
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the rating model pictogram with and without side-text (experiment 
2), χ2 (3, N = 180) = 2.836, P = .418. Looking at respondents’ ages and 
education levels in the understanding of the pictograms, 9 out of 74 
(12.2%) respondents between 20 and 39 years of age and 6 out of 70 
(8.6%) respondents between 60 and 89 years of age gave incorrect 
answers and 21 out of 74 (28.4%) respondents between 20 and 39 
years and 20 out of 70 (28.6%) respondents between 60 and 89 years 
old gave fully correct answers. Regarding education level, 5 out of 54 
(9.3%) respondents with a low level of education and 11 out of 123 
(8.9%) highly educated respondents gave an incorrect answer and 
12 out of 54 (22.2%) respondents with a low education level and 41 
out of 123 (33.3%) highly educated respondents gave fully correct 
answers. Age and education level did not statistically influence the 
interpretation of the pictograms (age: χ2 (6, N = 270) = 6.025, P = .420; 
and education level; χ2 (6, N = 270) = 9.250, P = .160). For all categories of risk, respondents who saw the rating model pictogram associated 
the pictogram significantly more often with risk of medication intake 
for driving than those who saw the triangle model pictograms (p(category1) 
= 0.013; p
(category2)
 = 0.003; p
(category3)
 = 0.015 calculated using the chi-
square test).
Figure 3 - Respondents’ understanding of the starting pictogram (n = 270; 90 respondents per 
pictogram group). The numbers presented in the graph are percentages.
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Evaluation of the PictogramsRespondents were asked to rate the pictograms on items related 
to perceived ease, clarity, complexity, ease of understanding of the 
pictogram, and level of ambiguity. The mean evaluation scores for each 
pictogram system (rating model with side-text, triangle model, and 
rating model without side-text) were, respectively, 5.80 (SD = 1.12), 
5.55 (SD = 1.12), and 5.76 (SD = 1.25). Overall, the pictograms were 
evaluated in the same manner by respondents (see Figure 4), without 
statistically significant differences between the 3 pictogram systems, F 
(2,267) = 1.23; P = .294, η2 = 0.009. The results showed no significant 
interaction effects between risk category and pictograms (in both 
experiments 1 and 2) on the evaluation of the pictograms.
Figure 4 - Evaluation of the pictograms. Left-side) experiment 1; Right-side) experiment 2. Every 
dot represents the mean comprehensibility value of 30 participants belonging to each category 
of the rating and triangle models pictogram. A p-value < 0.05 was considered to be statistically 
significant.
Estimated Level of Driving Risk
A comparison between estimated level of driving risk in all 3 
pictogram models as well as a comparison between each category 
within a pictogram model were made. The overall estimated level of 
driving risk (1 = harmless; 5 = very dangerous) was not significantly 
different among the pictogram systems, F (2,267) = 0.029; P = .972, η2 
< 0.001. However, the results showed a significant interaction effect 
between risk category (categories 1 and 3) and pictograms (triangle 
model and rating model, experiment 1), F (1,116) = 6.062, P = .015, 
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η2 = 0.05. There was no difference in estimated driving risk between 
categories 1 and 3 of the triangle model. However, respondents exposed 
to category 1 of the rating model estimated a lower level of driving 
risk than those exposed to category 1 of the triangle model, whereas 
respondents exposed to category 3 of the rating model estimated a 
higher level of driving risk than those exposed to category 3 of the 
triangle model. Simple effect analysis revealed that respondents 
exposed to the rating model also reported a significantly higher 
driving risk for category 3 compared to category 2 and for category 2 
compared to category 1. Within the triangle pictogram groups, these 
differences were not found. When analyzing differences per category 
in experiment 1, results of the estimated level of driving risk showed 
a significant difference, t(58) = −2.263; P = .027, between category 1 
of the rating model (M = 3.27; SD = 0.69) and the triangle model (M  = 
3.63; SD = 0.55).
Respondents exposed to one of the triangle model pictograms 
attached a similar level of danger to categories 1 (M = 3.63; SD = 0.55), 2 
(M = 3.80; SD = 0.61), and 3 (M = 4.03; SD = 0.81), whereas respondents 
exposed to the rating model pictogram associated the category 2 (M = 
3.87; SD = 0.57) and 3 (M = 4.27; SD = 0.58) pictograms of the rating 
model with more dangerous situations (experiment 1, Figure 5 left-
side). Perception of danger was not influenced by the presence of 
side-text in the rating model pictogram (experiment 2) for any of the 
categories (see Figure 5 right-side for statistical results). As displayed 
in Figure 5 right-side, the estimated levels of danger were, to a high 
extent, comparable between respondents exposed to the rating model 
pictogram with or without side-text, indicating that the level of danger 
was well estimated from the rating model pictogram itself (without 
side-text). In this specific case, the side-text showed no added value 
for any of the categories.
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Figure 5 - Estimated level of driving risk. Left-side) experiment 1; Right-side) experiment 2. 
Every dot represents the mean estimation of risk value of 30 participants belonging to each 
category of the rating and triangle models pictogram. A p-value < 0.05 was considered to be 
statistically significant.
Intention to Change Driving Behaviour
Considering the intention to change driving behaviour, 78.8 percent 
(213 out of 270) of the respondents stated that they were likely or 
very likely to change their behaviour, regardless of the pictogram or 
the category presented. The intention to change driving behaviour 
(considering all categories of risk) did not significantly differ among 
pictorial systems, F (2,267) = 1.443; P = .238, η2 = 0.01. The results 
showed a significant interaction effect between risk category 
(categories 1 and 3) and pictograms (triangle model and rating model), 
F (1,116) = 9.288, P = .003, η2 = 0.07. This indicates that, similar to the 
estimation of levels of driving risk, respondents exposed to the lower 
category of the rating model were less willing to change their driving 
behaviours compared to respondents exposed to the same category 
of the triangle model. However, respondents exposed to category 3 of 
the rating model were more willing to change their driving behaviours 
compared to respondents exposed to category 3 of the triangle model. 
Thus, when comparing the rating model with side-text and the triangle 
model (experiment 1) per category, it was found that the higher the 
category (or risk level), the greater the intention to change driving 
behaviour for the rating model (Figure 6 left-side) but not for the 
triangle model.
For experiment 2 (rating model with side-text and rating model 
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without side-text), a significant interaction effect between risk 
category (categories 2 and 3) and pictograms, F (1,116) = 4.448, P = 
.037, η2 = 0.04, was found as well. This indicates that respondents who 
were exposed to a category 1 rating model with side-text were less 
willing to change their driving behaviours than respondents exposed 
to a category 1 rating model without side-text, whereas respondents 
exposed to a category 3 rating model with side-text were more willing 
to change their driving behaviours than respondents exposed to a 
category 3 rating model without side-text.
As illustrated in Figure 6 right-side, if respondents were exposed 
to the rating model with side-text, the willingness to change their 
behaviours increased with the category. If the respondents were 
exposed to the rating model without side-text, their intentions to 
change their driving behaviours were greater in categories 2 and 3 
compared to category 1 yet still comparable in categories 2 and 3.
Figure 6 - Respondents’ intention to change driving behaviour. Left-side) experiment 1; right-
side) experiment 2. Every dot represents the mean intention value of 30 participants belonging 
to each category of the rating and triangle models pictogram. A p-value < 0.05 was considered to 
be statistically significant.
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Discussion
Approximately one third of the respondents fully understood the 
meaning of the rating model pictogram, with and without side-text, 
and these pictograms were significantly more related to the level of 
risk than the triangle model ones. The intention to change driving 
behaviour increased with higher risk categories. The added value of 
the side-text in the rating model pictogram was not confirmed in this 
research.
When used as the only source of information, the messages indicated 
by the pictogram models in this study were not fully self-explanatory in 
communicating the risk message. This percentage is low compared to 
recommendations from the American National Standard Institute (ANSI 
Z535.3) [37] and the Organization for International Standardization’s 
(ISO 3864) [38], which state that, in a comprehension test, symbols 
must reach at least 85 percent (ANSI) or 67 percent (ISO) of correct 
answers to be considered acceptable [15, 16].Despite the performance of the pictograms, the results showed that 
the rating model pictogram with and without side-text was associated 
with more correct answers than the triangle model (35.6% vs. 7.8%, 
respectively). However, if one considers that the correct answer 
does not need to make reference to the category of the pictogram, 
the percentage of correct answers would be essentially the same in 
both pictogram systems (80% for the triangle model vs. 82.3% for 
the rating model). In this case, both pictograms could be considered 
as comprehensible according to the ISO 3864 norm. This indicates 
that the definition of correct answers used may have been too strict. 
Because the results of experiment 2 showed that the side-text had no 
added value, differences in the interpretation could be explained by 
the layout and design of the rating model pictogram. It seems that the 
design of the rating model pictograms was better than the triangle 
model in conveying the information about the different levels of risk 
of driving under the influence of certain medicines. This is in line with previous research where the importance of an appropriate design of 
the pictograms was reported to influence the correct interpretation of 
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the message [15, 21-23, 34, 39]. Nevertheless, it should be stressed that 
these pictograms alone are unlikely to provide the complete message. This relates to the fact that respondents linked the pictogram to a 
traffic-related message but the majority failed to successfully associate 
it with the exact risk message. This supports the idea that pictograms 
are relevant when used in combination with oral and/or written 
information given by health care providers to avoid misinterpretations 
of any kind [14, 17] and to improve recall [14-19, 23, 24].
Regardless of the type of pictogram, respondents associated higher 
categories with higher levels of driving risk (experiments 1 and 2), 
which led to higher estimations of danger. This outcome shows that, 
despite the lower percentage of fully correct answers regarding 
understanding of the pictogram, respondents were able to link the 
different levels of driving risks to a pictogram category. Category 1 
pictograms of the rating model were associated significantly less with 
danger than the homologue from the triangle model (experiment 1), indicating that respondents tend to overestimate the lower categories 
of the triangle model pictogram and underestimate the higher ones. In the authors’ opinion, this could mean that the triangle model pictogram 
does not fully illustrate the magnitude of risk as well as the rating 
model because no reference to the number of categories was made, 
making it difficult for the target population to perceive the exact risk. 
The side-text did not have any added value to the estimated level of 
danger (experiment 2), implying that the design of the pictogram with 
the small line of text “your risk in traffic” was self-explanatory and, 
as a consequence, enough to estimate different levels of risk/danger. 
Respondents’ understanding of different levels of driving risk, given by 
the pictogram category, was supported by the fact that respondents’ 
intentions to change driving behaviour increased with the categories 
of risk.In general, respondents evaluated the triangle and the rating model 
(experiment 1) and the rating model with and without side-text 
(experiment 2) in a similar way. It was, however, expected that the 
rating model with side-text would have significantly higher evaluation 
scores than the equivalent model without side-text (experiment 
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2) to demonstrate the added value of the side-text. This result was 
unexpected but, simultaneously, indicates that the rating model 
pictogram was more self-explanatory than the triangle model.
The results of this study should be considered in the light of some 
limitations and strengths. First, this study was carried out in the general population and not among those patients who take driving-impairing 
medicines and are, assuredly, the most likely target population of 
the pictograms that were investigated. As presented, there could be 
an underestimation of the percentage of correct answers about the understanding of the pictogram’s message due to the fact that the 
general population might not be aware of the different levels of risk, 
failing to give a complete and correct answer. Or, because this was 
an open question, it could also be reasonable to hypothesize that 
respondents did not know that they were expected to be so specific 
about their travel risks; this was investigated, more precisely, with the perceived danger questions, which have shown higher percentages 
of understanding. Future research should be carried out in users of driving-impairing medicines to evaluate the real interpretation of the 
pictograms. The sample size, though common in this type of research 
[40], can also be considered to be small (N  = 270). Nevertheless, 
it is believed that the findings of this study, namely, those related to estimated level of driving risk and intention to change driving 
behaviours, show a rather sound trend that might not change in a 
larger follow-up study. Another important limitation of the present 
study deals with the intention to change driving behaviour instead of 
actual behaviour. This variable might be affected by social desirability 
bias, leading to an overestimation of the results. However, it is well 
defined in the literature that behavioural intention is one of the best 
determinants of actual behaviour [41]. The results of this study showed 
that the intention to change driving behaviour increased with the level 
of risk (higher categories), especially with the rating model pictogram, 
which gives consistency to the results achieved.
Several studies showed the relevance of pictograms in health [17, 
19, 42]. The present study, however, focuses on the use of pictograms 
in the field of medicines and driving and, to the best of our knowledge, 
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it is one of the few [31, 34] in this field and the first one to evaluate 
the use of such pictograms. Another important strength of the present 
study is the high response rate and good design.
Conclusion
The pictograms in our study were not fully self-explanatory in 
conveying warnings and safety-related information because the 
majority of the respondents did not fully understand the meaning of 
the pictograms. The rating model pictogram generated more correct 
answers compared to the triangle model used in France. Despite the moderate level of understanding, respondents associated the high categories of risk to more dangerous situations, indicating a good 
estimation of driving risks. Moreover, in the presence of the pictograms 
used in this study, respondents were willing to change their driving 
behaviours by driving less frequently. Future research should focus on how effective pictograms are in communicating a risk message when 
complementing oral or written information given to patients by health 
care providers.
Acknowledgments
This study, part of the DRUID project, was financed by the European 
Community within the framework of the EU 6th Framework Program 
(Contract No. TREN-05-FP6TR-S07.61320–518404-DRUID).
This article reflects only the authors’ views. The European 
Community is not liable for any use that may be made of the 
information contained therein. The authors do not have any conflict of 
interest to declare. The authors thank all of the respondents enrolled 
in this study for their collaboration in data collection. Furthermore, we thank the pharmacists who allowed us to conduct the interviews in 
their pharmacies.
108 | Chapter 4
References
1.  Davis RE, Dolan G, Thomas S, Atwell C, Mead D, Nehammer S, Moseley L, Edwards A, Elwyn G. 
Exploring doctor and patient views about risk communication and shared decision-making in the 
consultation. Health Expect. 2003 Sep;6(3):198-207.
2.  Edwards A, Elwyn G. How should effectiveness of risk communication to aid patients’ decisions 
be judged? A review of the literature. Med Decis Making. 1999 Oct-Dec;19(4):428-34.
3.  Edwards A, Elwyn G, Hood K, Robling M, Atwell C, Holmes-Rovner M, Kinnersley P, Houston 
H, Russell I. The development of COMRADE--a patient-based outcome measure to evaluate the 
effectiveness of risk communication and treatment decision making in consultations. Patient 
Educ Couns. 2003 Jul;50(3):311-22.
4.  Paling J. Strategies to help patients understand risks. BMJ. 2003 Sep 27;327(7417):745-8.
5.  Thomson R, Edwards A, Grey J. Risk communication in the clinical consultation. Clin Med. 
2005;5:465–469
6.  Gordon-Lubitz RJ. Risk communication: problems of presentation and understanding. JAMA. 
2003;289(1):95
7.  Lofstedt RE. Good and bad examples of siting and building biosafety level 4 laboratories: a 
study of Winnipeg, Galveston and Etobicoke. J Hazard Mater. 2002;93:47–66.
8.  Lofstedt RE. The impact of the Cox-2 inhibitor issue on perceptions of the pharmaceutical 
industry: content analysis and communication implications. J Health Commun. 2007;12:471–491.
9.  Lofstedt RE. Academic analysis of the Institute of Medicine report: the future of drug safety. 
Expert Rev Clin Pharmacol. 2008;1:617–625.
10. Lofstedt RE. Risk communication, media amplification and the aspartame scare. Risk Manag. 
2008;10:257–284.
11. Lofstedt RE, Perri. What environmental and technological risk communication research and 
health risk research can learn from each other. J Risk Res. 2008;11:141–167.
12. Edwards A, Elwyn G, Mulley A. Explaining risks: turning numerical data into meaningful 
pictures. BMJ.  2002;324:827–830.
13. Edwards A, Hood K, Matthews E, Russell D, Russell I, Barker J, Bloor M, Burnard P, Covey J, 
Pill R, Wilkinson C, Stott N. The effectiveness of one-to-one risk communication interventions in 
health care: a systematic review. Med Decis Making. 2000 Jul-Sep;20(3):290-7.
14. Katz MG, Kripalani S, Weiss BD. Use of pictorial aids in medication instructions: a review of 
the literature. Am J Health Syst Pharm. 2006;63:2391–2397.
15. Mansoor LE, Dowse R. Design and evaluation of a new pharmaceutical pictogram sequence 
to convey medicine usage. Ergonomics SA. 2004;16:29–41.
16. Dowse R, Ehlers MS. The evaluation of pharmaceutical pictograms in a low-literate South 
African population. Patient Educ Couns. 2001;45:87–99.
17. Dowse R, Ehlers M. Medicine labels incorporating pictograms: do they influence 
understanding and adherence? Patient  Educ Couns. 2005;58:63–70.
18. Hill LH, Roslan MR. Using visual concept mapping to communicate medication information 
to chronic disease patients with low health literacy. Paper presented at: First International 
Conference on Concept Mapping; September 14–17, 2004; Navarra, Spain.
19. Houts PS, Doak CC, Doak LG, Loscalzo MJ. The role of pictures in improving health 
communication: a review of research on attention, comprehension, recall, and adherence. Patient 
Educ Couns. 2006 May;61(2):173-90. Epub 2005 Aug 24.
20. Morrell RW, Park DC, Poon LW. Effects of labeling techniques on memory and comprehension 
of prescription information in young and old adults. J Gerontol. 1990;45:166–172.
21. Ngoh LN, Shepherd MD. Design, development, and evaluation of visual aids for communicating 
prescription drug instructions to nonliterate patients in rural Cameroon. Patient Educ Couns. 
1997;30:257–270.
22. Houts PS, Witmer JT, Egeth HE, Loscalzo MJ, Zabora JR. Using pictographs to enhance recall of 
spoken medical instructions II. Patient Educ Couns. 2001 Jun;43(3):231-42.
23. Sorfleet C, Vaillancourt R, Groves S, Dawson J. Design, development and evaluation of 
Chapter 4 | 109
pictographic instructions for medications used during humanitarian missions. Can Pharm J. 
2009;142:82–88
24. Houts PS, Bachrach R, Witmer JT, Tringali CA, Bucher JA, Localio RA. Using pictographs to 
enhance recall of spoken medical instructions. Patient Educ Couns. 1998 Oct;35(2):83-8.
25. Lemmon H, Hyman W. Pictowhat? Problems with the use of pictograms on medical devices. 
J Clin Eng. 2006;31:202–205
26. European Road Safety Action Program. European Road Safety Action Program for Halving the 
Number of Road Accident Victims in the EU by 2010. Available at http://europa.eu/legislation_summaries/internal_market/single_market_for_goods/motor_vehicles/technical_implications_
road_safety/l24257_en.htm (last accessed 16/12/2013).
27. Gómez-Talegón T, Fierro I, Del Río MC, Álvarez FJ. Establishment of framework for 
classification/categorisation and labelling of medicinal drugs and driving. DRUID Deliverable 
4.3.1, 2011. Available at http://www.druid-project.eu/cln_031/nn_107534/Druid/EN/
deliverales-list/deliverables-list-node.html?__nnn=true (last accessed 16/12/2013).
28. French Ministry of Health and Solidarity. French Decree SANP0522726A of 18 July 2005. 
Available at http://www.journal-officiel.gouv.fr/user.php (last accessed 16/12/2013).
29. Spanish Ministry of Health, Social Services and Equality. Spanish Royal Decree 1345/2007 of 
October 11th. Available at http://noticias.juridicas.com/base_datos/Admin/rd1345-2007.html 
(last accessed 16/12/2013).
30. Agence française de sécurié sanitaire des produits de santé. Medicinal products and 
driving. Available at http://ansm.sante.fr/var/ansm_site/storage/original/application/
e5f2e48d5344bcfef6ca865ac63e7c3d.pdf (last accessed 16/12/2013).
31. Orriols L, Delorme B, Gadegbeku B, Tricotel A, Contrand B, Laumon B, Salmi LR, Lagarde 
E; CESIR research group. Prescription medicines and the risk of road traffic crashes: a French 
registry-based study. PLoS Med. 2010 Nov 16;7(11):e1000366.
32. Driving Under the Influence of Drugs, Alcohol and Medicines. DRUID project. Available at 
http://www.druid-project.eu/ (last accessed 16/12/2013).
33. Meesmann U, Boets S, Monteiro SP, de Gier JJ, Fierro I, Álvarez FJ. Main DRUID results to be 
communicated to different target groups (DRUID deliverable 7.3.2). 2011. Available at http://
www.druid-project.eu/cln_031/nn_107534/Druid/EN/deliverales-list/deliverables-list-node.html?__nnn=true (last accessed 16/12/2013).
34. Veldhuijzen DS, van Wijck AJ, Verster JC, Kalkman CJ, Kenemans JL, Olivier B, Volkerts ER. The 
impact of chronic pain patients’ psychotropic drug knowledge and warning labels on the decision 
whether to drive a car or not. Traffic Inj Prev. 2006 Dec;7(4):360-4
35. Ajzen I. Constructing a theory of planned behaviour questionnaire. No date. Available at: 
http://people.umass.edu/aizen/pdf/tpb.measurement.pdf (last accessed 16/12/2013).
36. van Weert JC, van Noort G, Bol N, van Dijk L, Tates K, Jansen J. Tailored information for cancer 
patients on the Internet: effects of visual cues and language complexity on information recall and 
satisfaction. Patient Educ Couns. 2011 Sep;84(3):368-78.
37. American National Standard Institute. Accredited standard on safety colours, signs, symbols, 
labels, and tags, vol. Z535. Washington, DC: National Electrical Manufacturers Association, 1991. 
pp. 1–5.
38. International standard for safety colours and safety signs, ISO 3864. Switzerland: 
International Standards Organization, 1984.
39. Wolf MS, Davis TC, Tilson HH, Bass PF 3rd, Parker RM. Misunderstanding of prescription 
drug warning labels among patients with low literacy. Am J Health Syst Pharm. 2006 Jun 
1;63(11):1048-55.
40. Stevens J. Applied Multivariate Statistics for the Social Sciences. London, England: Lawrence 
Erlbaum Associates; 2002
41. Armitage CJ, Conner M. Efficacy of the Theory of Planned Behaviour: a meta-analytic review. 
Br J Soc Psychol. 2001 Dec;40(Pt 4):471-99.
42. Choi J. Literature review: using pictographs in discharge instructions for older adults with 
low-literacy skills. J Clin Nurs. 2011 Nov;20(21-22):2984-96.

Chapter 5Age and education related preferences for pictograms concerning driving-impairing medicines
Monteiro SP, van Weert JC, de Gier JJ, van Dijk L
 Submitted

Chapter 5 | 113
Abstract
Purpose: Pictograms to increase public awareness about driving-
impairing effects of some medicines have been developed. The impact 
and acceptance of new pictograms should be surveyed among drivers of different age groups and education levels to investigate whether 
there are misunderstandings in respondents who might have problems 
interpreting the correct meaning of the pictogram message. This study investigated participants’ preference for one of two pictograms related 
to the influence of driving-impairing medicines on driving fitness. 
Participants and Methods: Interviews among 270 drivers visiting 
a Dutch pharmacy were conducted. Participants were asked about 
their preference for the best pictogram expressing a warning message 
and expressing levels of impairment. A comparison between a 
pictogram with a more complex design (rating model) and an already 
implemented one (triangle model) was made. 
Results: The majority of participants preferred the rating model to 
express warning messages (74.4%) and levels of impairment (82.6%). 
Age was the strongest predictor influencing participants’ preference 
for pictograms to express a warning message and levels of impairment. 
Young participants (18-39 years old) with high education level had the 
highest preference for the rating model, whereas old participants (> 
60 years old) with low education level showed the lowest preference 
for this pictogram system.
Conclusion: Age and education level are sensitive factors to be 
considered when designing a pictogram. In order to be equally well 
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understood by older and low educated adults, pictograms should have 
a simple design and make use of familiar objects.  
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Introduction
Older patients (over 65 years) consume about one third of all 
prescribed medicines [1]. A substantial part of these patients 
use psychoactive substances, mainly benzodiazepines and opioid 
analgesics. These medicines act on the central nervous system and, 
thus, are likely to impair fitness to drive. The driving-impairing effects of 
such substances vary greatly, and several (pharmaco)epidemiological 
studies have shown an increased traffic accident risk associated with 
its use [2-4]. It has also been reported that older drivers lack awareness 
of the effects of psychoactive medicines on driving fitness [5]. The 
same holds true for adults with low education level. A recent study showed that patients with low education level had less knowledge 
about the influence of driving-impairing medicines than patients with 
high education level [6]. Raising older and lower educated adult’s 
awareness of medicines and psychomotor fitness to drive safely is 
positively associated with driving self-regulating behaviours [7,8].
As an attempt to increase public awareness and knowledge of the 
driving-impairing effects of certain medicines [9,10] pictograms 
related to the influence of driving-impairing medicines on driving 
fitness were developed and implemented in some European countries, 
like the Netherlands, Denmark, Finland, Norway and, more recently, 
France and Spain [11]. The pictogram developed in France (triangle 
model) was considered to be a step forward, as it encompassed a 
3-tier labelling system with a side-text (Figure 1). This system allowed 
making a distinction between different levels of impairment of a 
medicine on driving fitness, but it failed to give an overall perspective 
of all the existent levels of risks in one single pictogram. To overcome 
this gap, a new pictogram (rating model) was designed within the 
European project DRUID – DRiving Under the Influence of Drugs, 
alcohol and medicines [12] -, aiming at providing users of driving-
impairing medicines with a straightforward and clear grading system 
(Figure 1). In comparison, the triangle model pictogram appears 
to have a simpler design than the rating model pictogram. Complex 
pictograms are known to be more difficult to understand, meaning 
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that the rating model pictogram would be harder to understand. 
However, results from a recent study comparing these two pictograms 
have shown otherwise [13].
When designing a pictogram it is important to recognize and take into consideration the preferences of the target population so that 
the pictogram catches the target group’s attention. According to 
the Elaboration Likelihood Model (ELM) of persuasion [14], when 
an individual is exposed to a message perceived to contain relevant 
arguments, he/she is more likely to find motivation and ability 
to centrally process that information [14,15]. In other words, the information that is tailored to match individual preferences and 
interests is processed more deeply [16], improving comprehension 
and recall of information [14,17,18]. 
Despite some advantages associated to its use, especially in conveying 
warning messages [9,10,19-25], pictograms are figures representing 
ideas and concepts which may not always be clear to all, affecting the 
comprehension of the message [26,27]. Older and low educated adults 
are recognized to be particularly vulnerable to misunderstandings and 
often times have difficulties interpreting the message being conveyed 
[26-32]. 
Regardless of the growing number of pictograms related to driving-
impairing medicines that have been developed in the past few years, 
no published studies ever investigated the preference for driving-
impairing pictograms by old adults or people with low education levels. 
In order to fill this existent gap, this research aims at investigating older and lower educated adults’ preference for a pictogram related to 




This study among patients with a driving license visiting a pharmacy 
involved a 2 (rating model pictogram versus triangle model pictogram) 
by 3 (categories of impairment: minor driving risk versus moderate 
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driving risk versus severe driving risk) between-subjects design. 
Participants were exposed to one of three conditions in which the risk 
message and the risk category (category 1, 2 or 3) were manipulated. 
Ninety participants per pictogram category were interviewed, in a 
total of 270 participants. As illustrated in Figure 1, for the purpose 
of this study, participants were shown, at the same time, the same 
category of the triangle and rating model pictograms with the side-text 
message next to it. A pre-test was conducted in a small sample (n=20) 
of patients visiting a community pharmacy, not part of the actual study. 
The pre-test served to test the clarity of the questions asked and to 
estimate the time needed to complete the interview. No adjustments 
were necessary after the pre-test.
Figure 1 - Representation of how participants were shown the pictograms that allowed them to 
answer the questions: “which pictogram better expresses the warning message?” and “which 
pictogram better express different levels of impairment?”. The warning message for each 
category is presented on the left-side. For each category of impairment, participants were shown 
the correspondent triangle and rating pictogram at the same time.
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The structured experiment involved 270 participants visiting 1 out 
of 4 selected Dutch community pharmacies located in Groningen. 
Inclusion criteria were matched for participants 1) actively 
participating in traffic with motorized vehicles; 2) aged 18 years or 
older and 3) being able to speak and read Dutch. The interview was carried out in Dutch and participants were interviewed in the waiting 
area of the pharmacy by a research associate. The interview consisted 
of four distinct parts: 1) socio-demographic characteristics of the 
participant, 2) general knowledge about medicines and driving, 3) 
specific questions about the pictogram, and 4) comparison between 2 
pictograms. This study only focuses on the fourth part of the interview. 
It has to be stressed that for parts 2 and 3, participants were randomly 
exposed to only one out of three possible pictograms (triangle model, 
rating model with side-text and rating model without side-text) to 
investigate pictograms’ effectiveness in conveying the correct message 
and has been published elsewhere [13]. In total, 270 participants were 
needed for this study. Data-collection stopped once this number was 
reached (see results for response rates). In the Netherlands, no approval from the Medical Ethic Committee 
is needed for studies like this, since it only included an interview 
about interpretation of pictograms in a general context (not related 
to medication received) after explicitly asking for patients’ informed 
consent. Moreover, all healthcare professionals and participants 
involved were adequately informed about the nature of the study, 
participated voluntarily and anonymously. 
Measurements 
The pictogram preference (triangle or rating model pictograms) was 
investigated by asking participants “which pictogram better expresses 
the warning message?” and “which pictogram better expresses 
different levels of impairment?”. For both questions, participants were shown at the same time the triangle and the rating model 
correspondent to one pictogram category (category 1, 2 or 3) and had 
to select the pictogram of their choice, i.e., only one pictogram could 
be of their preference (Figure 1). Despite their association (X2 (1, 270) 
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= 121.8; p<.001), the two measurements were used as two separate 
dependent variables, as it is believed that, in case participants do 
have different preferences, this would be helpful to draw conclusions 
about the best pictogram. Additionally, it allowed investigating who were the participants that changed their preference depending on the 
pictogram message. 
Age and education level were the main independent variables. To assess age differences in the outcomes, the following age intervals 
were used: younger participants (18-39 years), middle aged 
participants (40-59 years), and older participants (60 years and 
older) [33,34]. Education level included low (not completed primary 
school, completed primary school, lower professional education), 
intermediate (moderate professional education) and high (higher 
educational or university degree) levels.
Gender (male, female), pictogram risk category (1, 2 or 3) and 
pictogram shown at the start of the interview (triangle model, rating 
model with or without side-text) were used as control variables. 
Statistical analysis
Descriptive analysis was conducted on participants’ characteristics, 
such as age, education level and gender. ANOVA and chi-square tests of independence were used, where appropriate, to investigate differences 
in age, education level and gender between participants exposed to 
different conditions, i.e. pictogram systems (triangle model, rating 
model with side-text and rating model without side-text).Chi-square tests of independence were conducted to investigate 
differences in participants’ preference for one pictogram to express 
a warning message and to express levels of impairment. Univariate 
analysis was used to investigate whether there were age and education 
level differences in the preference for one pictogram system (triangle 
or rating model pictograms).
Multiple logistic regression analysis was used to assess the influence of age and education level on participants’ preference for the pictogram 
in expressing a warning message (model 1) and on levels of impairment 
(model 2). These models were controlled for gender, pictogram’s 
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category, and pictogram shown at the start of the interview. A p-value 
of < 0.05 was considered to be statistically significant.
Results
A total of 360 persons were approached; 32 (of whom 75% females) 
did not possess a driving license and were excluded. Of the remaining 
328 persons, 58 (62.1% females) did not want to take part in the study 
for several reasons: no time (44.8%), no interest (29.3%), not feeling 
fit due to illness (12.1%), and other reasons (13.8%). The net response 
of the study was 82.3%; 270 out of 328 eligible persons were included 
in this study.
The total study population was equally distributed in terms of 
gender (N = 137; 50.7% males). The mean age of the participants 
was 48 years-old (sd = 14.4; range 20-78 years; 27.4% (n=74) “18-
39”; 46.7% (n=126) “40-59” and 25.9% (n=70) “69-79”). Regarding 
education level, 20.0% (n=54) of the participants had low education, 
34.4% (n=93) had intermediate level and 45.6% (n=123) had high 
education. No significant differences were found between age (F (2, 
270) = 0.242, p = .785), education level (Χ2 (4, 270) = 1.278, p = .865), and gender Χ2 (2, 270) = 1.452, p = .484) between conditions. 
The percentage of participants preferring the rating model (201 
out of 270; 74.4%) to express a warning message was significantly 
higher than those preferring the triangle model (69 out of 270; 
25.6%), X2(1,270)=12.6, p<.001. Statistically significant differences 
between preference for one pictogram and age were found, F(2, 
267)=6.39, p=.002; older adults (>60 years old) were more likely 
to prefer the triangle model pictogram over the rating model. This 
group significantly differ from middle aged participants (p=.035) and 
younger participants (p=.002) which have shown preference for the 
rating model pictogram to express a warning message. Statistically 
significant differences were found, F(2,267)=4.67, p=0.01 between 
pictogram preference and education level; participants with lower 
education were more likely to prefer the triangle model whereas participants with intermediate and high education levels preferred 
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the rating model pictogram to express a warning message.
Results from the multiple logistic regression (Table 1) confirmed the previous results and showed that age was the strongest predictor 
influencing preference for pictograms expressing warning messages. 
The independent variables explain 17.6% of the variance for pictogram 
preference in explaining warning messages.
As for the best pictogram expressing levels of impairment, 82.6% 
(223 out of 270) of the participants preferred the rating model 
pictogram. Results indicated statistically significant differences 
between pictogram preference and age, F(2, 267)=14.21, p<.001, and 
between education level and the condition, F(2, 267)=7.62, p=.001. 
According to the multiple regression model (Table 1), age was the 
strongest predictor influencing preference. Participants between 
20-39 years-old and 40-59 were, respectively, 11 and almost 4 times 
more likely to prefer the rating model pictogram over the triangle one 
when compared to participants between 60-79 years-old (reference 
group). Educational level also had an impact: participants with 
intermediate and high level of education were, respectively, 2 and 3 
times more likely to prefer the rating model to express different levels 
of impairment than those with low education level. The independent 
variables explain 26.7% of the variance.
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Table 1 - Factors influencing participants’ preference for one pictogram in expressing warning 
messages and levels of impairment: multiple logistic regression analysis. 
Participants preferred the rating model to express both a warning 
message and levels of impairment, but the percentage decreased 
among elderly and respondents with lower educational level. 
Combining the influence of age and education level in participants’ 
preference for the rating model pictogram (Figure 2), it can be depicted 
that participants in the category “younger (18-39 years old) with high 
education level” (n=46) had the highest preference for the rating model 
pictogram in expressing a warning message, whereas participants in 
the category “older (> 60 years old) with low education level” (n=10) 
showed the lowest preference for this pictogram system. Similar results 
were found regarding the preference for the rating model system in 
expressing levels of impairment (Figure 2). No interaction effects 
between age and education level were found, F(4, 270)=0.81, p=.52.
Independent variables
Preference for pictogram 
model in expressing a 
warning message (N=270)a
Preference for pictogram 




95% CI for OR Odds-
Ratio
95% CI for OR
lower upper lower upper
Age Categories  (60-79 used as reference)
20-39 3.11* 1.27 7.63 11.26* 2.94 43.12
40-59 2.30* 1.15 4.62 3.72* 1.70 8.15
Education level (low level as reference)Intermediate 1.35 0.63 2.89 1.94 0.82 4.56




1.08 0.58 2.00 1.33 0.63 2.79
Pictogram category (category 3 as reference)
Category 1 1.91 0.95 3.88 2.44* 1.02 5.83
Category 2 2.35* 1.12 4.94 1.71 0.72 4.05
Pictogram shown at the start of the interview (triangle model as reference)
Rating model with side-text 2.83 1.39 5.77 2.30* 1.01 5.20
Rating model without side-text 2.99* 1.46 6.12 4.16* 1.68 10.31
Nagelkerke R2 0.176 (17.6%) 0.267 (26.7%)
p-value (model) < 0.001* < 0.001*
a 0=Triangle model; 1=Rating model.
* P-value < 0.05 considered to be statistically significant.
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Figure 2 - preferences for the rating model to express a warning message and levels of impairment 
depending on participants’ age and education level.
Some participants shifted their preference between pictograms 
(Figure 2). From those who preferred the triangle model to express 
a warning message, 39.0% (27 out of 69) considered that the rating 
model pictogram was best to express levels of impairment. Those 
who preferred the rating model to express a warning message, 2.5% 
(5 out of 201) considered that the triangle model pictogram was best 
to express levels of impairment. Table 2 displays the characteristics 
(age and education level) of the participants who did and who did not changed their preference for one pictogram depending on the message 
being conveyed.
Table 2 - participants’ preferred pictogram to express warning messages and levels of impairment.
Preferred pictogram to express a warning message 










20-39 (N=74) 3 (4.1) 63 (85.1) 8 (10.8) 0
< .00140-59 (N=126) 16 (12.7) 93 (73.8) 14 (11.1) 3 (2.4)
60-79 (N=70) 23 (32.9) 40 (57.1) 5 (7.1) 2 (2.9)
Education level
Low (N=54) 18 (33.3) 33 (61.1) 3 (5.6) 0
< .001Intermediate (N=93) 13 (14.0) 63 (67.7) 13 (14.0) 4 (4.3)
High (N=123) 11 (8.9) 100 (81.3) 11 (8.9) 1 (0.8)
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DiscussionThis research investigated participants’ preference for one pictogram related to driving-impairing medicines and its risk in 
traffic. Both pictograms conveyed the same message but differed in 
the design. The rating model pictogram was more complex than the 
triangle model, requiring more complex cognitive aspects to process 
and integrate the information. Even so, the rating model pictogram 
was preferred over the triangle model pictogram to express both a warning message and levels of impairment in all age groups and 
education levels. However, older and low educated participants 
demonstrated to have less preference for the more complex rating 
model and they were also less likely to change their opinion towards 
this more complicated model. This study confirmed that both age and 
education level are sensitive aspects to be considered when designing 
a pictogram to be equally well understood by older adults and those 
who have a low education level. 
Adults over 65 years old represent a substantial and increasing 
proportion of drivers [35]. This group is also known to chronically take several medications, some of them recognized to impair driving 
fitness [35]. Considering that this group of the general population is not 
always fully aware of the risks posed by their medication intake [1,35], 
it is important to find strategies that will help these patients, not only 
to be fully aware of the risks of taking driving-impairing medicines, 
but also to be able to discuss these issues with a health care provider.Assuming that preference can help understanding, since the use 
of familiar objects or messages can foster information processes 
(elaboration likelihood model of persuasion [14]), hypothetically 
it could be argued that a pictogram that is preferred has a higher 
chance of being well understood and, therefore, effective in conveying 
messages. Results from this study indicated that the rating model pictogram was preferred over the triangle model and, therefore, could 
be seen as an effective tool to communicate the risk of driving under 
the influence of driving-impairing medicines to patients throughout all 
ages and education levels. Additionally, in another study, the warning 
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message conveyed by this pictogram model was better understood 
than the triangle model [13].
However, the proportion of participants above 60 years old and with 
low education preferring the pictogram model to express warning 
messages and levels of impairment decreased. This indicates that 
the rating model pictogram seems more suitable to younger and high 
educated participants than to older and low educated participants. 
A possible explanation for this deals with the fact that the design of the rating model pictogram, though more complete than the triangle 
model, is more complex and, therefore, may be more difficult to 
understand. This result is not surprising as, nowadays, complex 
pictograms and signs are widespread and part of daily life routines. 
Those who are younger and higher educated tend to be more prone to understand and follow those instructions, making them more 
adjustable to unfamiliar and complex pictograms. On the other 
hand, older and low educated adults respond better to what they are 
used to [36] and are highly penalized when they are requested to 
interpret icons with complex messages that require more cognitive 
resources for interpretation [36]. Applying this to the present study, 
it is reasonable to assume that familiarity influenced older and low 
educated participants’ preference for the triangle model pictogram. A 
stand-alone triangle (triangle model pictogram), can be more familiar 
than a rating scale with a triangle inside (rating mode pictogram) as 
it may recall caution or dangerous situations. Additionally, triangles 
are commonly used in traffic. Familiarity can equally explain why old and low educated participants were more reluctant to change their 
preference, as they were less likely to prefer a different pictogram to 
explain different information. Despite the encouraging results of the rating model pictogram, 
which seem to be well designed and able to convey a warning message 
and different levels of warning risk, attention should be paid to the 
fact that results on another study using on the understanding of the 
rating pictogram showed that 35.6% (32 out of 90) of the participants 
were able to fully understand the  meaning of the pictogram, i.e, 
were able to identify a traffic-related message and made a reference 
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to the risk category[13]. Worth mentioning that, in that same study, 
the percentage of participants who fully understood the message 
conveyed by the triangle model was notoriously lower (7,8%, 7 out of 
90). This re-enforces the message that pictograms should, at all times, 
be accompanied by other information given to patients at the time of 
consultation, by a healthcare provider. In this way, the efficacy of the 
message given to the patient can be improved.
This study should be seen in the light of some limitations and strengths. 
The main limitation of the study deals with the fact that the population 
might not be representative of the general population as this study 
was conducted in a small convenient sample (N=270) in the North of 
the Netherlands. Nevertheless, results from this study confirm that 
attention should be paid to specific target groups, namely older people and those with low education level, when designing pictograms which 
are known to be particularly useful for these two specific target groups. Another limitation deals with the fact that participants were shown 
one of the pictograms before being asked to indicate the one of their 
preference. Albeit this variable had been controlled for, it could have 
had an impact in the preference for one pictogram. Previous research 
indicated that familiarization plays an important role in understanding, 
as discussed above. The present study is, to be best of authors’ 
knowledge, the first one attempting to compare two pictograms related to the use of driving-impairing medicines and to investigate which one 
better illustrates warning messages in participants’ opinion. 
Future research should evaluate the rating and triangle model 
pictograms among different subjects, such as patients over 60 years old and with low education who take driving-impairing medicines and 
drive. If a pictogram related to driving-impairing medicines is to be 
implemented, specific training to healthcare providers regarding this 
topic should be given, as the pictogram may raise some questions from 
patients which need to be answered. It is equally important that health care providers are aware that older and low educated patients need 
special attention as they are particularly sensitive to pictograms and 
their understanding of the meaning of the pictograms is not always 
straightforward.   
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Abstract
Objectives: To assess the effectiveness of a pharmacist’s training on 
patients’ knowledge, attitudes, and reported behaviour concerning 
the safe use of driving-impairing medicines (DIMs).
Methods: Intervention group pharmacists attended a training on 
how to inform patients about DIMs and how to use supporting ICT 
tools. Patients 18 years or older with a first-time prescription for DIMs 
issued 1-month before (T0) and 6-months after (T1) the training were 
sent a questionnaire. 
Results: 421 patients at T0 and 509 at T1 participated. The pharmacist 
training did not affect patient knowledge about the role of DIMs in 
road accidents and attitudes towards driving under the influence of 
DIMs. Additionally no significant changes were found for self-reported 
driving behaviour, both before and after the training about 4 out of 
ten patients stated to drive less frequently because of the use of DIMs. 
A small decrease (26.6% to 25.2%) was found in the proportion of patients who stated to change the intake of DIMs when having to drive in the intervention group while the control group showed an increase 
of 8.2% (from 27.3% T0 to 35.5%) at T1; a statistically significant 
difference  (P-value=0.02) was verified. 
Conclusion: This pharmacist’s training did not change patients’ 
knowledge, reported driving behaviour and attitudes towards driving 
under the influence of DIMs. 
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Practice implications: To increase patients’ motivation to change 
driving behaviour, interventions should also focus on counselling 
rather than solely on providing patient information.
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Introduction
Some medicines, such as sedatives, anxiolytics, hypnotics, 
antidepressants, either by themselves or in association with alcohol 
or other psychotropic substances, are known to impair driving fitness 
[1-5]. As a consequence they are associated with an increased risk of 
traffic accidents [1-5] which is particularly frequent at the beginning 
of treatment [4]. Previous research concluded that patients like to be 
well informed about the risks [6] and side-effects [6-8] of the medicines 
they take. Additionally, patients expect to receive clear information on 
how to handle their medication, not only by knowing how to use it 
adequately but also what to do in case of side-effects. This is especially 
important with medicines that can affect driving, since patients may 
put themselves and others at risk of being involved in a traffic accident.An important pillar for patient information is the patient information 
leaflet (PIL) which is included in all medicine boxes. Here, patients 
can find a reference to medicines’ risks and side-effects. However, 
with respect to the influence of medicines on driving fitness, the text 
included in the PIL is general and therefore not tailored to patients’ 
individual needs and risks while participating in traffic [9, 10]. Another source of information for patients are pharmacists, who are considered 
to be one of the most accessible health care professionals (HCP) [11] and, in most cases, the last healthcare professional that patients visit 
before start taking their medication. Therefore, pharmacists can play an active role in patient counselling and education regarding the actual 
influence of medicines on driving fitness. Moreover, pharmacists can 
ensure that the information is fully understood [12] so that patients can make an informed decision on whether or not it is safe to drive 
their car while taking a driving-impairing medicine (DIMs).
Results from a recent study concluded that Belgian pharmacists 
underlined the importance of being informed on the risks of medicines 
on driving fitness underlined the importance of clear guidelines 
and recommendations on the risks of medicines on driving fitness. Pharmacists were more inclined to provide such information to patients 
if guidelines were easily accessible [13]. Guidelines for pharmacists 
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regarding how to inform patients on DIMs are indeed scarce [4] and 
not available in the majority of the EU countries [14]. The existing 
materials for HCPs are based on the report of a working group within 
the International Council on Alcohol, Drugs and Traffic Safety (ICADTS) 
[15]. More recently, and as part of the European DRUID (driving under 
the influence of drugs, alcohol and medicines) [16] project, guidelines 
[14]  and additional information materials were generated, including 
materials to increase the knowledge of pharmacists and other HCPs.
One possible way to overcome the need for more support on how 
to inform patients on DIMs is by means of pharmacists’ interventions. 
The most common key components of pharmacists’ interventions 
involve medication education, advice about alternative treatment 
options and providing written information [17]. Two intervention 
studies in the United Kingdom [18,19], involving a training course 
for community pharmacists covering several health education topics, 
such as coronary heart disease prevention, asthma, substance misuse, 
diabetes and diet [18], smoking cessation, blood pressure monitoring, 
pregnancy testing [19], improved pharmacists’ health education 
activity, showing positive outcomes in terms of the increased amount 
and quality of health related advice and patient-oriented information 
as well as positive outcomes at patient level [18,19]
By means of the present study, which is part of the European DRUID 
project [16], a training course for pharmacists was developed. The 
main objective was to train pharmacists on DIMs so that they were 
able to provide pro-active counselling to patients on this topic and 
were also ready to answer patient’s questions and doubts about DIMs. 
This would be expected to enhance patients’ knowledge about the risks of driving a car while using a DIMs and assist them in making informed decisions on whether to drive a car or not while taking a 
DIMs. Therefore, the main aim of this study is to assess the effects of pharmacists’ training on patients’ knowledge, attitudes, and reported 
behaviour concerning the safe use of DIMs. 
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Methods
Study design and participants
A randomised controlled intervention study was conducted in the 
Netherlands and consisted on the training of community pharmacists who were interested in improving their dispensing practices 
concerning DIMs, by supporting them during dispensing counselling. 
All users (n=1031) of the largest Dutch pharmacy software system 
supplier, Pharmacom®, were invited to participate in this study, which 
took place in October 2009. However, only those who did not actively 
use their software system  to help counselling regarding the medicine’s 
groups known to impair driving fitness, such as anxiolytics (ATC code: 
N05B), hypnotics (ATC code: N05C), and antidepressants (ATC code: 
N06A) were eligible to participate in this study and randomly assigned 
to either the intervention or the control groups. 
Pharmacists from both groups were asked to randomly select out of 
their computer system up to 35 patients who would meet the following 
inclusion criteria: aged 18 or older and with a first-time prescription 
(defined as no use in the preceding 18 months before the prescription 
date) for any anxiolytics, hypnotic, or antidepressant medicine(s), 
during a period of 1-month before the start of the study (T0) and 
6-months after the intervention (T1) (Figure 1). Patients included in 
both time periods differ, since only first-time users were selected for 
inclusion. Patients received a patient information letter to explain the goal of their participation, a questionnaire, and stamped addressed 
return envelope from their pharmacist. 
This study was approved by the Medical Ethical Committee 
of the University Medical Centre Groningen, in the Netherlands 
(METc2009/300). All data were extracted anonymously and the 
privacy of the participants was granted throughout the whole study.
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Figure 1 - study design and data collection.
Intervention (pharmacists’ training)
Pharmacists from the intervention group received five hours of 
educational training which focussed on background information 
allowing pharmacists to provide counselling and to be theoretically 
prepared to answer patients’ questions about DIMs, in particular 
with respect to the application of a four-level categorization system 
for medicines based on their impairing properties [20], as well as 
information to be given to patients during consultation [14]. All participants were given a folder with information materials concerning 
driving-impairing medicines (Figure 2). Additionally, pharmacists were asked to start using the Pharmacom® ICT module as additional source 
of information during patient counselling concerning anxiolytics, 
hypnotics, and antidepressants.
Data collection T0 Data collection T1
Sept ‘09 April ‘10Oct ‘09
6 - months time
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• Medicines and driving• Information about estimated fatalities due to driving under the influence of psychotropic medicines 
was provided. It was stressed that medicines within the same therapeutic class may have different 
levels of impairment. An introduction to the categorization system (hereby referring to the DRUID 
efforts) was given.• The Dutch juridical consequences on the prescription and delivery of driving impairing medicines 
were mentioned. Example of the categorization of well known medicines was shown. • Practical application• The consequences for patient information while dispensing DIM, as it is described in the guidelines 
for counselling patients and advising physicians. The available written materials, including warning 
signs, were shown and discussed.• The Pharmacom® ICT- tool was introduced, including information on how to install and use it. A 
demonstration was displayed. It was also discussed the use and limitations of the tool as well as how 
the tool displayed patient information. • The “in-pharmacy” training (how to coach the pharmacy team/technicians)• The attending pharmacists usually managed ten to fifteen employees, mainly pharmacy technicians 
and they are the ones who mostly used the ICT-tool and informed patients. Therefore, it was discussed, 
in detail, how the pharmacy team should be coached and how to motivate all employees. • The material for the “in-pharmacy training” included cases and some roll-plays. After making 
reference to these materials, the pharmacists had the opportunity to exercise themselves on how to 
inform patients or on how to discuss this issue with the prescribers. • Personalized medicines information leaflet generated through Pharmacom®• With the personalized medicines information leaflet, patients received complete information about 
their medicine(s), which included information on the influence of the medicine on driving fitness and 
advices how to adjust their behaviour to prevent accidents, e.g. information about how many hours or 
days they had to refrain from driving.• In this leaflet, a pictogram was included, as well. The pictogram (DRUID warning label) gives 
information on the severity of the impairment that is associated with the medicine (this implies a 
categorization system based on the level of impairment of a medicine on driving fitness).• The warning label, combined with oral information and written warnings and instructions in the 
leaflet provides personalized information to the patient. The leaflet was printed and given to the patient 
during the first-time dispensing of a medicine. 
Figure 2 - Summary of information materials provided during pharmacists’ training.
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Patient questionnaire
The written questionnaire was divided in 7 topics of interest, 
covering patients’ 1) background information, 2) participation in 
traffic, 3) use of medicines, 4) knowledge about influence of medicines 
in traffic safety, 5) information received concerning the influence of 
medicines in driving fitness, 6) reported behaviour in traffic after 
receiving information, 7) attitudes towards traffic. 
Outcome measures and measurements
A list covering the main information topics on DIMs (addressed in 
the pharmacists’ intervention) was part of the patient’s questionnaire. 
Patients could select from a list the topics they were informed about 
during consultation. The list covered the following topics: influence 
of medicine on driving fitness, severity of impairment, alternative medicines with less impairment, legal consequences of driving under 
the influence, how to decrease the risk of becoming involved in traffic 
accidents while taking a DIMs, influence on operating machinery and 
on other activities at home or which require attention, and lastly the 
duration of the affect on driving fitness (2, 8, 12, 16, 24 hours, 2-3 days, 
1-2 weeks, forever).
Patients’ knowledge regarding the influence of medicines on driving 
fitness was assessed by means of two parameters; 1) knowledge about 
causes of road accidents and 2) knowledge of the risks of being involved 
in a traffic accident while driving under the influence. Many factors 
can be attributable causes of road accidents, such as “driving under 
the influence of alcohol”, “speeding”, or “use of medicines that might 
impair driving”, among others. On a 4-scale parameter ranging from 
1 ”never” to 4 ”often”, patients were asked how often they thought the 
above mentioned factors could be seen as causes of road accidents. A scale for knowledge regarding causes of road accidents was generated 
(Cronbach’s Alpha = 0.90). Regarding knowledge about risk, patients 
were asked whether they would agree or disagree (4-scale parameter 
ranging from 1 “totally disagree” to 4 “totally agree”) with statements 
related to the risk of being involved in a traffic accident due to the intake 
of DIMs. Patients’ answers were, thereafter, recoded into “wrong” (0) 
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or “right” (1). When patients answered “don’t know”, their answer was 
considered to be wrong (0). For the 5 statements, patients could have 
a score of correct answers ranging from 0 (no correct answers) to 5 (5 
correct answers). 
Reported behaviour was analysed in terms of a reported change in 
1) patients’ frequency of driving, by driving less frequently (yes or no) 
and 2) a change in patients’ intake of DIMs (yes or no) after receiving information from their pharmacist, which could include no intake of 
the prescribed medicine at all, i.e., stopping medication, less intake of the medicine or for a shorter period of time, intake of the medicine at 
night instead of during the day, intake of medicine only when driving 
was not necessary, or switch to a less driving-impairing medicine, after 
consultation with HCP. 
A 4-scale parameter ranging from 1 “totally disagree” to 4 “totally 
agree” regarding patients’ attitudes towards behaviour in traffic while 
under the influence of DIMs was generated (Cronbach’s Alpha = 0.88), 
in order to be able to compare means regarding patients’ attitudes. Socio-demographic items included in the questionnaire were gender 
(male, female), age (18-34, 35-54, 55-75, >75 years), education level 
(low, intermediate, high), and frequency of driving motorized vehicles 
(frequent, sporadic).
Statistical analysis 
Since patients at T0 and T1 were not the same, data analysis were 
done at patient and pharmacy level (aggregated data).
At patient level, descriptive analysis was conducted to analyse patients’ socio-demographic characteristics, such as gender, age, 
education level, frequency of use of motorized vehicles, and experienced 
side-effects. Chi-square test of independence was used to investigate 
differences in the different socio-demographic characteristics. 
At pharmacy level, data were aggregated using pharmacy group 
and pharmacy code as grouping variables. In this way, it was 
possible to investigate changes in the dependent variables (outcome 
measurements) over time (T1-T0) in both pharmacy groups. Analysis 
was controlled for the baseline measurement (T0). Differences 
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between intervention and control patients were tested with ANOVA, 
Student’s t-test or Chi-square test where appropriate. 
For all comparisons, a p-value < 0.05 was considered to be statistically 
significant (95% confidence interval). Data were analysed using SPSS 
18.0 for Windows.
Results
Of the 1031 invited pharmacists, 277 accepted the invitation (26.9% 
response rate). Of those, 100 pharmacists were eligible to participate 
and were randomly assigned to the intervention (n=50) or control 
(n=50) group. Due to drop-outs, the final number of participants was 
91 (49 in the intervention group and 42 in the control group). 
A total of 421 patients (244 in the intervention and 177 in the control 
groups) returned their questionnaire. Since there is no data on the 
total number of patients approached by pharmacists at T0, it was not 
possible to calculate the actual response rate. Concerning the follow-
up (T1) measurement, a total of 2,968 patients were approached, and 
509 patients (311 in the intervention and 198 in the control groups) 
returned their questionnaire (17.1% response rate). The number of 
patients included per pharmacy ranged at T0 between 1 and 13, with 
an average of 6 patients included per pharmacy and between 1 and 18 
with an average of 7 patients included per pharmacy at T1. 
Overall, there were more females (61.0% at T0 and 65.8% at T1) than 
males. The mean age was 54.3 years (sd=14.8, min=19 years; max = 86 
years) at T0 and 52.9 years (sd=14.6, min=19 years; max = 90 years) 
at T1. As for education level, at T0, 40.5% of the patients had a low 
educational level, followed by intermediate (33.8%), whereas at T1, 
39.4% of the patients had an intermediate educational level, followed 
by a low educational level (39.4%). At both time measurements, at 
about 80% of the patients use their motorized vehicle frequently 
and almost 63% mentioned they have experienced side-effects 
which are known to impair driving fitness. For all socio-demographic 
characteristics considered, no statistical significant differences were 
found between intervention and control groups at T0 and T1 neither 
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between conditions and time measurements (Table 1). Table 2 displays 
the scores for relevant outcome measures at patient and pharmacy 
(aggregated data) level.
Table 1 - Patients’ socio-demographic characteristics.
Baseline measurement, T0 
(N=421)
Follow-up measurement, T1 
(N=509)
Intervention Control Intervention Control
Gender Male 98; 40.5% 64; 36.2% 109; 35.0% 64; 32.5%
Female 144; 59.5% 113; 63.8% 202; 65.0% 133; 67.5%
Age categories
18-34 years 23; 9.6% 21; 11.9% 36; 11.6% 24; 12.4%
35-54 years 80; 33.3% 72; 40.7% 117; 37.7% 82; 42.3%
55-75 years 117; 48.8% 69; 39.0% 132; 42.6% 78; 40.2%
> 75 years 20; 8.3% 15; 8.5% 25; 8.1% 10; 5.2%
Education level
Low 99; 41.1% 70; 39.8% 111; 35.7% 70; 35.7%Intermediate 76; 31.5% 65; 36.9% 114; 36.7% 86; 43.9%
High 66; 27.4% 41; 23.3% 86; 27.7% 40; 20.4%
Frequency of use of motorized vehiclesSporadic use 50; 20.5% 28; 15.6% 57; 18.3% 34; 17.2%
Frequent use 194; 79.5% 149; 84.2% 254; 81.7% 164; 82.8%
Experienced side-effectsNo 73; 32.6% 48; 29.1% 106; 35.2% 63; 33.2%
Yes 151; 67.4% 117; 70.9% 195; 64.8% 127; 66.8%
No statistically significant differences (p-value < 0.05) were found between intervention and 
control groups at T0 and at T1, neither between T1 and T0 (T1-T0). 
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Table 2 – Scores for relevant outcome measures at patient and pharmacy (aggregated data) level.
Baseline measurement, T0 Follow-up measurement, T1 p-value 
T1-T0Intervention Control p-value Intervention Control p-value


























Knowledge about causes of road 
accidents (mean*)
3.50 ± 0.55 
(n=190)
3.53 ± 0.59 
(n=135)
0.65
3.54 ± 0.54 
(n=241)




risks of being involved 
in a traffic accident 
due to DIMs (mean**)
3.73 ± 1.10 
(n=236)
3.67 ± 1.04 
(n=170)
0.90
3.73 ± 1.10 
(n=303)
3.55 ± 1.13 
(n=196)
0.37 0.047
Changes in driving 





















0.02+Stop of medicine intake n=2; 1.1% n=3; 2.2%
0.34
n=2; 0.7% n=5; 2.5%
0.035+









16.2%Intake of medicine when there is no need to drive n=12; 6.7% n=6; 4.3% n=9; 2.9% n=16; 8.1%
Prescribed a less impairing medicine n=0; 0.0% n=1; 0.7% n=2; 0.7% n=0; 0.0%No change in the medicine intake n=130; 73.4% n=101; 72.7% n=229; 74.8% n=127; 64.4%Attitudes towards driving under the 
influence of DIMs 
(mean***)
3.04 ± 0.59 
(n=162)






2.89 ± 0.65 
(n=147)
0.69 0.90
* mean values on a scale ranging from 1 “never” to 4”often”.
**mean values for the number of correct answers (0 “no correct answers” to 5 “all correct answers”).
*** mean values on a scale ranging from 1 “totally disagree” to 4 “totally agree”.
+ significant result, p-value < 0.05.
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Information received by patients 
At the start of the study (T0), 62.0% of patients from the intervention 
group and 70.5% from the control group reported being informed 
regarding the possible influence of medicines on driving fitness 
(Table 2). The percentage of informed patients, 6-months after the 
intervention (T1) increased 12.0% in the intervention group and 5.2% 
in the control group. 
Regarding the topics patients were informed about, the majority 
(over 85% in the intervention and in control groups) received 
information regarding the influence of medicines on their driving 
fitness, followed by information regarding the influence of medicines 
on operating machinery and the severity of impairment. Nevertheless, 
no statistically significant changes between T1 and T0 were found with 
respect to any of the topics patients were informed about (Table 3). 
Table 3 - Patients’ reported received information during consultation with the pharmacist in both 
groups (intervention and control), at both time measurements (T0 and T1).
Albeit the change in the percentage of informed patients being higher 
in the intervention group, this was not significantly different (F(1, 58) 
= 0.83; p = 0.37) from the change in the control group. 








Impairment on driving fitness 116; 86.6%* 101; 88.6%* 184; 86.0% 128; 88.9%
Severity of impairment 29; 21.6% 28; 24.3% 45; 21.0% 28; 19.4%Safer alternatives which can impair 
driving fitness less
4; 3.0% 1; 0.9% 2; 0.9% 5; 3.5%
Legal consequences of driving under 
the influence
4; 3.0% 4; 3.5% 12; 5.6%** 17; 11.8%**
Decrease the risk of being involved 
in a traffic accident
3; 2.2% 2; 1.7% 7; 3.3% 7; 4.9%
Influence on operating machinery 58; 43.3% 46; 40.0% 85; 39.7% 51; 35.4%
Influence on activities at home 2; 1.5%** 8; 7.0%** 5; 2.3% 9; 6.3%
Influence on other activities that require attention 8; 6.0% 6; 5.2% 9; 4.2% 4; 2.8%
* Total N = 248.
** Statistically significant result, p-value < 0.05.
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Knowledge regarding the influence of medicines on driving fitnessThe mean scores for the scale encompassing different causes of road 
accidents was very similar among patients from the different groups 
(Table 2), meaning that at both measurements patients rated the factors 
as being sometimes causes of road accidents. No significantly different 
changes in patients’ knowledge about causes of road accidents (T1-T0) 
were found between the intervention and in control groups (F(1, 57) 
= 1.36; p = 0.25). 
Results show that patients had sufficient knowledge about the risks 
of being involved in a traffic accident due to the intake of DIMs. The 
statements with lower percentage of correct answers (percentage < 
55%) were related to the risk of having a road accident when combining 
DIMs with an OTC (both in the intervention and control group, at T1) 
and to the risk of having a road accident when combining several 
DIMs (control group, at T1).The average of correct answers (ranging 
from 0 to 5) did not change over time in the intervention group (Table 
2). However, in the control group, a change of -0.12 was verified in 
patients’ knowledge, meaning that the mean values at T1 were slightly 
lower than at T0. In fact, the decrease verified in the control group 
was statistically significant different (F(1, 60) = 4.12; p = 0.047; beta = 
-0.19) from the (no) change in the intervention group. 
Reported behaviour concerning driving under the influence of medicines
Over time, the percentage of patients who reported a change in their 
driving frequency due to the intake of DIMs, by driving less, increased 
5.2% in the intervention group and decreased 10.6% in the control 
group (Table 2), No statistically significant changes (T1-T0) between intervention and control groups were found, despite the opposite 
trend verified in both groups (F(1, 59) = 3.04; p = 0.09).
Regarding changes in the intake of DIMs, it was verified over time 
a decrease of 1.4% in patients who reported to change the intake of 
DIMs in the intervention group and an increase of 8.2% in the control 
group (Table 2). These changes (T1-T0) in the intake of DIMs were 
statistically significant (F(1, 59) = 5.39; p = 0.02, beta = 0.19.
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Attitudes towards behaviour in traffic while driving under the influence 
of DIMsThe mean values for patients’ agreement with the statements 
concerning attitudes towards traffic while driving under the influence 
of DIMs (Table 2), decreased over time 0.13 and 0.06 in the intervention 
and control groups, respectively. The slight decrease in the intervention 
group was not significantly different (F(1, 47) = 0.02; p = 0.90) from 
the decrease in the control group. 
Discussion and conclusions
Discussion
This study shows that a pharmacist training, aimed at better 
informing patients about driving impaired medicines, did not change 
patients’ knowledge, reported behaviour and attitudes towards 
driving under the influence of DIMs. However, it demonstrated that 
the majority of patients were, at baseline, well informed about and had 
good knowledge of the influence of DIMs. Almost two third of patients 
mentioned having experienced side-effects known to impair driving 
fitness. Yet, experiencing side-effects did not seem to be a reason to 
refrain from driving, since 80% of patients used their motorized 
vehicle frequently. This is supported by previous research which has 
demonstrated that patients using psychotropic medicines regularly 
drive their car [21,22]. 
No differences were found in the number of informed patients between 
the intervention and the control group. This could be explained by the 
Dutch public campaign entitled “drive safely with your medicines” 
[23], launched in October 2008, where several information materials 
regarding DIMs were developed, aiming at properly inform HCP about 
the influence of medicines on driving fitness. The few discrepancies found in the information patients mentioned having received from their 
pharmacists makes it hard to conclude about the positive outcomes of 
the intervention in the information given to patients. The fact that the 
evaluation of the public campaign 2 years after being launched (2010) 
showed that the materials developed increased awareness about 
148 | Chapter 6
DIMs, in particular among pharmacists [24], and that in a similar the 
majority of participants received information from their healthcare 
provider about the influence of medicines on their driving fitness [21], 
could explain why patients from both groups were informed about 
the influence of DIMs on driving fitness and may imply that future 
interventions should focus more on patient behaviour changes rather 
than in improving patient knowledge. 
Patients’ knowledge about possible causes of road accidents was 
already high in the baseline measurement making it unlikely to 
improve due to an intervention. Concerning the overall mean of 
correct answers regarding patients’ knowledge about the risks of 
being involved in a traffic accident due to the use of DIMs, it was found that changes were higher in the intervention group than in the control 
group. In a previous study [21], where the same parameters were used, 
patients’ knowledge was considered to be rather low. Comparisons 
between the two studies should, however, be done carefully since the 
scale measured different outcomes. Nevertheless, it seems plausible to 
assume that Dutch patients’ knowledge increased, most likely due to 
several interventions conducted after 2008 [24,25].The information patients received from their pharmacists had 
rather low impact in changes in patients’ reported behaviour. In the intervention group, the percentage of patients who start driving less 
frequently to avoid the hazardous effects of medicines on driving 
fitness increased 5% at T1. Concerning changes in the consumption of DIMs to avoid the negative impact of such medicines on driving 
fitness it was verified that patients from the control group changed 
the intake of their medication significantly more than patients from 
the intervention group. Yet, given these results, it is likely that patients in the intervention group would rather stop driving than changing the 
intake of their medicines since less than 1/3 of the patients changed 
the intake of their medicines. This is in line with a previous study [21] where it was concluded that Dutch patients changed the intake of their 
medication less often than patients from other countries.
This study is one of the few aiming at training pharmacists regarding 
DIMs and their influence on driving fitness and it is the first one to 
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focus on patient outcomes. Additionally, many information materials 
addressed to health care professionals were developed [14, 20, 26]. 
Such materials, part of the DRUID project framework [16], are public 
and readily available [16] to anyone who would like to know more about 
this topic; this can be particularly useful to health care professionals 
who wish to improve patients’ counselling regarding DIMs. 
The study has, however, some limitations. First, it should be pointed 
out the relatively low response rate. At T0, despite not being possible 
to calculate, it is believed that the real response rate should not be that 
different from the one at T1. These values are in line with other study 
which followed the same methodology [21]. The reasons for such low 
response rate may be due to the fact that several patients, despite 
the reminders, did not return the questionnaire, perhaps because 
they did not relate with the research. Nonetheless, results should be 
considered with care and conclusions should be drawn with caution, 
as results might not be representative of the patients who take DIMs 
and still need to drive their motorized vehicle. Secondly, it is important 
to stress that the patients included at both time measurements were 
obviously not the same, since our research was focused on first-
time users of DIMs. As such, it may be sometimes difficult to clearly 
attribute changes in patients’ knowledge, reported behaviour and 
attitudes to the intervention, even if no statistically significant differences were found in patients’ socio-demographic characteristics 
in both time measurements (T0 and T1). Thirdly, the results were 
based on patients’ self-reported behaviour. However, self-report is 
a cost-effective, valuable and widely used method in social sciences 
research [27]. Fourthly, it should also be mentioned that the public 
campaign launched in 2008 [23] may still have a positive influence 
in pharmacists’ counselling and patient education. This may explain 
the high percentage of informed patients which may undercover the 
positive influence of the intervention. Future research should focus on 
the systematic implementation of other information campaigns and 
interventions to keep the topic under attention not only of pharmacists 
but also other HCPs. Ideally, collaboration between pharmacists and 
physicians should be seek in order to optimize the information that 
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is given to patients, stressing in this way the importance of shared 
responsibility in healthcare. Lastly, to analyse the differences at 
patient level, data from the same patients should have been collected 
at both time points. However that was not possible, since the purpose 
of the study was to analyse the information given to first-time users of 
medicines. 
Conclusion
This study tested the effectiveness of a pharmacists’ intervention 
training focusing on enhancing patients’ counselling about the 
influence of DIMs on driving fitness. Despite the fact that the intervention did not improve patient knowledge and self-reported 
behaviour, this study has illustrated that patients’ knowledge about 
driving under the influence of medicines proved to be high at baseline. 
Future interventions should focus more on patients’ motivation to 
change their driving and /or medicine intake behaviour, rather than 
on patient education.
Practice implicationsDespite the fact that pharmacists’ intervention was not translated 
into significant changes in patients’ knowledge and reported behaviour, 
it could be argued that this was due to the fact that Dutch patients 
possessed high knowledge about DIMs and their influence on driving 
fitness. It could, therefore, be believed that the Netherlands is a good 
example of a country where past efforts have been made with long-
term positive outcomes at patient level, showing that it is possible 
to improve patient care provided by pharmacists. As such, future interventions should rather focus on patient motivation to change 
behaviour rather than patient education. This could be done by means of motivational interviewing, which is a rather advantageous method 
to encourage people to make behavioural changes to improve health 
outcomes [28]. In particular, HCPs could motivate their patients to 
change their behaviour towards driving less frequently and/or change 
medicines’ intake in such way that it would not impair driving fitness. 
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General Discussion and Future Perspectives
Results from the published scientific evidence attesting to the driving-impairing effects of some medicines have shown that there is 
a clear lack of understanding regarding patients’ knowledge about this 
subject as well as about patients’ reported driving behaviour when 
driving under the influence of driving-impairing medicines (DIMs). 
The lack of awareness regarding the influence of medicines on driving 
fitness, by both patients who drive and health care professionals 
(HCPs), is worrisome. It brings into question whether HCPs have all 
the necessary instruments to inform their patients about the risks of 
driving under the influence. Consequently, it also questions whether 
patients receive sufficient and adequate information to support their 
decision-making on how to make the best use of their medicines and 
whether they should drive while taking DIMs or not.
Therefore, the main objectives of this thesis were to:
1) assess knowledge about DIMs and their influence on driving 
fitness as well as reported behaviour of patients who drive while 
taking driving-impairing medicines;
2) define the criteria and methodology for the development of a 
categorisation system for commonly used medicines, based on their 
influence on fitness to drive;
3) develop and evaluate the effectiveness and preference, at the 
patient level, of a warning symbol encompassing the different levels 
of impairment derived from the categorization system, and identify patients’ preferences for a pictogram related to patients’ age and 
education level;
4) evaluate the effect of a training course developed for community 
pharmacists in patients’ knowledge and reported behaviour, at the 
start of treatment.
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The work presented in this thesis provides insight towards patients’ 
understanding and reported behaviour regarding the influence of 
medicines on driving fitness. Additionally, it describes the efforts made to develop a standardized approach to categorize medicines according to their level of driving impairment and create a pictogram 
based on this categorization system. Lastly, it also contains the impact of a training course on medicines and driving given to pharmacists and 
evaluated at the patient level. Finally, some general considerations on 
the implications for clinical practice are presented. 
Main findings and discussion
Patients’ knowledge and reported behaviour towards driving under the 
influence of DIMs
Patients’ knowledge and reported behaviour towards driving under 
the influence of DIMs was evaluated in four European countries (Chapter 
2). The results of this study [1] were in line with previous studies 
[2-4] and confirmed that patients have little knowledge regarding 
the influence of DIMs on driving fitness. Patients’ knowledge was 
associated with patients’ age and education level: younger and higher 
educated patients had better knowledge than older and low educated 
patients. Additionally, the data suggested that patients’ knowledge 
was not associated with patients’ reported driving behaviour leading 
to the conclusion that knowledge may be a pre-requisite that triggers 
behaviour but it is not necessarily a condition to behavioural changes. 
Patients’ lack of awareness and knowledge regarding the influence 
of DIMs on driving fitness was a clear indicator of the need to develop 
information stressing the risks of driving under the influence of some 
medicines. Considering that medicines have different levels of driving-
impairment and that most of the information about medicines that 
patients receive is provided by HCP, it was appropriate to develop a 
categorization system that HCPs could use as a tool to better inform 
their patients. 
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A European approach to categorizing medicines based on the level of 
driving impairment
A review conducted in 2008 identified 15 categorization systems 
concerning driving-impairing properties of medicines available in 
Europe [5]. However, none of the identified systems clearly reported 
on the methodology that was followed to categorize such medicines. As a consequence, a standard and harmonized criterion to categorize 
commonly used medicines according to their potential to impair 
driving fitness was established (Chapter 3) [6]. Nearly half of the 1,541 categorized medicines were considered to have no driving impairing 
properties (category 0), 26% minor driving-impairing (category 1), 
and 11% moderate driving-impairing properties (category 2). About 
6% of categorized medicines were included in the severest category of 
impairment (category 3), of which the majority belonged to the ATC N 
group (nervous system), sub-category N05 (psycholeptics). 
Such a categorization system should be considered as a tool for 
improving prescribing and dispensing procedures and as an instrument 
to inform and involve HCPs and patients. This categorization system 
can be applied in different ways, since it can be linked to:• the SmPC and PIL (if the categorization system is taken into 
account by the European Medicines Agency (EMA), for example);• warning labels and pictograms;• information materials for HCPs;• prescribing and dispensing guidelines;• patient-oriented guidance, focusing on patient needs and 
individualization of the information.
Considering that pictograms have been widely used to convey warning 
and safety-related messages [7, 8], increasing patients’ understanding 
of risks [9-11], a pictogram was developed based on the categorization 
system (rating model pictogram). This pictogram encompassed the different categories of risk with aim of raising patients’ awareness of 
the risks of driving under the influence of medicines and helping them 
assessing such risks (Chapter 4). 
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Pictograms to convey risk messages regarding medicines and driving
The rating model pictogram was comparable to the pictogram 
developed in France [12, 13], referred to as triangle model pictogram. 
The main difference between the two pictograms dealt with design: 
the triangle model has a simpler design. The studies compared and evaluated these two pictogram models in communicating risk in terms of respondents’ level of understanding, estimated level of driving 
risk, and intention to change driving behaviour [14] (Chapter 4). 
Respondents’ preference for one of the two pictograms, based on age 
and education level, was also assessed (Chapter 5). 
Both pictogram systems proved not to be fully self-explanatory. Yet, 
respondents who were asked about the rating model pictogram could 
give more fully correct answers in terms of understanding. The majority 
of participants reported that they would probably change their driving 
behaviour by driving less frequently whenever their medicine would 
have such a pictogram. The likelihood to change driving frequency 
increased with the category of risk. 
The majority of respondents preferred the rating model pictogram to 
express warning messages and levels of impairment (Chapter 5). It is 
known that both elderly and low educated patients prefer simple and 
familiar pictograms [15]. Our study confirmed this finding that, among 
the indicators included in our study, age and education level were the 
ones most strongly associated with preference for a certain pictogram, 
with age being a stronger predictor than education level. Despite the 
preference for the rating model system throughout all age categories and education levels, a trend showing that preference for the triangle model pictogram, considered as having a more simplistic design, 
increased with an increase of age and a decrease of education level. 
From our analysis, it became clear that similar to what has been 
found in previous research regarding medication instructions [16, 17], 
stand-alone pictograms are unlikely to be successful. Considering that 
medicines’ leaflets with pictograms are greatly preferred by patients 
over text only leaflets [15], it can be assured that if the pictogram 
would be discussed during consultation and thereafter included in the written information materials, patient understanding and recall of 
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information would be better ensured. Therefore, it is recommended 
to support pictograms with oral and written information from HCPs in order to avoid misunderstandings and to improve comprehension, 
recall and adherence [15, 18-20].
Pharmacists’ training with information materials regarding driving-
impairing medicines
One of the pitfalls identified in the literature was the lack of 
professional guidelines to support HCPs during counselling of first-
time users of DIMs and lack of information materials for patients [21, 
22]. Chapter 6 describes the results of the intervention study conducted among pharmacists who were trained with several information 
materials and counselling tools, including the pictogram. The effects of 
the intervention were evaluated at the patient level. The study showed that the pharmacists’ training did not change patients’ knowledge, 
reported behaviour, or attitudes. However, it was evident that patients’ 
knowledge about the influence of DIMs on driving fitness was high 
among all patients. This was especially true when the knowledge of 
this study group was compared with the knowledge shown by Dutch 
patients in a previous study (Chapter 2). It remains unclear what caused the difference in Dutch patients’ 
knowledge between the two measurements. It can be hypothesized 
that it was due to a long-term effect from the “Drive Safely with your 
Medicines” public campaign, launched in 2008 in the Netherlands [23]. Several information materials regarding DIMs were developed for this 
campaign with the main aims being to properly inform HCPs about 
the influence of medicines on driving and to advise drivers who take DIMs to contact their general practitioner, specialist or pharmacist 
for more information. However, it is unlikely that this was the only 
possible cause of the differences knowledge between patient groups. 
It is also reasonable to assume that, due to the non-response in both 
measurements, the selection of the participants may have differed 
between the two measurements. In regards to patient knowledge, it was found that knowing that 
certain medicines can impair driving fitness did not necessarily lead 
160 | Chapter 7
to changes in driving behaviour. The first study that was conducted 
had an equivalent conclusion [1] (Chapter 2). This conclusion also is 
supported by another Dutch study [24], where the impact of chronic 
pain patients’ knowledge regarding psychotropic medicines was 
investigated. This leads to the conclusion that a set of strategies that 
concomitantly aim at improving knowledge and changing behavioural 
are needed. The studies conducted and presented here show that there is room for improvement with respect to raising awareness of patients and 
HCPs regarding driving under the influence of medicines. Additionally, 
we propose that the way the information is communicated to patients, 
as well as the type of information provided and which contributes to 
increase patients’ knowledge, can be improved.  In order to achieve such improvements, we suggest acting on three different levels: 
the patient level, the health care provider level, and the (national) 
organizational level. Next, some general considerations regarding 
these three levels are presented.
Patients
Improving patients’ role in the decision-making process
In today’s society, patients are encouraged to take an active role in 
the management of their own health, implying that they need to make 
constant decisions about their health care needs [25]. This active role 
patients play in their own care means that they are more engaged [26], 
better informed about illnesses, treatment options and medicines, 
and, consequently, more likely to actively participate in their health 
care [25]. But in order to do so, it is crucial to apply strategies focused on patient-centeredness and individualization of information during patient-provider communications, which promote a patient’s decision-
making capability.
Patient-centeredness and individualization of information during 
patient-provider communications and the role of health literacy
Due to the growing recognition of the need for health care to be 
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more explicitly centered on the needs of the individual patient [27], 
the concept of “patient-centeredness” has been intensively studied 
in health communication research over the past several years [28]. 
According to Epstein and colleagues (2005) [29], patient-centeredness 
should describe a moral philosophy focused not only on the needs of 
the patient but also on offering patients opportunities to provide input and participate in their care and on enhancing the partnership and 
understanding in the patient–provider relationship. In its essence, patient-centered care requires a focus on 
individualism, where individual needs are to be addressed [30]. 
When considering patient-centeredness, three points should be 
addressed: patient’s individual needs [28, 31, 32], patient-provider 
relationship and communication [30], and patient empowerment [25] 
to make decisions. Health care providers should take time during the consultation to understand each patient as a whole person in such a 
way that they would be able to provide patients with recommendations and information which are adequate to patients’ values and that are 
realistic given patients’ life circumstances.
Considering the particular situation of driving under the influence of 
potentially hazardous medicines, HCPs should try to understand what 
the actual driving needs of a patient are in order to be able to make an adequate treatment decision that will not jeopardize a patient’s 
traffic safety. This can be done either by selecting the least impairing 
medicine within the same pharmacotherapeutic class or by changing 
the timing of intake of the medicines in such a way that side-effects 
will not occur when the patient is driving. After exhausting all the alternatives, i.e., when a highly impairing medicine is to be prescribed, 
the patient should be advised not to drive for a certain period of time, which depends on the medicine and how the patient reacts to that 
same medicine.  
The patient-provider relationship, based on patient-provider communication and mutual trust, is important to make patients more 
aware of the risks of driving under the influence of DIMs and more 
confident in embarking on a process of change in driving behaviour, 
when and if it is necessary [33, 34]. But none of this would make sense 
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if the patient is not able to understand and make use of what has been 
said. It is therefore important that the individualized information is 
adequate to patients’ health literacy level. 
Recently, health literacy has been defined by Sørensen and her colleagues as “people’s knowledge, motivation and competences to 
access, understand, appraise, and apply health information in order 
to make judgments and take decisions in everyday life concerning healthcare, disease prevention and health promotion to maintain or 
improve quality of life during the life course” [35]. Keeping in mind this 
definition, if a patient’s literacy regarding DIMs is to be increased, it is 
crucial not only to enhance all types of information materials related 
to the influence of DIMs on driving fitness that patients can access, 
but it is also needed to tailor the information in a way that a large 
majority of patients can understand and apply it when needed. Yet, 
the information to be shared with patients regarding the influence of 
medicines on driving fitness is complex, since there are different levels 
of impairment. As a consequence, the information to be provided or 
received differs greatly depending on the disease, the medicine, the 
individual, and the need to drive a car.  Here, HCPs play a fundamental 
role, since they know the patient’s needs, and they have a perception 
of the patient’s literacy skills. Thus, HCPs are in a favourable position 
to create a bridge from general to individualized information, 
contributing in this way to a patient’s informed and shared decisions 
of whether or not to drive a car. 
In the studies conducted and presented here, health literacy was not 
investigated. But it was found that the level of education was associated with differences in terms of patients’ knowledge, awareness and, 
indirectly, reported behaviour towards driving under the influence of 
medicines, and the consequent risk of being involved in traffic accidents. 
In a recent study, van der Heide and colleagues (2013) [36] showed 
the interrelationships between education, health literacy, and health 
status. Previously, Nutbeam et al. (2001) [37] already defined health 
literacy as an outcome of education. As such, it is reasonable to assume 
that health literacy, which has been proven to be highly correlated with 
education level, influenced the outcomes of our studies. 
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Shared decision-making and patient decision aids
Shared decision-making has been defined as a process of exchange of 
information between the patient and the health care provider [25, 38, 
39]. Information sharing is a prerequisite to this process, in which the 
main objective is to reach a treatment decision that both parties agree 
upon [38, 39]. Elwyn et al. [38] concluded that the essential elements 
for shared decision-making included professional disclosure, exchange 
of information, deliberation about options, patients’ preferences, negotiation and coming to an agreement on a decision to implement 
[38]. The more individualized the risk information is, the greater the chance that it will improve patient participation in decision-making 
and agreement between the patient’s preference and the treatment 
choice [25]. As such, and in order to promote shared decision-making 
regarding the best use of DIMs, it is crucial that during consultation and patient-provider communication, the risks of driving under the 
influence of DIMs are well described and explained to and understood 
by the patient who ultimately has the decision of whether or not it is 
safe to drive while taking the medicines. It is important to realize that not all patients have the same 
willingness to be part of the shared decision-making process. Patients 
with higher health literacy or those who are relatively healthy are 
more likely to be involved in a shared decision-making process, 
expecting HCPs to give them the necessary information to do so [25]. 
On the other hand, elderly patients may not want to be left with the 
(shared) responsibility of deciding about their own care, leaving the 
decisions entirely up to the doctor or other health care providers 
[40], who should evaluate the driving needs of the patients in order to 
prescribe or dispense the safest medicine that will not put patients at 
unnecessary and unexpected risk. 
In regards to DIMs, it is particularly important to get those patients 
who drive involved in the decision-making process. This reinforces the need for adequate decision aids that help supplement, not replace, 
patient-provider exchange of information [25, 41]. Decision aids can 
be leaflets, interactive media, video, or compact discs [41]. If well 
designed, decision aids can have positive outcomes, namely in terms of 
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patient perceived involvement, agreement between values and choice, 
and in solving decision conflicts [42]. 
Health care providers (HCPs)
The role of HCPs in counselling their patients regarding the 
influence of driving-impairing medicines on driving fitnessTo help patients reach informed choices, clinical guidelines often recommend that healthcare professionals should involve patients in 
decisions about screening, treatment, and other interventions [43, 
44]. Epstein and colleagues stated “training physicians to be more mindful, informative, and empathic transforms their role from one 
characterized by authority to one that has the goals of partnership, 
solidarity, empathy, and collaboration [45].” 
It is now clear that HCPs need to be able to communicate with 
their patients efficiently—addressing their needs, concerns and 
expectations—and to take always into consideration whether the 
patient is able to understand and use such information. But with 
respect to driving-impairing medicines, what should HCPs be aware 
of? What should they tell their patients? 
First, HCPs should think about the medicine itself. Considering that the impairing effect of medicines is a consequence of its side-
effects, it is important that HCPs are acquainted with the undesirable 
effects that can impair driving fitness. Health care providers should 
be particularly attentive to undesirable effects such as somnolence, 
dizziness, drowsiness, decrease of reaction time, blurred vision, 
vertigo, hypoglycaemia, and hypotension. Here, the categorization 
system developed and presented in Chapter 3 can play an important role, since it allows a quick check of the level of impairment a medicine 
may cause.
Second, it is essential to collect information about the individual 
patient, since the undesirable effect can be influenced by several factors, such as: • patient’s age: with increasing age, patients renal and hepatic 
functions may be decreased and, as a consequence, the medicine’s 
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elimination and half life is increased, being responsible for an 
exacerbation the undesired effects of a medicine;• concomitant use of medicines: drug-drug interactions are common 
and may induce many unwanted effects [46];• consumption of alcohol: the effects of some psychoactive medicines 
are potentiated by alcohol [46]; in some cases, the consumption of 
alcohol is even a contra-indication during the treatment; • necessity of driving and driving frequency: are patients’ frequent 
drivers or not? In case they are advised not to driver, do they have alternatives? 
Lastly, HCPs need to be alert for the pathology itself, since it can 
per se be responsible for driving impairment: decreasing a patient’s 
driving skills [47]. For example, in the cases of epilepsy, allergic rhinitis 
and depression, [47] it is crucial to weigh the pros and cons of driving 
under the influence of DIMs, since a patient’s driving skills may be 
increased in the presence of the impairing medicine. 
Organizational level 
In 2001, the International Council on Alcohol, Drugs and Traffic 
Safety (ICADTS) wrote a report regarding prescribing and dispensing 
guidelines for medicinal drugs affecting driving performance [48]. The 
report provided several recommendations to support safe prescribing 
and dispensing of medicines to patients who need to drive. Additionally, 
the Working Group hoped to raise international awareness and 
acceptance of such guidelines by professional organizations and 
regulatory agencies [48]. Some of the recommendations given in the 
ICADTS report have been taken up by the European project DRUID 
[49], such as the development of warning labels based on different 
levels of impairment and a categorization system. 
The lack of prescribing and dispensing guidelines is just the tip of the 
iceberg. The more fundamental problem may be the lack of coordination among the different stakeholders involved in the whole process, 
located at the bottom of the command chain where political decisions 
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are made. It is necessary that either politicians at the European level or national governments internalize that the percentage of people driving 
under the influence of medicines is increasing, which is responsible 
for an increase in the number of accidents, injuries and deaths on the 
roads. There is an extensive body of pharmacoepidemiological and 
evidence-based research that supports the need to put this public 
health problem on the political agenda and to get other stakeholders 
involved, such as regulatory authorities, professional organizations 
of physicians and pharmacists, medical and pharmacy educators, and 
driving licensing authorities. But to do so, a very important bridge 
needs to be built between these stakeholders and research institutes 
given that research outcomes have to be disseminated and translated 
into meaningful messages for policy makers and the general public. 
The public campaigned “Drive Safely with your Medicines” conducted 
in 2008 in the Netherlands [23] is a good example of how coordination 
between different stakeholders can be achieved. 
It is true that each piece of the puzzle has different responsibilities 
and plays different roles. Nevertheless, it is crucial that all actors agree upon clear goals to raise awareness and knowledge regarding 
DIMs and traffic safety. In order to do so, a coherent and coordinated 
strategy, encompassing a whole-system approach that reinforces individual campaigns or interventions and involves in a consistent 
way both health care providers and patients, needs to be defined. 
Concerted actions directed towards HCPs at the organizational level have a good chance of producing the desired outcomes at the patient 
level. If this topic is brought up during consultations or by any other 
means of information, in a systematic and standardised manner, HCPs 
will become more aware of the influence of medicines on driving 
fitness. In this way, the likelihood of having patients receiving tailored 
information matching their needs about the risks of driving under 
the influence of medicines may increase, contributing to reduce the 
number of patients driving under the influence of medicines and 
consequently decrease the number of road accidents and increase 
traffic safety.
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Methodological considerations
Participants
This thesis describes different studies in which different participants 
are included. In the two studies investigating patients’ knowledge, reported 
behaviour, and attitudes towards driving under the influence of DIMs 
(Chapters 2 and 6), pharmacists were responsible for the recruitment 
of patients based on established inclusion criteria, duly sent to them. 
Unfortunately, the response rate in these two studies was low. This 
might have been due to the fact that questionnaires were sent to the 
patient’s home address. Instead, it would have been preferable, yet more time consuming, to ask patients with a prescription for DIMs to 
fill out the questionnaire in the pharmacy. Perhaps in this way, patients 
would have felt more involved and, therefore, more keen to participate. 
Another explanation for the low response rate can be explained by 
the fact that patients do not identify with this particular topic, either 
because they are not aware of the influence of medicines on driving 
fitness and, therefore, disregard its importance or because they are 
users of such medicines but do not want to stop driving and do not want 
to admit it, even in an anonymous questionnaire. As a consequence 
of not having the desirable number of participants, the conclusions 
should not be generalized to the whole population but instead should 
be seen as a good approximation of the current situation. 
Regarding the pharmacist intervention study (Chapter 6), 
pharmacists were recruited based on the “no use” of their pharmacy 
software system regarding DIMs to help them during counselling. 
Despite the efforts made to include as many pharmacists as possible, 
only 49 pharmacists participated in the intervention (training). Given 
the small number of participating pharmacists, the intervention 
group may not be representative of all community pharmacists in 
the Netherlands. Additionally, in the Netherlands, it is common that 
technicians provide medicines and medicine-related information. Being aware of this fact and in order to control for it, the intervention training included a section to help pharmacists instruct their team of 
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technicians about DIMs and their possible effects on driving ability. 
However, the possibility that technicians were not trained should not 
be disregarded.  In the studies where the effectiveness and preference of pictograms 
were investigated (Chapters 4 and 5 respectively), participants were 
not users of a driving-impairing medicine; the criteria for selection 
was that participants visiting a pharmacy had a valid driver’s license, 
were 18 years or older, and were able to read and speak Dutch. Such 
inclusion criteria, which could be seen as being rather general, was 
set mainly to evaluate the effectiveness and preference of pictograms among the general population where the awareness regarding the 
influence of medicines on driving fitness was believed to be smaller. 
In this way, the likelihood of having participants that understood the 
meaning of the pictogram because of the pictogram itself and not 
because of previous acquired knowledge was increased. However, the fact that patients who take DIMs were not recruited as participants 
may raise questions regarding external validity, i.e., whether the 
results can be extrapolated to the population that will actually see or 
need the pictogram.  
DesignTo achieve the aims of this thesis, several studies were conducted, 
with different designs, including: a comparison study (Chapter 2), a 
concerted action design (Chapter 3), an experimental design (Chapters 
4 and 5), and an intervention study (Chapter 6). Results from these studies point to the need to improve information materials related 
to DIMs and traffic safety, making them more flexible so that the 
information can be tailored to patients needs. In this way, it is likely that patients’ knowledge and awareness will increase and driving 
behaviour will change towards not driving while taking DIMs. 
To investigate patients’ knowledge and reported behaviour, paper 
questionnaires which patients could fill out on their own, wherever 
they wanted, were used. Such an approach does not allow for any 
control over the way patients answer the questions. This could be 
particularly sensitive for the knowledge questions since respondents 
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could use any source of information to give the most correct answer. 
However, since knowledge was similarly low in the four countries 
studied (Chapter 2), it is believed that respondents who sought for the 
correct answer were a residual percentage.Another methodological concern deals with the fact that the outcome 
measures related to knowledge and driving-behaviour were based on 
self-reported questions. In this case, there is a risk for social desirability 
bias, i.e., patients may have answered their questions based on what is 
socially acceptable and not really what they actually know or do. As 
such, an overestimation of the results should not be disregarded. 
Implications for clinical practice
From the results of the conducted studies, it became clear that 
patients, despite being aware of the fact that some medicines may have a negative effect on driving skills, are not willing to change their 
driving behaviour while taking medicines that can negatively effect 
their driving ability. Understanding the underlying motives that make 
patients less likely to change driving behaviour might be helpful when 
designing future strategies that are targeted at patient beliefs raising the awareness patients have of the consequences of driving while use 
these medications. In this way, patients’ attention can be captured 
more easily, contributing to an increase in patient’s motivation to stop 
driving under the influence of DIMs.  Motivational interviewing seems 
a suitable and feasible method when such behavioural changes are the 
aim [50].
However, patients still need to be informed about the influence of 
medicines on driving fitness and its consequences on traffic safety so 
that they feel encouraged to stop driving under the influence. In order 
to provide such information, HCPs first need to invest time in educating 
themselves about the subject so that they have a realistic awareness of 
the consequences of driving under the influence of medicines. More 
importantly, they should become familiar with the information they 
need to provide their patients about the subject. 
Currently, prescribing and dispensing guidelines are scarce. Therefore, 
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it is important to develop them to support HCPs’ counselling on this 
topic. Additionally, information materials also aimed at HCPs could be 
useful in raising their awareness. These materials could be designed 
as leaflets, posters, or editorials in specialty journals. However the information is disseminated, it is important that the guidelines and 
materials be consistent in their content and standardized in a manner 
that could be easily spread within and between European countries 
and, in this way, reach as many professionals as possible ensuring that 
patients receive similar counselling.
The development of the categorization system for medicines based 
on the different levels of driving impairment can be seen as a promising 
tool to support HCPs during consultation, since it may allow for the selection of the least impairing medicine without compromising a 
patient’s treatment options. Such a categorization system alone may 
not directly produce the desired changes in patients’ knowledge or 
reported behaviour, but it helps tailor the information according to 
patients’ needs.
In regards to the auxiliary warning labels, the study conducted on 
effectiveness of pictograms (Chapter 4) suggested the need to improve 
the pictograms, especially if the recommendations from ANSI and ISO 
regarding the (good) comprehensibility of symbols are to be met [51, 
52]. In the light of the results, it seems reasonable to say that, even 
though it performed better than the triangle pictogram, the rating 
model pictogram should not be used straightaway without further 
refinement and testing. It can also be concluded that the pictogram 
should never stand-alone and should never be used as a replacement 
for oral or written information. Instead, pictograms should complement 
the information provided by HCPs and can also be used as a reminder 
for HCPs of the need to counsel patients about the use of DIMs and 
their possible consequences on driving. 
Recommendations for future research
After conducting the studies, some questions remain unanswered. 
For example, do HCPs have all the information and support tools 
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they need to appropriately inform their patients, especially first-
time users, about the risks of driving under the influence of DIMs? Do 
patients possess all the information and knowledge they need to make 
informed decisions about driving or not while taking DIMs? How can 
changes in driving behaviour be measured? Is there a need to develop 
a new pictogram? Regarding the categorization system, who would 
take responsibility for the revision, updates, and maintenance of the 
system? Would it be the responsibility of a European organization, 
such as EMA, or should it be done at a national level by the professional 
organizations of HCPs? 
Such questions can surely be seen as windows of opportunity 
for future research, allowing for further study of the influence of communication and information training and the effectiveness of 
support tools, such as the pictogram and the categorization system, on 
the ability of HCPs to influence a patient’s choice to drive while using 
certain medications. 
A proposal should be made to coach HCPs on how to address a patient’s 
driving needs and, if necessary, make adjustments to treatment in 
order to ensure the traffic safety of a patient. In this way, patients may 
feel more involved and more willing to change their driving behaviour. 
This intervention could be compared against current practice to test 
whether the training of HCPs has any beneficial impact on patients’ 
knowledge and reported driving behaviour.Regarding the need to further improve the developed pictogram, it 
is essential to take into account the views and opinions of elderly and 
low-literate patients, since they are regarded as sensitive groups when 
it comes to understanding pictograms. A similar approach to the user 
testing of patient information leaflets could be implemented in order 
to understand what is the best design and what information should 
to be included or excluded from the current pictogram. According to 
the guideline on the readability of the labelling and package leaflet of 
medicinal products for human use [53], user testing is defined as a 
way “to test the readability of a specimen with a group of selected test 
subjects. It is a development tool which is flexible and aims to identify 
whether or not the information as presented conveys the correct 
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messages to those who read it.” In a more simplistic way, user testing 
involves individual interviews with lay participants in order to evaluate 
whether a patient information leaflet is legible, clear, and easy to use 
[54]. Once a pictogram is reasonably well understood by the elderly 
and low-educated people, it should be test in a real-life situation, i.e., 
affixed to a medicine box and given to those who need to take DIMs, 
irrespectively of their age or education level. Only after thorough testing and positive outcomes among different driving populations 
should the pictogram be used in the outer package of DIMs in order to 
ensure that the warning can be correctly understood by patients who 
drive while taking DIMs.  
The lack of tools that can support and guide HCPs in the process of 
sharing information with their patients leaves, without a doubt, an 
opportunity to test the long-term use of the categorization system 
developed in this dissertation. This should be complemented with 
access to fact sheets about the categorized active substances and the rating model pictogram, which needs some improvements, as 
previously mentioned. Integrating all of the above materials in a 
software system that HCPs can easily and quickly access during 
consultation with patients would support a best-practice that could be 
helpful to HCPs and should be considered in future research. 
ConclusionThe studies conducted and presented here have demonstrated that 
patients’ knowledge regarding the influence of medicines on driving 
fitness can still be improved and that more is needed to change patients’ 
driving behaviour. The information regarding the risks of driving 
under the influence of DIMs is complex, and pictograms were used to 
help communicating this risk message. However, it was shown that 
the rating model pictogram used in this research was not completely 
effective in conveying safety-related messages and stressing the 
importance of complementary information provided by the HCPs. 
Nonetheless, HCPs do not always communicate this information 
adequately to their patients, and the studies in this dissertation have 
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shown the need for supporting tools to improve how risk messages 
are communicated to patients and how to better tailor the information 
according to patients’ needs.
Future research is needed to evaluate the feasibility and applicability 
of the categorization system and to access the effectiveness of a 
redesigned pictogram. There is also a window of opportunity to help 
HCPs get acquainted with the risks of driving under the influence 
of medicines and to facilitate communication between HCPs and their patients in order to address the needs, values, concerns, and 
expectations that contribute to reaching a shared decision. 
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Recent data showed that more than 31.000 people lost their lives 
and over 1.473.000 were injured in road accidents, throughout 
Europe (Chapter 1). It is widely known that alcohol is one of the main 
contributors to road accidents. Less widely recognized is the role of 
driving impairing medicines (DIMs) on traffic accidents. However, 
epidemiological studies concerning the influence of medicines on 
driving fitness, which have been increasing over the past recent years, 
have shown a positive association between the exposure to DIMs and 
the risk of having a traffic accident. This is particularly evident for 
benzodiazepines.
As such, it is important to adequately inform patients regarding 
the influence of medicines on driving fitness and on traffic safety. 
This information can be found in a dedicated section of the patient 
information leaflet (PILs) or can be provided by health care providers 
(HCPs), such as general practitioners (GPs) and/or pharmacists, 
during patient consultations. In order to provide adequate advice to 
patients, HCPs need themselves to be well aware and informed of the 
risks associated to DIMs and they need to know how to communicate 
this effectively to their patients. However, up to date, practical 
recommendations for HCPs on how to inform patients on DIMs are 
scarce and professional guidelines regarding safe prescribing and 
dispensing of DIMs are an exception more than a rule in most European 
Union (EU) countries.So far, patients have shown low levels of knowledge and awareness 
about the impairing effects of various medicines on driving fitness, 
according to the few published studies on this topic (Chapter 1). One 
way of facilitating the communication of driving-impairment risks 
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is by using pictograms, which have been increasingly recommended 
and used to convey warnings and other safety-related information 
and are particularly useful to increase patient understanding of risk. Pictograms showing the potential risk of driving while using DIMs 
have been developed in some European Union countries but not in a 
standardized manner. 
In order to fill the gaps on this topic and to provide scientific support 
to the EU transport policy makers by suggesting guidelines, legislation, 
enforcement and rehabilitation measures to combat impaired driving, 
the European Commission funded the five-year (2006-2011) European 
DRiving Under the Influence of Drugs, Alcohol and Medicines (DRUID) 
project, one of the biggest research projects ever carried out in the EU 
on drugs and driving.This PhD dissertation was part of the DRUID project and aimed:
1) to assess patients’ knowledge about DIMs and their influence on 
driving fitness as well as reported behaviour of patients who drive 
while taking driving-impairing medicines (Chapter2); 
2) to define the criteria and methodology for the development of a 
categorization system for commonly used medicines, based on their 
influence on fitness to drive (Chapter 3); 
3) to develop and evaluate the effectiveness, at the patient level, of a pictogram encompassing different levels of impairment which have 
been derived from the categorization system (Chapter 4); 
4) to identify patients’ preferences for the developed pictogram 
(Chapter 5), and 
5) to evaluate the effect a training course developed for community 
pharmacists in patients’ knowledge and reported behaviour, at the 
start of treatment (Chapter 6).
The first step was to assess the current knowledge, and reported 
behaviour of patients taking DIMs. As such, Chapter 2 describes a 
study conducted in Belgium, Germany, Spain and the Netherlands. The 
study compared and determined factors that were not only associated 
with patients’ reported driving and medicines’ intake behaviour, but 
also their knowledge towards driving under the influence of DIMs. 
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Questionnaires were sent to patients who were prevalent users of DIMs 
(benzodiazepines, antidepressants or first generation antihistamines 
for systemic use), aged between 18 and 75 years and actual drivers of 
a motorised vehicle. Data from 633 patients were analyzed. Results 
confirmed that patients have poor knowledge regarding the influence 
of DIMs on driving fitness irrespectively of the country. Younger and 
higher educated patients showed better knowledge than elderly and 
low educated patients. The majority of patients did not change their 
driving frequency nor change the intake of their DIMs in order to be 
able to drive safely. Changes in reported driving behaviour were more 
likely to happen in patients who experience side-effects and those 
who have negative attitudes towards driving under the influence of 
impairing medicines. Patients’ lack of awareness and knowledge 
regarding the influence of DIMs on driving fitness was a clear indicator of the need to develop information stressing the risks of driving under 
the influence of some medicines. Considering that medicines have different levels of driving-
impairment and that most of the information about medicines that 
patients receive is provided by HCP, a categorization system to support 
HCPs while providing information related to DIMs was developed. 
Chapter 3 describes the methodology used to establish standard 
and harmonized criteria to categorize commonly used medicines 
according to their potential to impair driving fitness. A total of 1541 
active substances were categorized which nearly encompassed the full 
ATC index of active substances available on the EU market. Nearly half 
of the 1541 categorized active substances had no driving impairment 
(category 0), 26% had minor driving-impairment (category 1), 11% 
had moderate driving-impairment (category 2) and at about 6% were 
included in the severest category of impairment (category 3), of which 
the majority belonged to the ATC N group (nervous system), sub-
category N05 (psycholeptics). Such a categorization system can be 
considered as a tool to improve prescribing and dispensing procedures, 
and as an instrument to inform and involve HCPs and patients during 
consultation. 
Based on the categorization system, a pictogram was developed as 
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a proposal to communicate the risk of driving under the influence of 
medicines to patients. In this pictogram, referred to as rating model 
pictogram, the different levels of driving impairment ware displayed 
horizontally in a bar. From left to right, categories ranged from 0 (no 
impairment which means no driving risk) to 3 (severe impairment 
associated with a severe driving risk), which clearly places each level 
of risk within a range from 0 to 3, making it clear to the subject that the 
different levels of risk are relevant. A traffic-light colour was given to 
each category as people tend to associate the colour red to danger, the 
yellow to caution, and the green to safety. Therefore, green (category 
0), yellow (category 1), orange (category 2) and red (category 3) 
colours were chosen to represent each category. The rating model 
pictogram was compared to the pictogram used in France, referred to as triangle model pictogram, since this pictogram also took into account different levels of impairment and used similar colours to 
identify risk categories. However, the different levels of impairment 
were not included in one single figure. Chapter 4 describes the study conducted to evaluate and compare the effectiveness of these two pictograms in communicating risk in terms of respondents’ level of understanding, estimated level of driving risk, and intention to change 
driving behaviour. The added value of a side-text was also investigated. 
Two experiments were conducted among 270 drivers visiting a 
pharmacy. Results indicated that, although the majority of drivers 
understood that the pictograms were related to driving behaviour, less 
than 10% and about 36% of the drivers looking at the triangle model 
and at the rating model, respectively, understood it fully. Despite the low percentage, the rating model pictogram was associated with 
respondents’ intentions to change their driving behaviours which 
increased with higher categories of risk. The added value of a side-
text in the rating model pictogram was not confirmed. In Chapter 
5, respondents’ preference for one of the two pictograms to express 
a warning messages and levels of impairment was described. The 
majority of participants preferred the rating model to express warning 
messages (74.4%) and levels of impairment (82.6%). Despite the 
preference for the rating model system throughout all age categories 
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and education levels, a trend showing that preference for the triangle model pictogram increased with an increase of age and a decrease of 
education level. Considering that the design of the rating model was 
more complex than the triangle model, it was concluded that older respondents with a lower education level prefer pictograms with 
simpler design. From the analysis conducted and presented in chapter 
4 and 5, it became clear that similarly to what has been found in previous research regarding medication instructions, standing alone 
pictograms are unlikely to be successful. Therefore, it is recommended 
to support pictograms with oral and written information from HCPs, in order to avoid misunderstandings, and to improve comprehension 
and recall of information.
One of the pitfalls identified in the literature was the lack of 
professional guidelines to support HCPs during counselling of first-
time users of DIMs and lack of information materials for patients. 
Chapter 6 describes the results of an intervention study conducted among pharmacists who were trained with several information 
materials and counseling tools, including the pictogram developed. The effects of the intervention on patients’ knowledge, attitudes, and 
reported behaviour concerning the safe use of DIMs were evaluated in 
a randomized controlled study, with randomization at the pharmacy 
level. Pharmacists being trained to improve their dispensing practices 
sent out questionnaires to randomly selected patients who were 
18 years or older and holding a driving license with a first-time 
prescription for DIMs issued 1-month before (T0) and 6-months 
after (T1) the intervention. A total of 421 patients at T0 and 509 at 
T1 were included in the study. Results proved that the pharmacists’ 
training did not affect patient knowledge about the role of DIMs in 
road accidents nor attitudes towards driving under the influence. No 
significant changes were found for self-reported driving behavior due 
to the intake of DIMs. In the group of pharmacists who attended the training, the proportion of patients who stated changing the intake of 
DIMs in order to drive was lower in the measurement 6-months after 
the training (25.2%) than in the initial measurement (26.6%). In the 
control group, however, it was found the opposite, i.e., the proportion 
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of patients who stated changing the intake of DIMs in order to drive 
while was significantly (P-value=0.02) higher at T1 (35.5%) than 
at T0 (27.3%). The study showed that in order to increase patients’ 
motivation to change driving behaviour, interventions should also 
focus on counselling and motivating rather than solely on providing 
patient information.
The summary of the main findings of the studies described in the previous chapters was presented and discussed in Chapter 7.  Briefly, the results showed that there was room for improvement with respect 
to raising awareness of patients and HCPs regarding driving under 
the influence of medicines. Additionally, the way the information is 
communicated to patients, as well as the type of information provided 
and which contributes to increase patients’ knowledge, can also be 
improved. Therefore, it was suggested to act at three different levels: 
patients, HCPs and (national) organizational level. At patient level, it was theorized that patients’ role in the decision-making process should 
be improved. In order to do so, it is crucial to apply strategies focused on patient-centeredness and individualization of information during patient-provider communications, taking into account patients’ health 
literacy, promoting in this way patients’ decision-making capability.
Considering the particular situation of driving under the influence 
of potentially hazardous medicines, it was suggested that HCPs should 
try to understand what the actual driving needs of a patient are, in 
order to be able to make an adequate treatment decision that will 
not jeopardize patients’ traffic safety. Health care providers should 
be particularly attentive to undesirable effects such as somnolence, 
dizziness, drowsiness, decrease of reaction time, or blurred vision, and 
should also consider the role of the disease itself. As prescribing and 
dispensing auxiliary tool, HCPs could make use of the categorization 
system that was developed. 
Lastly, it was concluded that a coherent and coordinated strategy is needed to raise awareness regarding the risks of driving under the 
influence of DIMs among different stakeholders, such as regulatory 
authorities, professional organizations of physicians and pharmacists, 
medical and pharmacy educators, and driving licensing authorities. 
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Taking into consideration the work and results presented in this PhD 
dissertation, it can be concluded that patients’ knowledge regarding 
the influence of medicines on driving fitness can still be improved 
and new strategies are needed to change patients’ driving behaviour. 
The developed rating model pictogram was not fully self-explanatory 
in conveying safety-related messages, stressing the importance of 
complementary information provided by the HCPs. Nonetheless, 
HCPs do not always communicate this information adequately to 
their patients. Additionally, HCPs have shown the need for supporting tools on how to communicate risk messages and on how to tailor the 




Recente schattingen geven aan dat in Europa meer dan 31.000 mensen 
per jaar verongelukken in het verkeer en dat er meer dan 1.473.000 
gewonden zijn (Hoofdstuk 1). Alcoholgebruik is een van de bekendste 
oorzaken van verkeersongelukken. Minder bekend is de rol van het 
gebruik van rijgevaarlijke geneesmiddelen voor de verkeersveiligheid. Toch zijn er de laatste jaren steeds meer epidemiologische studies 
gepubliceerd, waarin een associatie is aangetoond tussen blootstelling 
aan dergelijke geneesmiddelen en het risico op betrokkenheid bij 
een verkeersongeval. Dit is vooral aangetoond voor het gebruik van 
benzodiazepinen. 
Het is dus van belang om patiënten die rijgevaarlijke geneesmiddelen 
gebruiken voldoende informatie te geven omtrent de beïnvloeding 
van de rijvaardigheid en de gevolgen voor de verkeersveiligheid. Deze 
informatie is te vinden in een speciale sectie van de patiëntenbijsluiter maar kan ook worden gegeven door zorgverleners, zoals huisartsen 
en apothekers, tijdens een consult met de patiënt. Om deze informatie goed te kunnen verstrekken, zullen de zorgverleners zelf ook goed op 
de hoogte moeten zijn van de risico’s van het gebruik van rijgevaarlijke 
geneesmiddelen en bovendien in staat moeten zijn om deze 
informatie goed te communiceren naar hun patiënten. Er is echter 
op dit moment weinig goede ondersteuning voor zowel patiënten als 
zorgverleners voorhanden. Ook is de beschikbaarheid van richtlijnen hoe rijgevaarlijke geneesmiddelen veilig zijn voor te schrijven en af te 
leveren eerder uitzondering dan regel in Europa.
Uit een beperkt aantal studies is bekend dat patiënten in de 
regel weinig kennis en besef hebben van de effecten die diverse 
geneesmiddelen die zij gebruiken hebben op de rijvaardigheid 
(Hoofdstuk 1). Een manier om die kennis te vergroten is door de risico’s 
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van rijgevaarlijke geneesmiddelen te communiceren met behulp van 
pictogrammen. Pictogrammen worden aanbevolen en op grote schaal 
gebruikt om waarschuwingen te geven. Ze zijn bruikbaar gebleken om 
het begrip over allerlei soorten risico’s bij patiënten te verbeteren. In enkele Europese landen zijn pictogrammen ontwikkeld om op de gevaren van rijden onder invloed van rijgevaarlijke geneesmiddelen te 
wijzen, maar dit gebeurt zeker niet op een uniforme manier. 
In een groot Europees project, dat vijf jaar lang (2006-2011) werd 
gefinancierd door de Europese Commissie (bekend als het DRUID-
project, DRiving Under the Influence of Drugs, alcohol and medicines) en als het grootste in zijn soort werd uitgevoerd, is getracht meer 
wetenschappelijke kennis bijeen te brengen om openstaande vragen 
te beantwoorden. De antwoorden moesten Europese beleidsmakers op het terrein van transport en transportveiligheid ondersteunen 
in het verbeteren van richtlijnen, wetgeving, politieoptreden en 
rehabilitatieprogramma’s in de strijd tegen rijden onder invloed.  Dit proefschrift was onderdeel van het DRUID-project en was gericht op:
1) het vaststellen van de kennis die patiënten hebben over 
rijgevaarlijke geneesmiddelen en beïnvloeding van de rijvaardigheid alsmede hun zelf-gerapporteerde gedrag over het rijden onder 
invloed van dergelijke geneesmiddelen (Hoofdstuk 2);
2) het bepalen van criteria en een beoordelingsmethode voor een 
categorie-indeling van veelgebruikte geneesmiddelen, gebaseerd op 
de mate waarin zij  de rijvaardigheid  beïnvloeden(Hoofdstuk 3);
3) het evalueren van de effectiviteit, op patiëntniveau, van een 
pictogram dat is ontwikkeld op basis van de verschillen tussen 
geneesmiddelen in de mate waarin zij de rijvaardigheid beïnvloeden 
(zoals bedoeld met de categorie-indeling)(Hoofdstuk 4);
4) het bepalen van de voorkeur van de patiënt als het gaat om 
verschillende pictogrammen die zijn ontwikkeld (Hoofdstuk 5);
5) het evalueren van het effect van een trainingsprogramma 
ontwikkeld voor openbaar apothekers op de kennis en het zelf-
gerapporteerd rijgedrag van patiënten die een behandeling met een 
rijgevaarlijk geneesmiddel starten (Hoofdstuk 6).
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Allereerst werden de kennis en het zelf-gerapporteerde gedrag 
(rijvaardigheid en gebruik van de rijgevaarlijk geneesmiddelen) van 
patiënten onderzocht, die rijgevaarlijke geneesmiddelen gebruiken. 
Hoofdstuk 2 beschrijft een studie  die hiertoe is uitgevoerd in België, 
Duitsland, Spanje en Nederland. De studie keek naar factoren, die 
samenhingen met het gebruik van rijgevaarlijke geneesmiddelen 
in combinatie met verkeersdeelname, maar ook hun houding ten aanzien het rijden onder invloed van rijgevaarlijke geneesmiddelen 
bepaalde. Gebruikers van bepaalde rijgevaarlijke geneesmiddelen 
(benzodiazepinen, antidepressiva of antihistaminica van de eerste 
generatie) in de leeftijd van 18 tot 75 jaar, die daadwerkelijk aan 
het gemotoriseerde verkeer deelnamen, ontvingen een vragenlijst. 
Gegevens van 633 patiënten werden geanalyseerd en de resultaten 
lieten zien dat patiënten, ongeacht het land waarin zij woonden, 
een beperkte kennis hebben over de invloed van rijgevaarlijke 
geneesmiddelen op de rijvaardigheid. Jongere en hoger opgeleide 
patiënten hadden een betere kennis dan oudere en lager opgeleide 
patiënten. De meerderheid van de patiënten veranderde hun frequentie van verkeersdeelname of  het innameschema van hun 
medicatie niet om veiliger aan het verkeer te kunnen deelnemen. Het 
veranderen van verkeersdeelname gebeurde vaker wanneer men 
bijwerkingen ervoer en ook als men het rijden onder invloed  van 
rijgevaarlijke geneesmiddelen als ongewenst gedrag aanmerkte. Het 
gebrek aan besef en kennis omtrent de invloed van geneesmiddelen 
op de rijvaardigheid bij patiënten was een duidelijk signaal om beter informatie over de risico’s van rijden onder invloed van rijgevaarlijke 
geneesmiddelen te gaan ontwikkelen.Aangezien rijgevaarlijke geneesmiddelen verschillen in  de 
mate waarin zij de rijvaardigheid  beïnvloeden en informatie over geneesmiddelen meestal door zorgverleners wordt gegeven, werd 
besloten om een categorie-indeling van rijgevaarlijke geneesmiddelen 
te ontwikkelen die ook door zorgverleners zou zijn te gebruiken. In hoofdstuk 3 is beschreven hoe de criteria voor het indelen van rijgevaarlijke geneesmiddelen op uniforme en gestandaardiseerde 
wijze tot  stand zijn gekomen. In totaal werden 1.541 werkzame 
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stoffen die beschikbaar zijn in Europese landen op ATC-niveau 
ingedeeld en beoordeeld op hun potentieel beïnvloedende effecten op 
de rijvaardigheid van de patiënt. Ongeveer de helft van deze stoffen 
had geen effect op de rijvaardigheid (categorie 0), 26% had slechts een 
zeer gering effect (categorie 1), 11% een matig effect (categorie 2) en 
ongeveer 6% werd ingedeeld in de hoogste categorie (categorie 3) met 
een ernstig effect. De meest voorkomende substanties in deze laatste 
categorie waren stoffen uit de ATC groep “ centraal zenuwstelsel” (N), 
sub-klasse psycholeptica (N05). Een dergelijke categorie-indeling 
kan worden beschouwd als een hulpmiddel om het voorschrijven en 
afleveren van rijgevaarlijke geneesmiddelen te verbeteren en is goed 
te gebruiken tijdens consulten met patiënten die informatie moeten 
ontvangen.
Vervolgens is een pictogram ontwikkeld gebaseerd op de categorie-indeling om het risico over rijden onder invloed van een rijgevaarlijk 
geneesmiddel aan de patiënt duidelijk te kunnen maken. In dit 
pictogram worden de verschillende categorieën (van 0 tot en met 3) in 
een horizontaal balkje getoond met behulp van een kleuraanduiding. 
Deze aanduiding kennen mensen ook uit het verkeer: groen (categorie 
0), geel (categorie 1), oranje (categorie2) en rood (categorie 3). Dit 
“scorebalk pictogram” werd vergeleken met een soortgelijk pictogram 
dat in Frankrijk al in gebruik is, het “driehoek pictogram”. Dit maakt 
gebruik van een vergelijkbare kleuraanduiding, maar laat de driehoek 
als symbool zien en dan alleen voor de categorie die van toepassing is en 
niet in relatie tot de andere categorieën. Hoofdstuk 4 doet verslag van 
een onderzoek waarin deze beide pictogrammen zijn vergeleken op hun 
mogelijkheden om risico te communiceren. Hierbij zijn het begrip van 
de mate van het risico en de intentie om het rijgedrag op basis hiervan 
aan te passen onderzocht. Er werden twee experimenten uitgevoerd 
met medewerking van 270 automobilisten die als patiënt een apotheek 
bezochten. De resultaten tonen aan, dat alhoewel de meerderheid van 
de bestuurders begrepen dat de pictogrammen betrekking hadden op 
rijvaardigheid, slechts 10% de volledige betekenis van het “ driehoek 
pictogram” begreep. Voor het “scorebalk pictogram” was dat 36%. Het 
zien van het “ scorebalk pictogram” was geassocieerd met een intentie 
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om het rijgedrag aan te passen, met name naarmate het pictogram 
een zwaardere categorie van beïnvloeding aangaf. Het hanteren van 
een bijschrift bij het pictogram met als doel de bestuurder beter te 
informeren op basis van de categorie-aanduiding, liet geen sterkere 
intentie tot het aanpassen van verkeersdeelname zien.In hoofdstuk 5 werd de voorkeur van de respondenten voor een 
van de beide pictogrammen onderzocht. Hierbij werd gevraagd welk 
pictogram de beste waarschuwing inzake de verkeersveiligheid weergaf 
en welke pictogram het best het risiconiveau. De meerderheid van de 
respondenten gaf de voorkeur aan het “ scorebalk pictogram” als het gaat om het geven van een waarschuwing inzake de verkeersveiligheid 
(74,4%) en het risiconiveau van het middel (82,6%). Deze voorkeur 
was bij alle leeftijdsgroepen en opleidingsniveaus waarneembaar. Echter, naarmate respondenten  ouder waren en/of een lagere 
opleiding  hadden werd deze voorkeur minder sterk.  Ervan uitgaande 
dat het “ scorebalk pictogram”  als ontwerp complexer ervaren kan 
worden dan het “ driehoek pictogram”,  was de conclusie dat oudere 
en/of lager opgeleide patiënten met een laag opleidingsniveau eerder 
dan andere patiënten neigen naar een eenvoudiger ontwerp, zoals het 
“ driehoek pictogram’’ . 
De resultaten in de hoofdstukken 4 en 5 lieten, evenals ander 
onderzoek naar instructies bij medicatiegebruik, zien dat wanneer 
een pictogram dat op zichzelf staat een boodschap moet overbrengen, 
dit niet erg succesvol doet. Daarom werd aanbevolen om het gebruik van pictogrammen te ondersteunen met mondelinge en schriftelijke 
informatie door de zorgverlener, om misverstane boodschappen 
te voorkomen en het begrip en de herinnering van de informatie te 
verbeteren.Een van de omissies die in de literatuur wordt gemeld, is het 
ontbreken van richtlijnen voor zorgprofessionals en bijbehorend 
patiëntenvoorlichtingsmateriaal, die de start van het gebruik van een 
rijgevaarlijk geneesmiddel door patiënten kunnen ondersteunen. In 
hoofdstuk 6 worden de resultaten beschreven van een interventiestudie 
uitgevoerd bij openbaar apothekers. Deze bestond uit een training 
om bij de eerste verstrekking van een rijgevaarlijk geneesmiddel 
192 | Addendum
hulpmiddelen gebaseerd op de eerder beschreven categorie-indeling 
te stimuleren. De effecten van de interventie op de kennis, attitude en 
het zefl-gerapporteerd gedrag van de patiënten werden geëvalueerd in een gecontroleerde gerandomiseerde studie, met randomisatie 
op het apothekersniveau. Openbaar apothekers (zowel degenen die zouden gaan deelnemen aan de training als de apothekers in de 
controlegroep), stuurden vragenlijsten naar patiënten van 18 jaar en 
ouder en in het bezit van een rijbewijs, die in de maand ervoor (T0) een eerste verstrekking van een rijgevaarlijk geneesmiddel hadden 
ontvangen. Zes maanden na de training stuurden de apothekers 
wederom vragenlijsten naar patiënten die voor het eerst een 
rijgevaarlijk geneesmiddel hadden gekregen (T1).  In totaal ontvingen 
421 patiënten op T0 de vragenlijst tegenover 509 bij T1. De resultaten 
lieten zien dat de training van de openbaar apotheker geen effect had 
op de kennis van de patiënt omtrent de gevaren van rijgevaarlijke geneesmiddelen en ook niet op attitude ten opzichte van rijden onder 
invloed van rijgevaarlijke geneesmiddelen. Ook was er geen effect op 
de door de patiënt zelfgerapporteerde mate van verkeersdeelname na 
het gebruik van rijgevaarlijke geneesmiddelen. Het aandeel patiënten dat rijgevaarlijke geneesmiddelen anders was gaan innemen  door de informatie was in de groep  apothekers die een training hadden 
ontvangen nagenoeg hetzelfde op beide meetmomenten (25,2% vs 
26,6%). In de controlegroep gingen op T1 juist meer mensen hun 
gedrag aanpassen naar aanleiding van de informatie. De studie toonde aan, dat interventies verder moeten gaan dan het verstekken van 
patiëntinformatie, maar waarschijnlijk ook gericht moeten zijn op 
counseling en motiverende gesprekstechnieken.
De samenvatting  en de discussie van de belangrijkste bevindingen 
van het proefschrift   zijn beschreven in hoofdstuk 7. Er is ruimte 
voor verbetering van het besef onder patiënten en zorgverleners 
dat rijgevaarlijke geneesmiddelen een probleem kunnen geven bij 
gebruik door bestuurders van motorvoertuigen. Ook de wijze waarop 
de informatie wordt verstrekt aan patiënten en de inhoud van de 
informatiematerialen kunnen duidelijk verbeteren.  Om dit te bereiken zullen activiteiten op drie niveaus moeten worden uitgevoerd: 
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patiënt-, zorgverleners- en koepelniveau. Op het patiëntniveau moet 
de rol van de patiënt in de besluitvorming versterkt worden. Dit kan 
door het ontwikkelen van een strategie waarin patiëntgerichtheid en 
het aanbieden van informatie op maat (afgestemd op de individuele 
patiënt) gecombineerd worden. Oftewel, er moet rekening gehouden 
worden met de gezondheidsvaardigheden van de patiënt  om een 
juiste besluitvorming bevorderen.
Voor zorgverleners is het belangrijk om na te gaan welke behoeften 
bij patiënten bestaan  om aan het verkeer deel te nemen en welke 
medicatie daar het beste bij past om te zorgen dat de veiligheid in 
het verkeer niet in gevaar wordt gebracht. Zorgverleners moeten 
navraag doen naar het optreden van bijwerkingen die de veiligheid 
van de patiënt in het verkeer in gevaar brengen, zoals slaperigheid, 
duizeligheid, sufheid, afname van reactievermogen of wazig zien. 
En daarbij dienen zij ook de rol van de ziekte of aandoening in 
aanmerking te nemen bij het kiezen van de geschikte medicatie. Het 
gebruik van de categorie-indeling van rijgevaarlijke geneesmiddelen 
wordt aanbevolen als goede ondersteuning hierbij. Tenslotte is een eenduidige en gecoördineerde strategie waarin 
‘stakeholders’ , zoals wetgevende instanties, beroepsorganisaties van artsen en apothekers, wetenschappelijke opleidingsinstituten 
en de uitgevende instantie voor rijbewijzen, samenwerken aan 
het verbeteren van het besef onder de bevolking dat rijgevaarlijke 
geneesmiddelen belangrijke risico’s geven bij gebruik in het verkeer. 
Op basis van de bevindingen in dit proefschrift kan worden gesteld 
dat er meer kennis bij de individuele patiënt nodig is omtrent de 
gevaren van rijgevaarlijke geneesmiddelen in zijn of haar specifieke 
situatie. Ook moeten er interventies komen die gericht zijn op het veranderen van verkeersdeelname wanneer de gevaren van 
rijgevaarlijke geneesmiddelen te groot zijn.  Het binnen het DRUID-
project ontwikkelde “ scorebalk pictogram”  was niet voldoende om 
patiënten de risico’s van het gebruik van  de medicatie voor het verkeer 
goed te doen inschatten. Dit betekent dat aandacht van zorgverleners 
maatwerk in hun consulten met de patiënt daarnaast nodig is. Ook 
hierin is nog ruimte voor verbetering. Zorgverleners  hebben meer 
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behoefte aan beslissingsondersteunende systemen om de individuele 
patiënt op basis van zijn of haar eigen behoefte op de juiste wijze te voorzien van informatie om risico’s van het rijden onder invloed van 
rijgevaarlijke geneesmiddelen in te kunnen schatten. 
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Resumo (Portuguese summary)
Dados recentes revelam que mais de 31.000 pessoas perderam a 
vida e mais de 1.473.000 ficaram feridas em acidentes de automóvel 
em toda a Europa (Capítulo 1). Diversos estudos epidemiológicos dão conta do risco aumentado de sofrer acidentes de viação aquando 
da condução sob o efeito do álcool. À semelhança do que acontece 
com o álcool, as conclusões dos estudos científicos apontam para a 
influência de alguns medicamentos na condução, como, por exemplo, 
os medicamentos psicoativos, com particular incidência no efeito 
negativo das benzodiazepinas. 
Neste sentido, é importante que os doentes que consomem medicamentos que possam afetar a condução de veículos sejam 
devidamente informados deste efeito secundário e das potenciais 
consequências na segurança rodoviária. Este tipo de informação pode 
ser encontrado numa secção específica do folheto informativo (FI), à 
qual todos os doentes têm acesso. Paralelamente, pode ser dada por 
um profissional de saúde, como médicos e/ou farmacêuticos que, 
para informarem os seus doentes eficazmente, devem, também eles, 
estar devidamente informados e conscientes dos riscos inerentes à 
condução de veículos sob influência de medicamentos. Contudo, há 
uma enorme escassez de diretrizes com recomendações práticas que 
visem auxiliar os profissionais de saúde durante a comunicação com 
os seus doentes sobre os efeitos secundários e os riscos que alguns 
medicamentos possam ter na condução.
De acordo com a literatura disponível (Capítulo 1), os doentes 
estão pouco sensibilizados para os efeitos negativos que alguns medicamentos possam ter na condução de veículos, demonstrando, 
de forma sistemática, poucos conhecimentos neste sentido. Uma das 
formas encontradas para alertar para o risco de conduzir sob influência 
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de medicamentos foi o uso de pictogramas, que são frequentemente recomendados para transmitir mensagens de alerta, precisamente 
porque facilitam a compreensão dos riscos. O uso de pictogramas para 
ilustrar o potencial perigo de conduzir sob influência de medicamentos encontra-se disponível em alguns países Europeus, mas não de forma 
uniformizada ou padronizada. 
Decorrente das lacunas existentes e da falta de evidência científica 
nesta área, a Comissão Europeia financiou o projeto DRUID (European 
DRiving Under the Influence of Drugs, Alcohol and Medicines) com 
vista a criar bases sólidas e harmonizadas, a nível Europeu, para a 
regulamentação e legislação relativa à condução sob a influência 
de álcool, drogas e medicamentos. O projeto DRUID, com a duração 
prevista de 5 anos, tornou-se num dos maiores projetos Europeus de 
investigação alguma vez realizados nesta área.
O trabalho desenvolvido e apresentado nesta tese de doutoramento 
faz parte do projeto DRUID e teve como principais objetivos: 
1) Avaliar o conhecimento e o comportamento dos doentes no que 
respeita à condução de veículos sob influência de medicamentos 
(Capítulo 2);
2) Definir o critério e a metodologia para o desenvolvimento de um 
sistema de classificação de medicamentos com base no seu grau de 
influência na condução (Capítulo 3);
3) Desenvolver um pictograma que inclui as diferentes categorias de risco decorrentes do sistema de categorização de medicamentos 
(Capítulo 3) e avaliar a eficácia deste pictograma nos doentes 
(Capítulo 4);
4) Identificar os fatores associados à preferência dos doentes para o 
pictograma desenvolvido (Capítulo 5);
5) Avaliar as consequências de um curso teórico para farmacêuticos 
comunitários sobre a influência de medicamentos na condução, no conhecimento e comportamento de doentes em início de tratamento 
com estes medicamentos (Capítulo 6). Para avaliar os conhecimentos e os comportamentos associados 
aos doentes que tomam medicamentos que podem influenciar a 
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condução, realizou-se um estudo, na Alemanha, Bélgica, Holanda e Espanha, que se encontra descrito no Capítulo 2. Neste estudo foram determinados e comparados os fatores associados ao comportamento 
dos doentes no que respeita aos seus padrões de condução e à toma 
de medicamentos que a influenciam, bem como aos conhecimentos 
que detêm sobre a influência de medicamentos na condução. O 
questionário usado como ferramenta de estudo foi enviado para 
doentes que consomem benzodiazepinas, antidepressivos, ou anti-histamínicos de primeira geração, com idades compreendidas entre 
os 18 e os 75 anos e que sejam parte ativa do trânsito rodoviário. 
Dados referentes a 633 doentes foram usados na análise estatística. 
Os resultados confirmaram que os doentes participantes deste estudo, 
independentemente do país de origem, têm poucos conhecimentos 
acerca da influência de medicamentos na condução. No entanto, os níveis de conhecimento foram mais elevados nos doentes das 
faixas etárias mais baixas e com mais escolaridade. A maioria dos 
doentes não alterou os seus padrões de condução enquanto tomavam 
medicamentos que influenciam o desempenho desta atividade, nem 
tão pouco alteraram os padrões de consumo destes medicamentos por 
forma a conduzirem em maior segurança. Verificou-se, ainda, que as 
alterações nos padrões de condução são potenciadas em doentes que 
experienciaram efeitos secundários associados a estes medicamentos 
ou em doentes que apresentam atitudes negativas relativamente à 
condução sob a influência de medicamentos. A falta de conhecimento apresentado pelos doentes foi um indicador claro da necessidade de 
desenvolver materiais informativos para realçar os riscos inerentes à 
condução de veículos sob influência de medicamentos. 
Dado que os medicamentos têm diversos graus de influência na 
condução e que grande parte da informação que os doentes recebem 
lhes é dada por um profissional de saúde, surgiu a necessidade de 
desenvolver um sistema de classificação de medicamentos para auxiliar 
os profissionais de saúde durante o processo de aconselhamento ao 
doente relativamente à influência de medicamentos na condução. No Capítulo 3, encontra-se descrita a metodologia usada durante o 
desenvolvimento deste sistema de classificação de medicamentos. 
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Foi classificado um total de 1541 princípios ativos, o que significa 
a quase totalidade do sistema ATC de princípios ativos existentes, à 
data do estudo, no mercado Europeu. Cerca de metade dos princípios 
ativos classificados não apresenta qualquer influência na condução, 
pelo que lhes foi atribuída a categoria 0; cerca de 26% tem uma 
influência menor (categoria 1), 11% tem uma influência moderada 
(categoria 2) e cerca de 6% tem uma influência severa na condução 
(categoria 3). Dos princípios ativos incluídos na categoria 3, a grande 
maioria pertence ao grupo ATC N (sistema nervoso), subclasse N05 
(psicolépticos). Um sistema de classificação de medicamentos deste 
género pode ser considerado como uma ferramenta útil para melhorar 
os procedimentos de prescrição e dispensa de medicamentos, bem 
como para informar e envolver profissionais de saúde e doentes 
durante o aconselhamento. 
Como base no sistema de classificação, foi desenvolvido e proposto um pictograma para comunicar aos doentes mensagens de risco inerentes 
ao consumo de medicamentos durante a condução. Neste pictograma, 
referido como modelo gradativo, os diferentes níveis de influência na condução encontram-se dispostos horizontalmente, sendo que a 
categoria que representa “não influência” (categoria 0) na condução 
se encontra à esquerda enquanto a categoria de maior influência na 
condução (categoria 3) se encontra à direita do pictograma. A cada 
uma das categorias foi atribuída uma cor, à semelhança do sistema 
de cores que é usado nos semáforos de trânsito. Neste sentido, a 
cor verde (categoria 0), amarela (categoria 1), laranja (categoria 2) 
e vermelha (categoria 3) foram escolhidas para representar cada 
uma das categorias de risco. Um carro dentro de um triângulo preto colocado por cima de uma das categorias de risco indica qual a 
categoria correspondente ao princípio ativo em causa. O tipo de design 
escolhido possibilita ao público-alvo uma noção clara dos diferentes 
níveis de risco (que varia entre 0 e 3), bem como a noção de qual a 
categoria que é atribuída ao medicamento. O modelo gradativo foi 
comparado com o pictograma usado em França, referido como modelo 
triangular, uma vez que também considera as diferentes categorias de 
risco e usa um sistema de cores idêntico ao usado no modelo gradativo. 
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A diferença entre estes dois modelos prende-se com o facto de no sistema triangular os diferentes níveis de risco não se encontrarem 
todos descritos numa única figura, mas sim individualmente, isto é, 
existe um pictograma diferente para cada uma das categorias de risco. 
O Capítulo 4 descreve o estudo conduzido para avaliar e comparar 
a eficácia dos modelos acima descritos na comunicação do risco 
associado à condução sob influência de medicamentos. Neste sentido, 
270 pessoas que se encontravam na zona de espera de uma farmácia foram entrevistadas para se investigar qual o grau de compreensão da mensagem descrita no pictograma, a estimativa do risco de conduzir 
sob a influência de medicamentos decorrente da interpretação dos 
pictogramas e a intenção dos respondentes para mudar a frequência de 
condução caso um medicamento tivesse afixado um dos pictogramas 
em estudo. O valor acrescentado do texto auxiliar presente nos 
pictogramas foi igualmente avaliado. Os resultados demonstraram que, apesar de a maioria dos respondentes ter entendido que os pictogramas estariam relacionados com comportamento ao volante, 
menos de 10% e cerca de 36% dos respondentes que visualizaram o modelo triangular e o modelo gradativo, respetivamente, entendem 
por completo a mensagem veiculada nos pictogramas. Apesar da baixa percentagem de respondentes que compreenderam por completo 
a mensagem do pictograma, verificou-se que, no caso do modelo gradativo, a intenção para mudar comportamentos ao volante, conduzindo menos frequentemente, aumenta proporcionalmente com 
o aumento da categoria de risco. Contrariamente ao que vem descrito 
na literatura científica, os resultados do estudo não confirmaram o 
valor acrescentado do texto que acompanha o pictograma gradativo. 
A preferência dos respondentes para o modelo que melhor descreve 
a mensagem de risco de conduzir sob influência de medicamentos, 
bem como para o modelo que melhor traduz os diferentes graus 
de influência na condução, encontra-se descrito no Capítulo 5. A 
preferência dos respondentes recaiu claramente sobre o modelo 
gradativo para descrever a mensagem de risco (74.4%) e para traduzir 
os diferentes graus de influência de medicamentos na condução 
(82.6%). A preferência pelo modelo gradativo é transversal a todas 
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as faixas etárias e a todos os níveis de escolaridade. No entanto, 
constatou-se que os respondentes da faixa etária mais elevada e aqueles com menos escolaridade tendem a preferir o modelo 
triangular. Tendo em conta os resultados obtidos e considerando que 
o design do modelo gradativo é mais complexo do que o do modelo triangular, foi concluído que os respondentes mais idosos e com 
menos escolaridade preferem pictogramas com um grafismo mais 
simplista. Os resultados dos estudos apresentados nos capítulos 4 e 
5 permitem concluir que, à semelhança do que se encontra publicado 
noutros estudos, os pictogramas, isoladamente e por si só, têm pouca 
probabilidade de ser bem sucedidos. Assim sendo, foi recomendado o reforço da mensagem veiculada por um pictograma, oralmente ou por 
escrito, por profissionais de saúde de forma a evitar interpretações 
erradas e, deste modo, potencia-se a compreensão da informação bem 
como a sua lembrança no futuro.
Duas das maiores falhas identificadas na literatura prendem-
se com a falta de diretrizes que auxiliem os profissionais de saúde durante o aconselhamento de doentes que tomem, pela primeira vez, 
medicamentos que podem influenciar a condução, assim como com a 
falta de materiais informativos respeitantes a esta matéria e que sejam 
dedicados aos doentes. No Capítulo 6, apresentam-se os resultados 
de uma intervenção na qual um grupo de farmacêuticos comunitários 
foram treinados especificamente para aconselhar os doentes que se veem confrontados, pela primeira vez, com a toma de medicamentos 
que influenciam a condução. Para este efeito, foram desenvolvidos 
diversos materiais informativos e ferramentas de suporte informático 
que incluem o pictograma (modelo gradativo) desenvolvido, com 
o objetivo de auxiliar o farmacêutico durante o aconselhamento ao 
doente. Os efeitos desta intervenção (curso teórico) ao longo do tempo foram testados ao nível do conhecimento, atitudes e comportamento 
dos doentes no que à influência de medicamentos na condução 
diz respeito. Doentes com 18 anos ou mais e com uma primeira 
prescrição para um medicamento que influencia a condução, datada 
um mês antes (T0, medida de referência), e 6 meses após (T1, follow-
-up) a intervenção, foram selecionados para participar no estudo, 
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tendo-lhes sido, aleatoriamente, atribuído um grupo (intervenção ou 
controlo). Os participantes receberam, através do seu farmacêutico, 
um questionário. Um total de 421 doentes foram incluídos na medida 
de referência (T0) e 509 fizeram parte do follow-up (T1). Os resultados 
obtidos demonstraram que o curso teórico que os farmacêuticos do 
grupo da intervenção frequentaram não alterou significativamente 
o conhecimento, atitudes e frequência de condução dos doentes pertencentes ao grupo da intervenção, quando comparado com os 
doentes do grupo de controlo, isto é, doentes que pertencem ao grupo 
dos farmacêuticos que não participaram em qualquer curso teórico. A proporção de doentes no grupo de intervenção que referiu ter mudado 
os padrões de consumo dos medicamentos para poder conduzir em segurança diminuiu ligeiramente ao longo do período de estudo, tendo 
passado de 26.6% (T0) para 25.2% (T1), tendo-se verificado exatamente o oposto no grupo de controlo, ou seja, a proporção de doentes que diz 
ter alterado os padrões de consumo dos seus medicamentos aumento 
significativamente (p-value=0.02) ao longo do período de estudo, de 
27.3% (T0) para 35.5% (T1). Os resultados deste estudo permitiram concluir que, para aumentar a motivação dos doentes a alterar os seus 
padrões de condução aquando do consumo de medicamentos que a 
afetam, o aconselhamento farmacêutico terá que se focar não só na 
partilha de informação, mas também em técnicas de motivação. 
O resumo dos principais resultados e conclusões dos estudos implementados encontram-se descritos no Capítulo 7. Em suma, 
os resultados obtidos ilustraram que há ainda um longo caminho 
a percorrer e que muito pode ser feito para sensibilizar doentes 
e profissionais de saúde quanto à problemática da condução sob 
influência de medicamentos. Adicionalmente, o tipo e o conteúdo 
de informação a que o doente tem acesso e que contribuem 
grandemente para enriquecer os seus conhecimentos nesta área, 
podem ser melhorados. Neste sentido, foram sugeridas diversas ações concertadas dirigidas aos intervenientes comumente envolvidos neste 
processo: doentes, profissionais de saúde e instituições. 
Intervenções ao nível dos doentes passam por promover o seu papel 
ativo e autónomo nas decisões relacionadas com a sua saúde e com o 
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impacto que o tratamento tem na vida quotidiana. Para tal, é necessário 
implementar estratégias centradas no doente e na individualização 
da informação que lhe é transmitida durante as consultas com um 
profissional de saúde que, por sua vez, deve ter capacidade de adaptar 
a informação à literacia do dente, promovendo-se, deste modo, a sua 
capacidade de participação nas decisões médicas. 
Relativamente aos profissionais de saúde, e tendo em conta a situação 
particular de conduzir sob influência de medicamentos, recomenda-
se que deem particular atenção às necessidades dos doentes no que respeita ao uso de veículos motorizados para que possam ajustar a 
terapêutica à realidade do doente, não comprometendo a segurança 
rodoviária do doente e dos que com ele interagem. Os profissionais 
de saúde devem, também, estar particularmente atentos aos efeitos 
secundários que podem afetar a condução, nomeadamente, sonolência, 
tonturas, diminuição do tempo de reação, ou visão turva, bem como ao 
impacto que a doença em si pode ter na condução. Sugere-se ainda 
a utilização do sistema de classificação desenvolvido para auxiliar 
profissionais de saúde durante a prescrição ou dispensa destes 
medicamentos. 
Por último, foi constatada a necessidade de implementar uma 
estratégia coerente e coordenada que sensibilize todos os intervenientes, como autoridades nacionais reguladoras do medicamento, ordens 
dos médicos e dos farmacêuticos, ou escolas de condução, quanto ao 
verdadeiro impacto que a condução sob influência de medicamentos 
pode ter na sociedade. 
Tendo em conta todo o trabalho desenvolvido e os resultados obtidos, pode concluir-se que os doentes desconhecem em larga escala os efeitos de alguns medicamentos na condução e que, neste sentido, são 
necessárias medidas várias para sensibilizar este grupo de doentes 
quanto aos perigos em que podem incorrer. O pictograma desenvolvido 
(modelo gradativo) não terá sido completamente bem-sucedido na transmissão da mensagem, indicando claramente a necessidade de complementar a informação durante o aconselhamento por parte de 
médicos e/ou farmacêuticos. No entanto, os profissionais de saúde nem sempre transmitem a informação da forma mais adequada, 
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invocando a necessidade de utilizar ferramentas que os auxiliem a 
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